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ABSTRACT
Intermittent hypoxia (IH) is a major pathophysiological manifestation of
obstructive sleep apnea (OSA). Previous studies have implicated IH in mediating
many pathophysiological outcomes associated with OSA. Only few studies have
examined IH-induced alterations to central signaling pathways important in
cardiovascular and metabolic phenotypes associated with OSA. This thesis
employed a rodent model of IH to examine changes to molecular neural pathways
associated with metabolic and cardiovascular pathophysiological outcomes of OSA.
Acute IH induces a specific negative body energy balance phenotype. This is
concomitant to a reduction in body weight and food intake, with an elevation in food
conversion

efficiency.

Increased

plasma

leptin

concentrations

also

occur

immediately following acute IH, which is mirrored by increased activation of leptinsignaling and satiety-inducing molecules within the arcuate nucleus of the
hypothalamus (ARC). The effects observed on body energy balance following acute
IH are attenuated in the homozygous leptin-deficient KILO rat, suggesting the
importance of elevated leptin in mediating the body energy balance responses
following acute IH. Over chronic IH exposure, rats have a complex metabolic
phenotype, which includes a reduction in body weight and body fat mass.
Throughout the chronic period of exposure, animals develop a resistance to the
hormone leptin, the primary hallmark for the development of obesity. This is
concomitant to increased food intake and fat-standardized plasma leptin
concentrations. Within ARC, leptin-associated signaling pathways are not activated,
and there is less protein content of satiety-inducing proteins. There is also more
protein of a negative regulator of leptin signaling in ARC following chronic IH.
ii

Chronic IH also elevates resting blood pressure and reduces baroreceptor reflex
gain, which are associated with reduced neuroplasticity markers within the nucleus
of the solitary tract. Some of the changes observed over acute IH in these markers
are leptin-dependent, as they are abolished in the leptin-deficient KILO rat. Leptin
appears to interact at the major sensory site for IH, the carotid body, with the reninangiotensin system, as blockers captopril and losartan inhibit IH-induced alterations
to leptin signaling molecules. This thesis shows potential mechanisms by which IH
can induce cardiovascular and metabolic phenotypes observed in OSA patients.
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CHAPTER 1
INTRODUCTION AND BACKGROUND

2

1.

INTRODUCTION
This thesis focuses on consequences of intermittent hypoxia, a major

pathophysiological manifestation of obstructive sleep apnea. In particular,
alterations to energy balance, and the cardiovascular system were assessed. In
addition to these physiological changes, associated neural pathways were
evaluated for alterations that may serve as determinants in mediating these
changes. The first chapter will provide 1) an overview of obstructive sleep apnea,
2) current understanding and mechanisms of hypoxia in body energy balance
and cardiovascular disease, and 3) an overview of the leptin hormonal system as
it pertains to body energy and cardiovascular systems.

1.1 OBSTRUCTIVE SLEEP APNEA

1.1.1 Disease description
Obstructive sleep apnea (OSA) is a chronic, progressive disease. OSA
patients experience episodic partial (apnea) or complete (hypopnea) closure of
the upper airway during sleep (Dempsey et al., 2010). These closures prevent
appropriate air flow into and out of the lungs, despite respiratory effort. As a
result, alveolar partial pressure of oxygen is reduced, leading to a hypoxic state
during the airway closure. This, in turn, causes a reduction in blood-oxygen
pressure and hypoxemia. The overall effect of these repeated closures during
sleep is a state of intermittent hypoxia (IH) and intermittent hypoxemia. These
events and their resultant IH lead to arousals, disrupting sleep architecture and

3

elevating activity of the autonomic nervous system above normal levels.
Resulting from the reductions in gas exchange across the blood-gas barrier,
hypercapnea is also commonly observed in patients with OSA. Likewise,
intrathoracic reductions in pressure are observed as an individual struggles to
breathe without success.
The first reports of OSA come from British physicians in the 1870s, who
described individuals having “fruitless contractions of the inspiratory and
expiratory muscles against glottis obstruction… during sleep” (Lavie, 2003). It
was not until the 1960s that OSA was described in obese subjects experiencing
arousals resulting from episodic airway obstruction (Gastaut et al., 1966). These
results brought to light the concept that obesity, sleepiness, sleep disruption and
nocturnal airway obstruction may be linked.

1.1.2 Diagnosis and treatment of OSA
OSA is diagnosed following overnight observation and polysomnography.
Determinations of the number of apneic or hypopneic events per hour are
calculated, representing the Apnea-Hypopnea Index (AHI). A patient with an AHI
greater than five is considered to have a mild form of OSA, while those with an
AHI greater than 30 are considered to have severe OSA. Significant reductions
blood-oxygen saturation have also been described as important markers for
OSA, with a measure of time below 90% blood-oxygen saturation being utilized
to identify susceptibility to cardiovascular events (Nieto et al., 2000).
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OSA is primarily treated using continuous positive airway pressure
(CPAP) devices, since CPAP is highly effective at reducing apneic events and
pathophysiology associated with OSA (Faccenda et al., 2001; Jenkinson et al.,
1999). That said, there is still a considerable problem with adherence among
individuals using CPAP, despite the association between daytime sleepiness and
severity of OSA with the likelihood of using the CPAP system (Hoy et al., 1997).
Alternative treatments for OSA include surgery, particularly for individuals
with anatomical-related disposition to apnea. The most common surgical
intervention for OSA is the uvulopalatopharyngoplasty, which is not necessarily
recommended for OSA patients without anatomical dispositions to apnea, since
less than half of individuals treated in this way have AHI reduced to less than 20
events per hour.
Oral appliances are another major form of treatment for patients with OSA.
The devices used are generally either mandibular advancement devices or
tongue retainers, which prevent the collapse of the upper airway (Ferguson et al.,
1996, 1997). Certainly these devices have their place in the treatment of mild-tomoderate cases of OSA, and are more effective than surgical interventions,
though they are generally less effective than CPAP (American Academy of Sleep
Medicine Task Force, 1999).
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1.1.3 Prevalence of OSA
The Wisconsin Sleep Cohort, a study involving 602 middle-aged (30-60
years old) subjects, found the proportion of males and females with OSA to be
24% and 9%, respectively. Despite this prevalence, only 4% of males and 2% of
females experience daytime somnolence, although having an AHI >5, suggesting
a significant under-diagnosis of the disease (Young et al., 1993). More recently, it
was estimated that 17% of this same age-group in the United States suffered
from at least mild sleep apnea, and approximately 6% suffered from at least
moderate sleep apnea, and 41-58% of the burden of sleep apnea was due to
excess body weight (Young et al., 2005). Interestingly, countries such as Brazil
and some Asian countries have higher prevalence of OSA, despite lower
prevalence of obesity (Ip et al., 2001; Sharma and Ahluwalia, 2010).
Nonetheless, obesity is a major risk factor for the development of OSA, as an
increase of 6 kg/m2 on the body mass index (BMI) scale results in an increased
risk of OSA by 4-times (Young et al., 1993). It is estimated that 70% of OSA
patients suffer from obesity (Malhotra and White, 2002).

1.1.4 Comorbidities of OSA
While obesity is a major risk factor for the development of OSA, there are
many other comorbidities of OSA. There are three major categories of OSA
comorbidities: cardiovascular, metabolic and neurocognitive.
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1.1.4.1

Cardiovascular comorbidities

1.1.4.1.1 Systemic Hypertension
Blood pressure in normal individuals is reduced during sleep, compared to
normal waking pressures. This “dipping” is not observed in many patients with
OSA, attributable to vasoconstriction during the apneic period (Golbin et al.,
2008). An event-associated increase in both systolic and diastolic blood pressure
was observed in the Sleep Heart Health Study, which involved more than 6000
patients (Nieto et al., 2000). Likewise, Lavie and colleagues (2000) showed a
one percent increased risk of hypertension for every increase of one unit on the
AHI scale. The Wisconsin Sleep Cohort, a prospective study, determined an
event-associated increase in hypertension at four years follow-up, even after
accounting for known confounders. Other studies have not displayed a significant
effect of OSA on blood pressure, especially when BMI is taken into
consideration. However, OSA is considered by many to be a major risk factor for
the development of secondary hypertension (Bradley and Floras, 2009;
Chobanian et al., 2003). Likewise, use of CPAP is able to reduce blood pressure
and sympathetic activity in patients (Dimsdale et al., 2000; Haentjens et al.,
2007).

1.1.4.1.2 Pulmonary Hypertension
Pulmonary hypertension is diagnosed following right heart catheterization
measurement of pulmonary arterial pressure of greater than 25 mmHg. The
pathophysiology of pulmonary hypertension in OSA could be explained by the
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fact that chronic respiratory diseases that induce hypoxia appear to remodel the
pulmonary arteries (Presberg et al., 2003). Pulmonary hypertension prevalence
in patients with OSA has been estimated at 41%, when adjusted for confounding
variables, including BMI (Sajkov et al., 1994). CPAP reduces pulmonary arterial
blood pressure (Arias et al., 2006).

1.1.4.1.3 Cardiac Arrhythmias
In the cross-sectional Sleep Heart Health Study, severe OSA patients had
four times the frequency of having atrial fibrillation, when adjusted for
confounders, including BMI. OSA patients had three-times the frequency of
having nonsustained ventricular tachycardias when adjusted for confounders
(Mehra et al., 2006). Bradyarrhythmias are also found in patients with OSA, and
it has been shown that CPAP use can reduce this difference (Guilleminault et al.,
1983).
Cardiovascular mortality is elevated in men and women with severe OSA
and mortality can be reduced by implementation of CPAP (Marin et al., 2005;
Campos-Rodriguez et al., 2012). This may be due to alterations in the timing of
severe cardiac events, as it has been shown that these are more likely to occur
during sleep hours of patients with OSA, while it is more frequent in the morning
for normal people (Gami et al., 2005).
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1.1.4.1.4 Stroke
In a prospective study by Redline and colleagues (2010) stemming from
the Sleep Heart Health Study, it was shown that moderate-to-severe OSA is
associated with a three-fold risk of stroke over an eight year period. This
association is supported by findings of the Wisconsin Sleep Cohort, which shows
moderate-to-severe OSA is a significant risk factor for stroke (Arzt et al., 2005),
and this may be associated with the severity of the disease (Yaggi et al., 2005).
Interestingly, the development and progression of OSA may be bidirectionally
associated with incident stroke, as apneas are associated with decreased blood
flow following stroke, which may induce thrombosis (Netzer et al., 1998). CPAP
therapy has beneficial effects in decreasing mortality in OSA patients with stroke
(Martinez-Garcia et al., 2009).

1.1.4.2

Metabolic comorbidities

1.1.4.2.1 Obesity
Obesity is an energy balance disease, resulting from a chronic state of
positive energy balance, such that energy consumed is not adequately utilized.
Excess calories are stored in adipose tissue depots located throughout the body.
A concomitant increase in lean mass is also observed, resulting in significant
weight gain and elevation of body mass index (BMI; Williams and Fruhbeck,
2009). OSA is associated with obesity, as previously mentioned and illustrated by
the fact that obese patients with OSA that undergo bariatric surgery have
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improvements in OSA parameters such as oxygen saturation and sleep
disturbances (Haines et al., 2007). Similar results have been obtained in studies
using sibutramine-induced weight loss (Sutherland et al., 2011). Patients
diagnosed with OSA appear to have trouble losing excess weight when
compared to non-apneics with the same level of obesity. Likewise, patients with
OSA tend to gain weight over the course of their disease (Phillips et al., 1999).
As a result, it is clear that a bidirectional relationship exists between obesity and
OSA, though this has not received much scientific study.

1.1.4.2.2 Metabolic syndrome
The metabolic syndrome is a cluster of metabolic pathophysiologies that
include obesity, insulin resistance, hypertension and dyslipidemia. The criteria by
which individuals are diagnosed with the metabolic syndrome include specific
cut-offs of specific measures that fall under the umbrella of the pathophysiologies
mentioned above, including altered cholesterols, elevated blood pressure and
triglycerides, glucose intolerance, and elevated BMI (American Medical
Association, 2001). Current guidelines suggest that a patient experience any
combination of three of these issues, and obesity is not a requirement for
diagnosis. It is estimated that the prevalence of the metabolic syndrome in
developed countries is 23% (Ford et al., 2002).
Studies have emerged examining a potential relationship between OSA
and the metabolic syndrome. OSA was found to be associated with specific
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criteria of the metabolic syndrome, and the syndrome itself, with an odds ratio of
around 9 (Coughlin et al., 2004). The severity of OSA may also predict the
number of criteria of the metabolic syndrome (Lam et al., 2006). Interestingly,
OSA is associated with a worse metabolic profile of individuals who were not
obese, and associated with the presence of the metabolic syndrome (Kono et al.,
2007).

1.1.4.2.3 Insulin resistance
Insulin resistance is a hallmark manifestation of the metabolic syndrome,
and type II diabetes mellitus. The prevalence of OSA within type II diabetics is
estimated at 23%, and OSA is correlated with type II diabetes, regardless of
appropriate confounders such as BMI, age and neck size (West et al., 2006). The
use of CPAP in modulating glycemia has only provided weak, observational
evidence to support a role of OSA treatment in improving hyperglycemia (Babu et
al., 2005; Hassaballa et al., 2005). The Wisconsin Sleep Cohort failed to show
provide an increased incidence of diabetes in OSA patients after adjustment at
follow-up, and so a causal role for OSA in diabetes is not able to be made
(Reichmuth et al., 2005).

1.1.4.2.4 Dyslipidemia
Many studies have observed associations between OSA and poor lipid
profiles. The Sleep Heart Health Study, for example, showed a significant
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negative association between OSA severity and high-density lipoprotein levels,
whereas a significant positive association was observed between OSA severity
and circulating triglyceride concentrations when adjusted for confounders
(Newman et al., 2001). Other studies have shown similar effects in patients
matched by BMI (McNicholas et al., 2007; Coughlin et al., 2004). Despite this,
CPAP

intervention studies

have

failed to

show convincing significant

improvement in cholesterol or triglyceride levels (Coughlin et al., 2007; Robinson
et al., 2004).

1.1.4.3

Neurocognitive comorbidities

One of the primary symptoms of OSA is excessive daytime somnolence.
This experience of increased sleepiness is associated with a variety of cognitive
deficits including decreased alertness, reduced psychomotor speed and impaired
executive function (Beebe et al., 2003). These abnormalities result in increased
risk of automobile accidents and a significant reduction in the perceived quality of
life (Beebe et al., 2003). A loss of gray matter has been observed in OSA
patients, associated with these symptoms, an effect which can be altered by
CPAP use (Canessa et al., 2011; Thomas et al., 2012). Interestingly, the use of
CPAP appears to have greater beneficial effect on these variables in children,
compared with adults (Sanchez et al., 2009; Ferini et al., 2003; Marcus et al.,
2012; Gurubhagavatula, 2010).
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1.1.5 Intermittent hypoxia as a model for OSA
Animal models employing IH have been used for the study of mechanistic
effects of OSA-induced IH since 1992 (Fletcher et al., 1992). There are two major
types of rodent IH models: sleep-dependent and sleep-independent IH. Sleepdependent IH relies on the presence of sleep for the induction of the model and
requires

significant

physiological

measurement,

including

electroencephalography and electromyography (Tagaito et al., 2001). This model
is expensive, time-consuming, low-throughput, and rarely employed.
The second, more commonly used IH model is sleep-independent.
Reductions in available oxygen and a subsequent return to normoxia are applied
to the animal as many as 60 times per hour, with oxygen nadirs ranging from as
low as 3% to as high as 10% (Polotsky et al., 2006; Veasey et al., 2004; Gozal et
al., 2001; Peng et al., 2003). Specific experimental conditions vary widely
between research groups. Exposure to these conditions is typically during the
sleep-cycle of the animal, and has been shown to correlate well with oxygen
saturation values observed in patients with OSA (Jun et al., 2010; Louis and
Punjabi, 2009). Recently, sleep-independent models of IH have been employed
(Louis and Punjabi, 2009).

13

1.2 HYPOXIA-SENSING AND THE CARDIOVASCULAR SYSTEM

1.2.1 Peripheral arterial chemoreceptors
Within the body, hypoxia is primarily sensed by peripheral arterial
chemoreceptors. These specialized tissues are made up of type I glomus cells
and type II sustentacular cells within the carotid and aortic bodies. These small
pieces of tissue are located near the carotid bifurcation and aortic arch. Glomus
cells are specialized receptors that are hypoxia-sensitive and release a number
of neurotransmitters in response to altered O2 and CO2/H+ homeostasis
(Gonzalez et al., 1994). Sustentacular cells are supportive in nature, and don’t
appear to have a function related to hypoxia-sensing. Changes in altered blood
gas homeostasis activate glomus cells, causing the release of excitatory
neurotransmitters onto the terminals of the carotid sinus branch of the
glossopharyngeal nerve (Gonzalez et al., 1994; Nurse, 2010; Lopez-Barneo,
2003). The subsequent neuronal activity results in activation of cardiorespiratory
reflexes within the brainstem to alter blood gases to appropriate levels. Activation
of the arterial chemoreceptors initiates what is known as the peripheral
chemoreceptor reflex, resulting in an elevation of phrenic motor output to the
diaphragm, and both sympathetic and parasympathetic efferent branches of the
autonomic nervous system, with a resulting elevation in ventilation and blood
pressure, and paradoxical bradycardia (Alsberge et al., 1988; Kumar, 2009).
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1.2.2 Chemoreceptor reflex activation of the sympathetic nervous system
Much of the evidence indicating the neural structures underlying the
sympathetic responses to peripheral chemoreceptor reflex activation has been
acquired in anaesthetized animal preparations. Nonetheless, activation of the
peripheral

chemoreceptor

reflex

induces

phrenic

nerve

discharge

and

sympathetic nerve activity to the heart and blood vessels following specific
activation of the carotid bodies or hypoxia (Koshiya et al., 1993; Koshiya and
Guyenet, 1996a). This activation is eliminated following denervation of the carotid
bodies (Koshiya and Guyenet, 1996a). The sensory component of the carotid
chemoreceptor reflex begins with the release of excitatory neurotransmitter onto
the afferents of the carotid sinus nerve, resulting in activation of the nucleus of
the solitary tract (NTS). The NTS is the primary site of the termination of
cardiorespiratory reflexes originating in the aortic and carotid bodies (Ciriello,
1994), and contains neurons that are activated by chemoreceptor stimulation and
project to the rostral ventrolateral medulla (RVLM; Koshiya and Guyenet, 1996b;
Ciriello and Moreau, 2013). It is believed these NTS-RVLM neurons are
independent of baroreceptor input and respiratory entrainment, regardless of the
activity of the chemoreceptor reflex (Koshiya and Guyenet, 1996b).

The

sympathetic outflow from the activation of the chemoreceptor reflex originates as
signals from the pre-sympathetic neurons of the RVLM, perhaps due to activation
of these NTS-RVLM neurons. The recruitment of a given subset of these neurons
will alter the tissue to which sympathetic tone will be changed by activating
specific sympathetic pre-ganglionic neurons of the spinal cord (Dampney, 1994).
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How these neurons are recruited to mediate an elevation in sympathetic tone is
still a matter of controversy (Guyenet, 2000). Increases in hypoxia-related
sympathetic activity will cause vasoconstriction (Hudson et al., 2011) and a
release of catecholamines from the adrenal medulla (Prabhakar et al., 2012).

1.2.3 Intermittent hypoxia and cardiorespiratory reflexes

1.2.3.1

Effect on peripheral chemoreceptor reflex

Individual bouts of short-term hypoxia are observed during IH, which
activate the peripheral chemoreceptor reflex in the same way as continuous
hypoxia mentioned above, though with a reduced ventilatory response
(Prabhakar et al., 2005; Reeves et al., 2003). In fact, a potentiation of the
chemoreceptor reflex due to sensory long-term facilitation (sLTF) of the
chemoreceptors has been identified in animals exposed to IH (Prabhakar et al.,
2005; Prabhakar et al., 2009), but not sustained hypoxia (Baker and Mitchell,
1999; 2000). Likewise, acute IH alters expression of glutamatergic receptors
within the dorsocaudal brainstem (containing the NTS region), whereas
sustained hypoxia does not (Reeves et al., 2003). This sLTF is concomitant to an
elevation of sympathetic nervous tone and blood pressure following acute IH in
both rats (Dick et al., 2007; Xing and Pilowsky, 2010; Mandel and Schreihofer,
2009) and humans (Leuenberger et al., 2005). Even after acute exposure to IH,
this increased sympathetic activity persists following the discontinuation of
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hypoxia (Fuller et al., 2000), though the increased blood pressure was transient
(Leuenberger et al., 2005).
Chronic
consequences.

IH

(CIH),

like

Long-lasting

acute

IH,

elevations

in

has

significant

resting

blood

cardiovascular
pressure

and

sympathetic activity are found in animals (Zoccal et al., 2007, 2008; Bao et al.,
1997) and humans (Tamisier et al., 2011) following CIH. These changes in blood
pressure are likely mediated by a combination of the sympathetic nervous
system (Fletcher et al., 1992b), and vascular factors such as angiotensin II (Ang
II), catecholamines and vasopressin (Foster et al., 2010; Bao et al., 1997;
Fletcher et al., 1999; Fernandes et al., 2005).
The role of the peripheral chemoreceptor reflex in mediating the CIHinduced blood pressure effects are highlighted by the fact that denervation of the
carotid sinus nerve prior to exposure to CIH in rats, eliminates the cardiovascular
alterations observed (Fletcher et al., 1992a). Meanwhile, the autonomic
alterations observed following hypoxia are eliminated when chemoreceptors are
inhibited by hyperoxia (Querido et al., 2010).
CIH potentiates the sympathetic response to additional bouts of hypoxia.
In studies assessing the afferent signaling from the carotid bodies, previous
exposure to CIH, but not normoxia, caused an increased cellular response (Peng
and Prabhakar, 2004; Rey et al., 2004). A similar effect was observed for efferent
sympathetic responses to hypoxia (Huang et al., 2009; Greenberg et al., 1999).
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At least some of this response is mediated by an alteration in central responses
within NTS (Kline, 2010).

1.2.3.2

Effect on arterial baroreceptor reflex

In opposition to the peripheral chemoreceptor reflex, activation of the
arterial baroreceptor reflex causes a reduction in sympathetic tone and blood
pressure. The baroreceptors are located within the walls of the vasculature of the
carotid sinus and the aortic arch and send neural projections into the NTS
(Ciriello, 1983; Davies and Kalla, 1981), which projects to the caudal VLM.
Activation of the baroreceptor reflex causes an inhibition of the RVLM via
monosynaptic connections from the caudal VLM (Agarwal and Calaresu, 1991;
Agarwal et al., 1990).
During IH, the baroreceptor reflex would activate to buffer the elevation in
blood pressure. In animals with experimental peripheral chemoreceptor activation
using potassium cyanide, baroreceptors become activated following the initial
rise in blood pressure, resulting in a biphasic response that includes subsequent
hypotension and bradycardia (Braga et al., 2008).
Given that animals and humans exposed to CIH develop hypertension, it
may be concluded that the baroreceptor reflex is inhibited or desensitized
following long-term IH exposure. In the short-term, IH resets the baroreceptor
reflex to operate at higher levels of blood pressure and sympathetic tone, not
changing the sensitivity of the reflex (Monahan et al., 2006), independent of
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changes to ventilatory responses (Halliwill et al., 2003). However, following CIH,
desensitization of the baroreceptor reflex may also occur (Gu et al., 2007; Lai et
al., 2006).

1.3 HYPOXIA AND BODY ENERGY BALANCE
Hypoxia induces, above all else, a state of negative energy balance. This
occurs initially at the level of the mitochondria, reducing the capacity for oxidative
phosphorylation, and thus production of ATP. The response to this reduction in
energy production is manifested by the release of macromolecules from
appropriate storage sites, likely mediated by the sympathetic nervous system,
resulting in a reduction in body weight.

1.3.1 Cellular energy responses to hypoxia
Cells are sensitive to alterations in available oxygen concentrations within
their environment. Given the role of oxygen in energy production through
mitochondrial oxidative phosphorylation, it is not surprising that cells are able to
alter both the supply and demand of oxygen within their interstitium through
various mechanisms including augmented glycolytic and reduced oxidative
phosphorylation pathways.
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1.3.1.1

Hypoxia-inducible factor 1

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein made up of α
and β protein subunits. HIF-1β is a constitutively expressed protein that does not
have activity independent of HIF-1α and isn’t affected by oxygen tension. In
contrast, HIF-1α is the primary activator of the HIF-1 complex (Wang et al.,
1995). HIF-1α has domains for binding to HIF-1β, an oxygen-sensitive core and a
DNA-binding domain for regulation of transcriptional promoters or enhancers
containing a hypoxia-responsive element (Jiang et al., 1997). During normoxia,
oxygen binds to the oxygen-sensitive core, resulting in hydroxylation,
ubiquitination and subsequent degradation of HIF-1α. During hypoxia, there is
less oxygen to bind to the oxygen-sensitive core, and HIF-1α is free to
translocate to the nucleus to associate with HIF-1β, forming HIF-1. The
heterodimer HIF-1 binds to regulators of genes, which are deemed to be
hypoxia-responsive (Chandel, 2010).

1.3.1.2

Generation of ATP

During hypoxic insults, mitochondria reduce their uptake of oxygen
thereby limiting their production of ATP, and increasing anaerobic ATP
production. This is done to avoid forming anoxic cellular conditions, which may
ultimately lead to cell death.
HIF-1 acts as a “switch” to augment the translocation and activity of
glucose transporters in the cell membrane, increasing the influx of glucose for the

20

use in so-called fermentative pathways (Gleadle et al., 1997; Maxwell et al.,
1997). The production of ATP by these pathways is oxygen-independent and
less efficient at producing ATP than oxidative phosphorylation. Despite this, cells
can maintain glycolytic production of ATP at nearly the same level due to an
elevated capacity for glucose transport and an increase in glycolytic enzymes,
mediated by HIF-1 (Gleadle et al., 1997; Maxwell et al., 1997; Mathupala et al.,
2001; Semenza et al., 1994, 1996).
The shunting of pyruvate and other necessary co-factors of oxidative
phosphorylation away from the mitochondria and into glycolytic pathways
prevents an elevation in reactive oxygen species associated with inefficient
electron transport chain activity (Weideman and Johnson, 2008). The enzymes
important in these effects are regulated by HIF-1 (Kim et al., 2006; Papandreou
et al., 2006).
Reactive oxygen species production has also been shown to occur
following the reoxygenation events observed in IH. The increase in available
oxygen within tissues following a return to normoxia not only provides the
substrate for the production of reactive oxygen species, but also may alter the
antioxidant capacity of cells (Singh et al., 2001), leading to lipid peroxidation,
formation of reactive nitrogen species and oxidative stress (Row et al., 2003; Xu
et al., 2004)
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1.3.2 Organism energy responses to hypoxia
1.3.2.1

Body weight and food intake

It has been largely reported that hypoxia of both a continuous and
intermittent nature causes an acute reduction in body weight (WesterterpPlantenga et al., 1999; Martinez et al., 2008). Interestingly, this effect in
sustained hypoxia is mirrored by a reduction in food intake, when locomotion,
stress and temperature are taken into consideration. Alterations in food intake
were concomitant with an increase in the number of meals taken per day.
Subjects of this study indicated they felt hungry, but did not have the drive to
consume food, an effect observed during altitude sickness. This imbalance in
body energetics is currently without a potential mechanism, but has been
suggested to be the result of elevated plasma leptin concentrations (Tschop et
al., 1998). Ratios of the consumption of specific macronutrients do not appear to
be affected by chronic hypoxia (Westerterp et al., 1992; Westerterp et al., 1994;
Westerterp et al., 1996). Currently, there are no studies examining food
consumption and body energy balance during intermittent hypoxic exposure,
though losses in body weight have been reported (Martinez et al., 2008; Ling et
al., 2008; Drager et al., 2011).

1.3.2.2

Lipid metabolism

In normal and atherosclerosis-prone animals, chronic IH increases total
cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein and
triglycerides, effects which are amplified by the level of the hypoxic stimulus (Jun
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et al., 2010; Li et al., 2005; Li et al., 2007). In support of these findings, increased
lipid synthesis pathways of the liver have been shown to be altered (Li et al.,
2005; Li et al., 2007; Savransky et al., 2007; Li et al., 2007), an effect which
mimics acute exposure to hypoxia (Piguet et al., 2009). Likewise, this effect may
be mediated partially by HIF-1 (Li et al., 2006).
In addition to elevated production of lipids, IH has been shown to induce
lipolysis, releasing free fatty acids from adipose tissue, likely through activation of
the sympathetic nervous system (Jun et al., 2010; Jaworski et al., 2007; Lafontan
and Langin, 2009; Zechner et al., 2009). Chronic IH has been shown to induce
liver enzymes and liver injury in rodents (Savransky et al., 2007), as well as
cause the release of pro-inflammatory cytokines (Savransky et al., 2007).

1.3.2.3

Glucose metabolism

IH is capable of producing an acute insulin resistance in lean mice, and
potentiating that found within obese leptin-deficient mice (Iiyori et al., 2007;
Polotsky et al., 2003). As well, in human IH models, these effects have been
observed without increasing the circulating level of leptin (Louis and Punjabi,
2009). These effects could be mediated by changes in lipid production within the
liver, or by increased sympathetic tone leading to lipolysis and ultimately an
increase in free fatty acids. Free fatty acids have been shown to reduce glucose
uptake by inhibition of insulin pathways within skeletal muscle (Delarue and
Magnan, 2007; Kim et al., 2001). Meanwhile, glycogen is released from, and

23

glucose uptake is reduced, in muscle. Elevated hepatic gluconeogenesis and
hyposecretion of insulin may also be mediated by the sympathetic nervous
activation following IH. Additional mechanisms mediating insulin resistance in IH
include inflammation (Cai et al., 2005; Yuan et al., 2001) and corticosteroid
release (Yokoe et al., 2008; Morton, 2010).

1.4 LEPTIN SIGNALING

1.4.1 Leptin and its receptors
The hormone leptin is produced from the ob gene, located on
chromosome 6 of mice and chromosome 7 in humans. The genes are 84%
homologous, containing 3 exons. Leptin is produced as a non-glycosylated
protein made up of 167 amino acids, including a 21 amino acid signal peptide
(Auwerx and Staels, 1998). The protein contains 4-alpha helices, each of which
is 5-6 turns long, connected by lengthy crossover linkages, similar to cytokines
like ciliary neurotrophic factor and leukemia inhibitory factor. A single disulphide
bridge exists between cysteines 96 and 146, which appears to be crucial for the
proper folding and receptor binding of leptin (Zhang et al., 1997). Two major
types of mutations occur, which affect the ob gene: a non-sense mutation
producing a premature stop codon; and a mutation within the gene promoter,
inhibiting transcription altogether (Halaas et al., 1995).
Leptin exerts its physiological responses through the leptin receptor
(ObR). ObR contains a single transmembrane spanning region, and is located on

24

chromosome 1 in humans. The receptor protein belongs to the class-1 cytokine
receptor family (Tartaglia et al., 1995). ObR can be alternatively spliced to form
several receptor isoforms (ObRA-F), which share common extracellular and
transmembrane domains, though a variable intracellular domains. These
receptors can be classified as short-form (ObRA, C-D, and F), long-form (ObRB),
or soluble/secreted (ObRE) (Wang et al., 1998; Lee et al., 1996; Tartaglia et al.,
1995). The long-form, ObRB, contains intracellular motifs for the binding and
activation of janus kinases (JAK) and signal transducers and activators of
transcription (STAT; the so-called JAK/STAT pathway will be discussed in
section 1.4.4).
The various isoforms of ObR have unique roles in leptin signaling and
secretion. ObRB mediates most of the intracellular signaling associated with
leptin binding to the extracellular motifs. ObRA, containing a short intracellular
motif, is important for the movement of leptin across membrane barriers,
including the blood-brain barrier and from the cerebrospinal fluid into brain
parenchyma (Tartaglia et al., 1995; Mercer et al., 1996; Fei et al., 1997; Bjorbaek
et al., 1998; Hileman et al., 2000). The ObRE soluble leptin receptor is important
for modulation of circulating leptin and its secretion from adipocytes (Ge et al.,
2002; Huang et al., 2001; Lammer et al., 2001; Yang et al., 2004).
1.4.2 Regulation of leptin secretion
The hormone leptin is produced by many tissues in the body, including
adipose tissue, heart, carotid bodies, brain and gonads. Primarily, white adipose
tissue is the major site of production of leptin. White adipose tissue is found
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throughout the body in major depots, including the visceral, subcutaneous,
retroperitoneal and epididymal fat pads. Each fat pad releases different amounts
of leptin, with the epididymal pad releasing the most (approximately 10 ng/10
million cells) in rats. In humans, the subcutaneous fat pad releases the most
leptin (Zheng et al., 1996; Arner, 2001). The average circulating level of leptin in
normal adults is 3-5 ng/ml, though this value can be much higher (8-90 ng/ml) in
obese individuals (Shek et al., 1998; Klein et al., 2004). Initially, it was held that
leptin secretion was proportional to the level of white adipose tissue within an
individual. The white adipose tissue produces, stores and secretes leptin. The
amount of leptin from rough endoplasmic reticulum to golgi to secretory vesicles
of adipocytes increases, suggestive of a concentration of leptin prior to its
release. Basally, leptin is produced and secreted into the interstitium of adipose
tissue to maintain a set leptin concentration within and outside of the adipocyte
(Cammisotto and Bendayan, 2007).
Leptin secretion is strongly linked to circadian rhythm: its plasma
concentration is lowest in the morning and highest in the middle of the night
(Licinio et al., 1997; Mastronardi et al., 2000; Nagatani et al., 2000). Postprandial elevations in insulin have also been described as an important factor for
leptin secretion, though this occurs long after mealtime, suggestive of a longterm, not short-term role of leptin in energy balance (Koopmans et al., 1998;
Lynch et al., 2006).
The stimulation of leptin secretion from the adipose appears to be
calcium-independent (Cammisotto and Bukowiecki, 2004), though leptin
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synthesis is dependent on the presence of glucose (Whitehead et al., 2001). This
effect is likely mediated by alterations in ATP (Mizuno et al., 1996; Mueller et al.,
1998). Insulin, within the physiological range, is sufficient to increase the
secretion of leptin, which is potentiated by the presence of amino acids such as
leucine (Cammisotto and Bukowiecki, 2002; Cammisotto et al., 2005; Lynch et
al., 2006). The post-prandial insulinemic response, and subsequent glucosedependent induction of ATP may explain the rise in adipocyte ATP following food
consumption (Thompson, 1996; Lynch et al., 2006). Glucocorticoids have been
shown to increase leptin release from adipose tissue, likely through alterations in
transcription of the protein (De Vos et al., 1995; Bradley and Cheatham, 1999).
Intriguingly, plasma fatty acids do not alter leptin production or secretion,
though lipolysis significantly attenuates leptin release (Cammisotto et al., 2003).
This is likely due to the role of catecholamines in lipolysis, as exercise, cold
exposure and adrenergic stimulation all inhibit leptin secretion, and are lipolytic
events associated with cyclic adenosine monophosphate signaling (Bramlett et
al., 1999; Rayner and Trayhurn, 2001; Gettys et al., 1996).
Hypoxia is also an important regulator of leptin secretion. Recently, a
hypoxia-response element (HRE) was discovered in the 5’ flanking region of the
human ob gene. It was also shown that leptin transcription was increased
following hypoxic exposure (Ambrosini et al., 2002). This increase in leptin
transcription was induced by HIF-1α/β binding to the HRE domain of the leptin
promoter (Ambrosini et al., 2002; Grosfeld et al., 2002).
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1.4.3 Leptin-related signaling pathways
Given that ObR is homologous to class I cytokine receptors, it is likely that
ObR activity will resemble that of other cytokines. Like other cytokine receptors,
ObRB

activates

JAK/STAT

pathways.

Upon

leptin

binding,

JAK2

autophosphorylates ObRB on specific tyrosine residues (Kloek et al., 2002;
White et al., 1997; Banks et al., 2000). When phosphorylated at Tyr 1138, ObRB
recruits signal transducer and activator of transcription 3 (STAT3), resulting in
phosphorylation of tyrosines on STAT3, resulting in homodimerization and
translocation of pSTAT3 to the nucleus (White et al., 1997; Banks et al., 2000;
Vaisse et al., 1996). Activated STAT3 acts as a transcription factor, and can
activate the transcriptional activity of genes associated with leptin signaling
including pro-opiomelanocortin (POMC), immediate early genes and suppressor
of cytokine signaling 3 (SOCS3) (Banks et al., 2000; Munzberg et al., 2003;
Bates et al., 2003). In addition to the activation of the JAK2/STAT3 pathways,
extracellular signal-regulated kinase 1/2 is also phosphorylated, though this may
be done directly by JAK2, instead of ObRB (Banks et al., 2000) SOCS3 acts as
an important negative feedback regulator of ObRB activation, inhibiting the
phosphorylation of JAK2, and thus ObRB and extracellular signal-related kinase
1/2 (ERK1/2). SOCS3 may accumulate following the chronic activation of ObRB
(Anubhuti and Arora, 2008). Protein tyrosine phosphatase 1B (PTP1B) is also an
important regulator of leptin receptor activity, and has been shown to inhibit JAK2
phosphorylation (Sahu, 2004; Bjorbaeck and Kahn, 2004; Zabolotny et al., 2002;
Kaszubska et al., 2002; Cook and Unger, 2002; Figure 1.1). Interestingly, some
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have shown that ObRA has the capacity to phosphorylate JAK2, though it is
unable to induce STAT3 activation (given that the crucial phospho-Tyr1138 is
absent in ObRA), suggestive of a potential activation of ERK1/2 by ObRA
(Bjorbaek et al., 1997; Ghilardi et al., 1996).

1.4.4 Leptin and energy balance

1.4.4.1

Food intake

Leptin has many sites of action throughout the body, though the brain is
the primary site for its major physiological effect to reduce food intake.
Hypothalamic sites of leptin action have drawn particular interest from the
scientific community, primary of which is the arcuate nucleus of the
hypothalamus (ARC). Within this region exist specific populations of neurons that
respond to leptin and contain ObRB. Neuronal cell bodies expressing POMC are
found within this region (Elias et al., 1998; Korner et al., 1999). POMC is cleaved
within these neurons by prohormone convertases to produce alternative
cleavage products that may regulate the autonomic and anorectic effects of
leptin, including the production of α-melanocyte stimulating hormone (α-MSH).
By acting through the
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Figure 1.1 Relevant leptin signaling pathways.
Graphical representation of signaling pathways associated with the binding of
leptin to the long-form (ObRB) of its receptor. Upon leptin binding, JAK2
becomes phosphorylated, resulting in the phosphorylation of ObRB at Tyr1138,
which causes the phosphorylation and homodimerization of STAT3. pSTAT3
translocates to the nucleus to regulate the transcription of genes and ultimately
their protein products including immediate early gene product Fra-1/2, POMC
and SOCS3. SOCS3 will cause inhibition of the activation of the leptin receptor
through inhibition of JAK2, which can also be regulated by PTP1B. ERK1/2 may
also be phosphorylated by activation of ObRB. Arrows indicate activation,
blunted lines indicate inhibition.
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melanocortin 3/4 receptor (Schwartz et al., 2000), this peptide is able to reduce
food intake. The Pomc gene is transcribed as a result of leptin, which can also
drive the production of other anorexigenic proteins such as cocaine- and
amphetamine-related transcript (CART) and corticotrophin releasing hormone
(CRH; Arora and Anubhuti, 2006). Specific sets of neurons within ARC express
POMC and CART together, are activated by leptin and induce satiety. Specific
deletion of ObRB from these neurons causes hyperphagia and obesity (Dhillon et
al., 2006; Balthasar et al., 2004). Leptin acting within the ARC also inhibits and
reduces the production of orexigenic factors, including neuropeptide Y (NPY) and
agouti-related peptide (AgRP) (Elmquist et al., 1998; Baskin et al., 1999;
Erickson et al., 1996).
In non-ARC regions of the brain, leptin acts through ObRB to mediate
reductions in homeostatic food intake. Some of these regions include the
ventromedial hypothalamus (Dhillon et al., 2006) and NTS (Hayes et al., 2009).
Hedonic food intake has also been shown to be reduced by leptin through the
dopaminergic mesolimbic system, namely the ventral tegmental area and
accumbens nucleus (Leinninger et al., 2011; Hommel et al., 2006; Fulton et al.,
2006).

1.4.4.2

Energy expenditure

Although leptin is primarily known for its effects on satiety and food intake,
leptin is best described as a hormone that causes a shift to negative body energy
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balance, as it is able to increase energy utilization. Leptin increases energy
expenditure through three major mechanisms: 1) increased metabolism (Dieguez
et al., 2011); 2) increased locomotion (Mendoza et al., 2011); and 3) increased
thermogenesis (Scarpace et al., 1998).

1.4.5 Leptin and sympathetic nervous activity
Leptin acts to augment the sympathetic nervous activity in part to
complete its negative feedback loop with energy balance. That is, release of
leptin due to energy intake will cause the activation of the sympathetic nervous
system, which will cause lipolysis in white adipose tissue, thermogenesis in
brown adipose tissue and elevated metabolic activity within the liver and skeletal
muscles. These physiological mechanisms will cause net energy expenditure.
Given that leptin acts in many homeostatic systems, the increase in
sympathetic tone by leptin also regulates many physiological functions. Bone
resorption, for example, has recently been shown to be regulated by the effect of
leptin on the sympathetic nervous system (Eleftriou et al., 2005). Likewise, leptin
is able to increase sympathetic nervous activity to the kidney and arterial
vasculature to cause an increase in blood pressure (Mark et al., 2009). These
effects may be caused by an inhibition of the baroreceptor reflex (Ciriello, 2013a,
b; Arnold et al., 2009). Injections of leptin into the ARC increases sympathetic
effects on the hindlimb and kidney, as well as the brown adipose tissue
(Rahmouni and Morgan, 2007; Montaro et al., 2005). The role of leptin in ARC on
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sympathetic outflow to both kidney and cardiovascular system appears to be
dependent on the melanocortin system (do Camo et al., 2011; Morgan et al.,
2008).

1.4.6 Leptin and neuroplasticity
Recent advances in the understanding of neuroplasticity in response to
hormones such as leptin have provided a novel mediator of homeostatic
functions such as food intake and sympathetic tone. Plastic alterations within
specific brain regions such as ARC (McNay et al., 2013) and NTS (Kline, 2008)
have demonstrated that these regions undergo dynamic regulation of function,
neural morphology and synaptogenesis.
The role leptin may play in neuroplasticity and synaptic plasticity has only
recently come to light. Leptin receptor has been localized to, not only somatodendritic regions of neurons, but also axonal processes and synapses (Shanley
et al., 2002). Animals deficient in leptin have electrophysiological deficits in longterm potentiation and long-term depression, both of which are important
functional outcomes of neuroplasticity (Li et al., 2002). In vivo, leptin induces
long-term potentiation (Wayner et al., 2004), which is dependent on N-methyl-Daspartate (NMDA) receptor function (Collingridge et al., 1983). Leptin augments
NMDA receptor signaling, increasing intracellular calcium influx (Shanley et al.,
2001; Harvey et al., 2005). Likewise, there is a crucial role for GluN2 subunit of
NMDA receptors in mediating the excitatory transmission of leptin (Moult and
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Harvey, 2011). It appears that in adult life, the neuroplastic effect of leptin on
synaptic strength is mediated by phosphoinositide-3 kinase, whereas at younger
points of development this effect is likely due to ERK1/2 (Moult and Harvey,
2011).
In addition to the functional neuroplasticity associated with leptin, there are
also significant morphological remodelling events that have been shown to occur,
which likely contribute to the overall ability of leptin to modulate neuroplasticity
(Maletic-Savatic et al., 1999). Leptin is able to increase the density and motility of
dendrites, and alter the actin cytoskeleton (O’Malley et al., 2005, 2007; Ning et
al., 2006). Both of these alterations are important for neurite outgrowth, as well
as synaptogenesis (Fiala et al., 1998; Munno and Syed, 2003). Such alterations
have been shown to be related to changes in growth-associated protein 43
(GAP-43) and the synaptic marker synaptophysin (Bottner et al., 2013;
Routtenberg, 1985). These morphological alterations are mirrored in activitydependent neuroplasticity (Fukazawa et al., 2003).
Neurotrophic factors such as brain-derived neurotrophic factor (BDNF)
and its receptor tropomyosin receptor kinase B (TrkB) have recently been
implicated in the satiety-inducing effects of leptin in both the hypothalamus and
NTS (Liao et al., 2012; Spaeth et al., 2013). It appears these neuroplastic
effectors exist downstream from the leptin receptor, and may be necessary for
leptin to exert its effect (Liao et al., 2012).
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1.4.7 Leptin resistance
When leptin was first discovered in 1994, it was believed the satietyinducing hormone would act to resolve positive body energy balance syndromes
like obesity. However, the finding of hyperleptinemia, as opposed to
hypoleptinemia, in obese subjects suggested otherwise. An increase in hormone
concentration with a reduction in its effect is suggestive of a resistance to that
hormone, as seen with insulin in type II diabetes mellitus (Friedman, 2010).
Application of leptin to obese mice have varying sensitivities to the hormone, with
the leptin-deficient ob/ob mouse being the most sensitive and the leptin-receptor
mutated db/db being the least sensitive (Halaas et al, 1997). This effect is
mirrored in humans, where obese leptin-deficient people are sensitive to leptin,
while most other forms of obesity are leptin-resistant. Primary leptin-deficiency in
human populations is extremely rare (Farooqi et al., 1999), but secondary leptindeficiency is slightly more common, arising from lipodystrophy and hypothalamic
amenorrhea. In all cases, administration of recombinant leptin was able to
resolve many resulting neuroendocrine, reproductive and metabolic issues
(Farooqi et al., 1999; Oral et al., 2002; Welt et al., 2004).
The mechanisms associated with leptin resistance are not completely
understood. As is found with insulin resistance, many changes in leptin signaling
and transport systems may accumulate to mediate the resistant state.
Hyperleptinemia associated with leptin resistance may play an important role as
both a cause and result of the pathophysiology, given that overexpression of
leptin within the brain induces leptin resistance, and blockade of leptin receptors
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in obese animals exaggerates diet-induced obesity (Scarpace and Zhang, 2007).
The resistance to leptin may be the result of decreased transport across the
blood-brain barrier (Katsin et al., 1999; Banks et al., 2002; Burguera et al., 2000;
Dube et al., 2000), and obese humans have a reduced cerebrospinal fluid-serum
ratio of leptin despite concomitant hyperleptinemia (Caro et al., 1996; Schwartz
et al., 1996).
A reduction in downstream signaling of leptin within ARC may also play an
important role in leptin resistance, either at the level of the receptor availability,
reduced post-receptor activities, or by augmented negative feedback at the
receptor (Friedman et al., 2010; Mark, 2013).
Despite this reduced leptin effect on satiety, thus causing positive energy
balance, it has been noted that the sympathetic effects of leptin are maintained
during leptin resistance (Rahmouni et al., 2002; Correira et al., 2002). This has
given rise to the concept of a selective leptin resistance in obesity, and has
recently garnered attention as a contributor to obesity-related hypertension (Kuo
et al., 2001). The selective nature of leptin resistance is poorly understood, but
may be the result of alternative signaling mechanisms in sympathetic-related
neurons and brain regions following leptin binding (Mark, 2013).
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1.5 HYPOTHESIS AND OBJECTIVES

1.5.1 Hypothesis
We hypothesize that IH in rats will lead to metabolic and hypertensive
cardiovascular phenotypes, which will be associated with alterations in brain
regions known to regulate body energy balance and the cardiovascular system.
This thesis will focus largely on manipulations of various hormones released in
response to IH, and how they may mediate or affect the phenotypes observed.

1.5.2 Objectives
The major objectives of this thesis are as follows:
1) characterize the body energy balance phenotype that may be associated
with both short- and long-term IH and its concomitant alterations in
hormonal release;

2) determine alterations in the ARC of animals exposed to short- and longterm IH that may be associated with body energy balance and the role
leptin signaling may play in mediating these effects;

3) measure cardiovascular alterations, including baroreceptor reflex function,
following short- and long-term IH, which may be associated with
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alterations in neuroplasticity within NTS, and the role leptin may play in the
short-term changes, and

4) determine the role of angiotensin II in modulating leptin release and
signaling in the carotid body following IH.
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2.

CHAPTER 2

2.1 CHAPTER SUMMARY
This study was done to investigate the effects of acute intermittent hypoxia (IH)
on metabolic factors associated with energy balance and body weight, and on
hypothalamic satiety-inducing pathways. Adult male Sprague-Dawley rats were
exposed to either 8h IH or normoxic control conditions. Food intake, locomotion
and body weights were examined after IH. Additionally, plasma levels of leptin,
adiponectin corticosterone, insulin and blood glucose were measured following
exposure to IH. Furthermore, adipose tissue was removed and analyzed for
leptin and adiponectin content. Finally, the hypothalamic arcuate nucleus (ARC)
was assessed for alterations in protein signaling associated with satiety. IH
reduced body weight, food intake and active cycle locomotion without altering
adipose tissue mass. Leptin protein content was reduced while adiponectin
content was elevated in adipose tissue after IH. Plasma concentration of leptin
was significantly increased while adiponectin decreased after IH. No changes
were found in plasma corticosterone, insulin and blood glucose. In ARC,
phosphorylation of signal transducer and activator of transcription-3 and proopiomelanocortin (POMC) expression were elevated. In addition, POMCexpressing neurons were activated as determined by immediate early gene FRA1/2 expression. Finally, ERK1/2 and its phosphorylation were reduced in
response to IH. These data suggest that IH induces significant alterations to body
energy balance through changes in the secretion of leptin which exert effects on
satiety-inducing pathways within the hypothalamus.
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2.2 INTRODUCTION
While white adipose tissue is the major storage site for triglycerides in the
body, this organ also appears to play a role in endocrine function, partly through
the production and release of a class of hormones known as adipokines.
Adipokines are used by the body to provide information regarding energy
balance, which in turn may influence thermogenic activity, food intake and
glucose homeostasis (Ahima and Osel, 2008).

Leptin, a 16 kDa hormone

produced by the ob gene (Halaas et al., 1995), is an adipokine that functions as a
satiety-inducing hormone. The primary site of secretion of leptin into the
bloodstream is the white adipose tissue, and this secretion generally occurs
directly in relationship to the white adipose tissue mass (Maffei et al., 1995).
However, the release of leptin into the circulation can be altered by a number of
different stimuli, including hypoxia (Reinke et al., 2011; Sherry et al., 2009) and
acute intermittent hypoxia (IH) (Messenger et al., 2012). Hypoxia elevates leptin
production and release from white adipose tissue in both in vitro (Grosfield et al.,
2002) and in vivo (Sherry et al., 2009). Similarly, acute IH has been shown to
increase the circulating levels of leptin (Messenger et al., 2012). Although the
functional role of this upregulation of the leptinergic system is unknown, it may be
involved in the regulation of the sympathetic nervous system activity (Mark et al.,
2009; Ciriello and Moreau, 2012), and this may be mediated partly through its
effects on hypothalamic neurons (Harlan et al., 2011). Leptin not only reduces
food intake largely by acting on pro-opiomelanocortin (POMC) neurons of the
arcuate nucleus (ARC; Hill et al., 2008), but these POMC neurons may also
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affect blood glucose levels (Berglund et al., 2012; Shi et al., 2008). Leptin binds
to POMC neurons through the long-form leptin receptor (Ob-Rb), resulting in the
homodimerization and phosphorylation of signal transducer and activator of
transcription-3 (STAT3; Calvino et al., 2012). Phosphorylated STAT3 (pSTAT3)
translocates to the nucleus of these neurons and alters gene transcription of
various targets including Pomc and immediate early genes (Bousquet et al.,
2000).
As adipose tissue is responsive to hypoxia, and that many factors
produced by adipose tissue are related to energy balance, this study was done to
determine whether acute 8 h IH altered the signaling of the adipose, resulting in
alterations in energy balance.
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2.3 METHODS AND MATERIAL
2.3.1 Animals
Adult, male Sprague-Dawley rats (320 – 400 g: n = 48) were purchased from
Charles River Canada and housed singly at a temperature of 22°C and 60%
relative humidity with access to food and water available ad libitum, except
during the acute 8 h IH or normoxic (Norm) exposure, in 12h light/dark cycle
conditions. Animals were handled in accordance with the guidelines set forth by
the Canadian Council on Animal Care and the Animal Use Committee at the
University of Western Ontario.

2.3.2 Groups
Animals were divided into different subsets: the first subset (n=7 per condition)
was used to determine physiological measures including food and water intake
and body weight changes; the second subset (n=7 per condition) was used for
active cycle locomotion studies; the third subset (n=7 per condition) was used for
immediate sacrifice following exposure, from which plasma samples (used for
hormone analysis), blood glucose, adipose tissue and brains were removed; the
final subset of animals (n=3 per condition) were perfused immediately following
exposure, and were used for immunohistochemistry and immunofluorescence.
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2.3.3 IH or Norm exposure
Animals were exposed to 8 h (0900-1700) of acute IH or Norm during their sleep
cycle, as previously described (Messenger et al., 2012). In brief, animals were
placed in a chamber (35 L volume) consisting of four separate animal tubes (10
cm diameter by 35 cm length) and a zero-pressure escape valve. For IH-exposed
animals, a computer that regulated solenoid valves altered the input of N 2 or
room air to generate IH and Norm conditions. The gases were pushed through
the system using fans and passed through a mixing chamber prior to entering the
animal tubes. Flows of N2 and room air were set to be equal, requiring the same
amount of time to drop from 21% to 6.5% O2, as required returning to 21% from
6.5% O2. Animals were exposed to 80s hypoxia (6.5% O2) followed by 120s
normoxia. The levels of O2 and CO2 were monitored by sensors on the chamber,
which relayed information back to the computer to ensure proper cycling.
Conditions within the chamber were isobaric (770 ± 11 mmHg) and eucapnic
(<0.1% CO2). Norm animals were exposed to identical chambers with only room
air input during cycling. No alterations in sleep duration or locomotion were
observed between IH or Norm animals during exposure.

2.3.4 Measures of body weight, food intake and water intake
Animals were weighed immediately before and after IH or Norm exposure. These
values were used to calculate body weight changes during the IH or Norm
exposure period and 24 h body weight change. Additionally, food and water
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intake measurements were recorded for the 16 h period immediately following
exposure

2.3.5 Locomotion assay
In a subset (n=7 per group), immediately following acute IH or Norm exposure,
animals were placed in home cages with ad libitum access to food and water.
Thirty minutes into the dark (active) cycle (1930h), animals were placed into large
cages (60 cm x 40 cm) with a floor 4x5 grid system in the dark (red light on).
Animals were acclimatized for 10 min to the testing cage. Over a five-minute
period, the number of crosses of a line by an animal was determined by two
independent, blinded observers to determine horizontal locomotion. At the same
time, vertical locomotion was determined by the number of rearing events. An
average value was then calculated from these two observers for both horizontal
and vertical locomotion. These animals were not used for determination of food
or water intake.

2.3.6 Blood glucose measurement
Immediately following exposure conscious animals had blood glucose measured
three times using an Accu-Check Aviva glucometer (Roche Diagnostics Canada;
Laval, QC) from a tail vein puncture.
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2.3.7 Plasma collection and enzyme immunoassays
Subgroups of rats exposed to IH (n=7) or Norm (n=7) were immediately
sacrificed under equithesin anaesthesia [0.3 ml/100 g b.w.; i.p. (2.88 mg/100 g
b.w. sodium pentobarbital; 12.79 mg/100 g b.w. chloral hydrate; 6.37 mg/100 g
b.w. MgSO4; 0.12 ml/100 g b.w. propylene glycol; 0.03 ml/100 g b.w. ethanol)]
immediately following exposure. Blood samples were collected by cardiac
puncture in the presence of 7% ethylenediaminetetraacetic acid at a volume of
10 µl/ml blood. This blood was immediately centrifuged at 10 000 RPM for 10 min
at 4 °C to isolate the aqueous plasma. This aqueous plasma phase was removed
and stored frozen at -80 °C until analyzed for hormone content. Plasma samples
were analyzed using enzyme immunoassays for rat leptin (sensitivity: 67.2 pg/ml;
Enzo Life Sciences; Farmingdale, NY), adiponectin (sensitivity: 0.12 ng/ml;
Phoenix Pharmaceuticals; Burlingame, CA), corticosterone (sensitivity: 26.99
pg/ml; Enzo Life Sciences; Farmingdale, NY) and insulin (sensitivity: 0.12 ng/ml;
Alpco Diagnostics; Salem, NH), according to manufacturer instructions. Enzyme
immunoassay plates were read on a SpectraMax M5 plate reader using SoftMax
Pro v.5 microplate analysis software (Molecular Devices; Sunnyvale, CA).

2.3.8 Tissue collection and preparation
Immediately after exposure to IH (n=7) or Norm (n=7), additional subgroups of
the animals were sacrificed under equithesin anaesthesia and the brain and
retroperitoneal fat pad were removed and frozen at -80 °C until analyzed. Brains
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were sectioned at 100 µm in a cryostat (Bright Instruments; Cambridgeshire, UK)
until ARC was identified using cytoarchitectural landmarks and a rat brain atlas
(Paxinos and Watson, 1986). Using a circular 1 mm (internal diameter)
micropunch tool, bilateral punches of ARC were made to a depth of 0.5 mm and
the frozen tissue was then homogenized in cold radioimmunoprecipitation assay
buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium deoxycholate,
1 mM NaF, 1 mM sodium orthovanadate, 25 mM β-glycerophosphate) with
protease inhibitor cocktail (Roche Applied Science; Laval, QC) by an electric
homogenizer (VWR International; Radnor, PA). Homogenates were then
sonicated over three passages for 15s each on ice (55%; Sonic Dimembrator
Model 150; Fisher Scientific). Samples were then rotated for 10 min at 4 °C and
centrifuged at 4°C for 20 min at 14 000 RPM. Adipose tissue samples were taken
while frozen and processed using the same procedure. Protein content of
homogenates was quantified using the Bio-Rad Dc protein assay kit (Bio-Rad
Laboratories; Hercules, CA). Protein samples were added to 25% LDS sample
buffer and 10% reducing buffer (Life Technologies; Burlington, ON) and water to
a standard protein concentration of 1.67 mg/ml.

2.3.9 Western blots
Electrophoresis was carried out using a 10% discontinuous polyacrylamide BisTris gel (Life Technologies; Burlington, ON), followed by standard protein
immunoblotting techniques. For each animal, 25 µg of protein of each sample
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was loaded. Electrophoresis was carried out at 200 V and terminated when the
dye front reached the bottom of the gel. Proteins were transferred to a
polyvinylidene fluoride membrane using a wet transfer method in the presence of
methanol and SDS (50 mM Tris, 40 mM glycine, 0.3% SDS, 20% methanol) and
wet transfer apparatus (Mini Trans-Blot Electrophoretic Transfer Cell; Bio- Rad
Laboratories; Hercules, CA) at 100 V for 2 h. After transfer, the membrane was
washed in Tris-buffered saline + Tween-20 (TBST; 20 mM Tris, 0.5 M NaCl,
0.1% Tween-20; pH 8.0) blocked for 1 h with 5% skim milk made in TBST buffer
at room temperature. The membrane was then incubated with primary antibodies
diluted in skim milk over night at 4 °C. The following day, the membrane was
washed with TBST before being incubated with horseradish peroxidaseconjugated secondary antibodies-specific to the appropriate host of the primary
antibody being analyzed, for 1 h at room temperature. For detection, the
membrane was washed with TBST, followed by distilled water and then detected
using a horseradish peroxidase substrate ECL chemiluminescence system
(Luminata Forte, EMD Millipore; Billerica, MA). Blots were visualized using a
VersaDoc imaging system (Bio-Rad Laboratories; Hercules, CA) and analyzed
using ImageLab v.3.0 (Bio-Rad Laboratories; Hercules, CA). All comparisons
presented were made within the same blot.
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2.3.10 Immunohistochemistry
Immediately following acute IH (n=3) or Norm (n=3) exposure, rats were deeply
anesthetized with equithesin and perfused transcardially with 200-300 ml 0.9%
physiological saline, followed by 450 ml of 4% paraformaldehyde in 0.1 M
phosphate-buffered saline (PBS; pH 7.4).

Brains were removed and placed

overnight in fixative at 4ºC. Brains were then gradually dehydrated through a
series of alcohols, and placed in xylene followed by paraffin wax. Serial,
transverse sections (6 µm) through the region of ARC were cut on a microtome,
mounted on double-gelatinized microscope slides and placed on a slide warmer.
Tissue sections were later de-paraffinized in xylene and rehydrated using graded
alcohol solutions. Sections were equilibrated using three 20 min washes of PBS
(pH 7.4), and then underwent an antigen-retrieval protocol using a citrate buffer
(10 mM sodium citrate, 0.05% Tween; pH 6.0) heated to 90-95ºC in a microwave
for 15 min (von Boguslawsky, 1994). Slides were rinsed and endogenous
peroxidase activity was inhibited by exposing the sections to a 1% hydrogen
peroxide solution for 10 min. Sections were washed in PBS and allowed to
incubate overnight at 22ºC in primary polyclonal rabbit anti-rat POMC antibody in
PBS/0.3% Triton-X 100 and 4% normal goat serum. The sections were rinsed in
PBS and exposed to goat anti-rabbit IgG for 1 h, followed by 75 min in ABC Elite
Kit reagent (Vector Laboratories; Burlingame, CA).

Following three rinses in

PBS, the sections were immersed for 5 min in a solution of 0.05% 3,3’diaminobenzidine containing 0.01% hydrogen peroxide, resulting in a redbrownish reaction product. The sections then underwent a similar protocol, but
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using an overnight incubation in primary polyclonal rabbit anti-rat FRA-1/2
antibody, after an avidin-biotin block (Vector Laboratories; Burlingame, CA).
FRA-1/2 was detected using a solution of 0.05% 3,3’-diaminobenzidine
containing 0.015% hydrogen peroxide and 0.05% nickel ammonium sulphate in
PBS, resulting in a dense, black reaction product. Sections were rinsed and
coverslipped. Some adjacent tissue sections were rehydrated, stained with
thionin and cover-slipped for identification of cytoarchitectonic boundaries.
Controls for immunoreactivity included forebrain brainstem sections processed
following the omission of the primary antibody or preadsorption of the primary
antibody with the appropriate antigen (Messenger et al., 2012). Under these
conditions no POMC or FRA-1/2 immunoreactivity was demonstrated.
Cells containing POMC- and FRA-1/2-like immunoreactivity were identified
on sections through the region of ARC using bright-field microscopy (Letiz
Diaplan), and digital images were obtained with a Nikon DS-Fil camera and NIS
Elements Basic Research 3.0 software (Nikon Canada, Mississauga, ON,
Canada). Cell counts of POMC-containing neurons co-expressing FRA-1/2-like
immunoreactivity were determined by two independent, blinded observers and
averaged to calculate a final value for each animal.

2.3.11 Immunofluorescence
Immunofluorescence was performed in a similar manner as described above for
immunohistochemistry, except paraffin-embedded sections through the region of
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ARC were exposed to specific antibodies for POMC and FRA-1/2 overnight,
exposed to either biotinylated secondary antibody, and then exposed to
streptavidin-linked Texas Red (1:100; GE Healthcare; Buckinghamshire, UK) or
Alexa-488-linked secondary antibodies.
Cells containing POMC- and FRA-1/2-like immunofluorescence were
identified throughout the region of ARC using a microscope fitted with various
filters to detect Texas Red and Alexa-488. Digital images were obtained with a
Nikon DS-Fi1 camera and NIS Elements Basic Research 3.0 Software
(Messenger et al., 2012).

2.3.12 Antibodies
For western blots the following antibodies were used: rabbit anti-β-actin-HRP
(1:50 000; A3854, Sigma-Aldrich; St. Louis MO), rabbit anti-GAPDH (1:2500; sc25778, Santa Cruz Biotechnology; Santa Cruz, CA), rabbit anti-leptin (1:1000; sc843, Santa Cruz Biotechnology; Santa Cruz, CA), chicken anti-ObRB (1:10 000;
CH14104, Neuromics; Edina, MN), rabbit anti-FRA-1/2 (1:2000; sc-605, Santa
Cruz Biotechnology; Santa Cruz, CA), rabbit anti-STAT3 (1:2000; #9132, Cell
Signaling; Boston, MA), rabbit anti-pSTAT3 (Tyr705) (1:1000; #9131, Cell
Signaling; Boston, MA), rabbit anti-ERK1/2 (1:2000; #9102, Cell Signaling;
Boston, MA), rabbit anti-pERK1/2 (Thr 202/Tyr204) (1:1000; #9101, Cell
Signaling; Boston, MA), rabbit anti-adiponectin (1:5000; AB3267P, Millipore;
Billerica, MA), rabbit anti-POMC (1:2000; RayBiotech; Norcross GA), donkey
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anti-rabbit IgG-HRP (1:10 000; 711-035-152, Jackson Immunoresearch; West
Grove, PA), donkey anti-chicken IgY-HRP (1:10 000; 703-035-155, Jackson
Immunoresearch;

West

Grove,

PA).

For

immunohistochemistry

and

immunofluorescence the following antibodies were used: rabbit anti-POMC (1:10
000; H-029-030, Phoenix Pharmaceuticals; Burlingame, CA), rabbit anti-FRA-1/2
(1:1000; sc-253, Santa Cruz Biotechnology; Santa Cruz, CA), goat anti-rabbit
IgG-biotin (1:500; BA-1000, Vector Laboratories; Burlingame, CA) goat antirabbit IgG-Alexa-488 (1:200; 711-545-152, Jackson Immunoresearch; West
Grove, PA).

2.3.13 Statistics and analysis
Differences between acute IH and Norm groups were determined by unpaired,
two-tailed Student t-test, and a p-value < 0.05 was taken to indicate statistical
significance. All values are expressed as mean ± standard error. All bar charts
were made using GraphPad Prism v.5 graphing software (GraphPad Software;
La Jolla, CA).
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2.4 RESULTS
2.4.1 Body weight, adipose tissue mass, food and fluid intake and
locomotion after acute IH
Animals in acute IH and Norm groups did not differ in starting body weight (365 ±
9 g and 366 ± 10 g, respectively). Animals immediately after exposure to acute 8
h IH had significantly (p < 0.01) greater body weight loss (-28 ± 2 g) compared to
those exposed to Norm conditions (-13 ± 1 g). However, these differences in
body weight change 24 h after the initiation of the exposure were reversed as
animals exposed to acute IH (-5 ± 3 g) were not different from animals that were
exposed to Norm conditions (1 ± 3 g). No changes were found in retroperitoneal
(IH, 4.6 ± 1.2 g; Norm, 5.0 ± 1.1 g) or epididymal (IH, 2.8 ± 0.7 g; Norm, 3.2 ± 0.9
g) adipose tissue mass (Fig 2.1).
Despite the overnight body weight regain, food intake was significantly
lower (p < 0.01) in acute IH animals (total food intake, 21.1 ± 2.1 g/16 h; food
intake normalized to body weight, 5.9 ± 0.5 g/100 g body weight/16 h) compared
to animals exposed to Norm conditions (total food intake, 35.4 ± 5.5 g/16 h; food
intake normalized to body weight, 9.4 ± 1.3 g/100 g body weight/16 h). Water
intake was not altered in response to acute IH exposure (total water intake, 42.6
± 3.5 ml/16 h; water intake normalized to body weight, 12.0 ± 0.8 ml/100 g body
weight/16 h) compared to Norm conditions (total water intake, 39.5 ± 7.0 ml/16 h;
water intake normalized to body weight, 10.5 ± 1.9 ml/100 g body weight/16h).
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Figure 2.1 Changes in body weight and fat mass following IH.
Acute IH causes a greater reduction in body weight compared to Norm
conditions, independent of alterations in adipose tissue mass. (a), line graph
indicating significant (p<0.01) body weight loss as a result of the IH compared to
Norm. This body weight loss is normalized 24h after the initiation of IH, and is not
different from Norm. Bar graphs showing (b) retroperitoneal and (c) epididymal
adipose tissue mass were not different following IH exposure compared to Norm
animals. Data shown are means ± SEM. *, p<0.05. n = 7-11 per group.
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Animals exposed to acute IH had significantly (p < 0.05) reduced
horizontal locomotion (IH, 88.5 ± 4.1 line crossings/5 min; Norm, 115 ± 9.7 line
crossings/5 min). In contrast, vertical locomotion (IH, 28.0 ± 2.6 rearings/5 min)
compared to Norm (32 ± 3.4 rearings/5 min) were not different. These data are
summarized in Figure 2.2.

2.4.2 Plasma leptin, adiponectin and leptin:adiponectin ratio are altered by
acute IH
Plasma leptin concentrations in animals exposed to acute IH (10.0 ± 1.3 ng/ml)
were significantly (p < 0.05) greater than in animals exposed to Norm conditions
(3.2 ± 1.3 ng/ml) immediately following exposure. Plasma adiponectin
concentration was significantly (p < 0.05) less in acute IH compared to Norm
exposure (2.2 ± 0.1 µg/ml and 2.6 ± 0.1 µg/ml, respectively). The ratio of the
concentration of leptin to adiponectin in the plasma of the IH group was
significantly (p < 0.01) higher than in the Norm group (0.0045 ± 0.0008 and
0.0012 ± 0.0003, respectively). Plasma corticosterone concentrations were not
changed by acute IH compared to Norm control (4.8 ± 1.2 ng/ml and 5.3 ± 1.1
ng/ml, respectively). Similarly, plasma insulin concentrations were unchanged in
the acute IH group compared to Norm conditions (6.4 ± 0.8 ng/ml and 7.2 ± 0.6
ng/ml, respectively). Furthermore, blood glucose levels immediately following
acute IH or Norm exposure were not different from each other (8.2 ± 1.0 mmol/L
and 7.9 ± 1.3 mmol/L, respectively). These data are summarized in Figure 2.3.

78

Figure 2.2 Changes in food intake and locomotion following IH.
Acute IH results in reduced food intake and locomotion compared to Norm
conditions. Bar graphs indicating overnight food intake (a), standard food intake
(b), water intake (c), standard water intake (d), horizontal locomotion measure
(e), and vertical locomotion measure (f) between IH and Norm animals. Data
shown are means ± SEM. *, p<0.05. n = 11 per group.
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Figure 2.3 Changes in plasma hormones in response to IH.
Plasma hormones are altered after acute IH. Bar graphs showing plasma levels
of leptin (a), adiponectin (b), leptin:adiponectin ratio of plasma concentrations (c),
corticosterone (d), insulin (e), and blood glucose (f) immediately after IH or Norm
exposure. Data shown are means ± SEM. *, p<0.05. n = 7 per group.
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2.4.3 Adipose tissue content of leptin and adiponectin protein is altered as
a result of acute IH exposure
As summarized in Figure 2.4, retroperitoneal adipose tissue displayed reduced (p
< 0.01) expression levels of leptin protein after acute IH exposure compared to
Norm animals (0.01 ± 0.01 and 0.28 ± 0.05, respectively). On the other hand, the
protein expression of adiponectin in this tissue was significantly (p < 0.05)
elevated between acute IH and Norm conditions (0.11 ± 0.02 and 0.05 ± 0.01,
respectively).

2.4.4 IH exposure alters signals associated with leptin signaling within ARC
Within ARC, acute IH exposure increased the expression of phosphorylation of
STAT3 protein approximately 8-fold (p < 0.001) over Norm (0.86 ± 0.05 and 0.11
± 0.05, respectively) without changing total STAT3 protein expression (0.32 ±
0.06 and 0.34 ± 0.05, respectively). A significant (p < 0.05) decrease in the total
amount of ERK1/2 protein expression was also detected in ARC of acute IH
exposed animals compared to Norm control (0.41 ± 0.08 and 0.56 ± 0.02,
respectively). In addition, the expression level of phosphorylation of ERK1/2
protein was reduced between IH and Norm conditions when compared to total
ERK1/2 (1.05 ± 0.09 and 1.41 ± 0.13, respectively) and compared to β-actin
(0.42 ± 0.07 and 0.79 ± 0.08, respectively). On the other hand, acute IH did not
alter SOCS3 protein expression in ARC, compared to Norm (0.45 ± 0.07 and
0.38 ± 0.08). Additionally, acute IH did not induce an alteration in the expression
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Figure 2.4 Adipose adipokine protein content following IH.
Adipose tissue protein content of leptin and adiponectin are altered by acute IH
exposure. Bar graphs and representative blots indicating a reduction in
retroperitoneal adipose tissue protein content of leptin (a) and an increase in
adiponectin (b) protein content relative to GAPDH protein loading control, after IH
compared to Norm. Data shown are means ± SEM. *, p<0.05. n = 7 per group.

84

85

of the Ob-Rb protein compared to Norm control (0.32 ± 0.03 and 0.41 ± 0.05,
respectively). These data are summarized in Figure 2.5.

2.4.5 Acute IH activates POMC-containing neurons and increases POMC
protein within ARC
Exposure of animals to acute IH increased the number of POMC-like
immunoreactive neurons that also expressed the immediate early gene product
FRA-1/2 compared to Norm animals (15.1 ± 2.2% and 2.3 ± 2.5%, respectively)
within ARC (Fig. 2.6). The expression of POMC protein within ARC was
significantly (p < 0.01) elevated in animals exposed to IH compared to Norm
(0.21 ± 0.07 and 0.08 ± 0.02, respectively; Fig. 2.6).
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Figure 2.5 ObR related intracellular pathways activated following IH
Acute IH activates specific long-form leptin receptor (Ob-Rb)-related intracellular
pathways in ARC. Bar charts and representative blots indicating relative protein
content of phosphorylated STAT3 (a), phosphorylated ERK1/2 (b), SOCS3 (c)
and Ob-Rb (d) within ARC of animals exposed to IH or Norm conditions. These
values are expressed as a ratio to total β-actin protein. Data shown are means ±
SEM. *, p<0.05. n=7 per group.
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Figure 2.6 ARC POMC-containing cell activation following IH.
Acute IH increases activation of POMC-containing cells and POMC protein
content in ARC. Photomicrographs of ARC indicating POMC-containing cells
(brown), which display FRA-1/2 (black), a marker of neuronal activation, in both
IH (a-b) and Norm conditions (c). Calibration marks represents 50 µm. (b) Highmagnification image of inset in (a). (d) Immunofluorescent image of ARC
following exposure to IH. Note that POMC immunoreactivity is shown with green
fluorescent marker and FRA 1/2 immunoreactivity with Texas red fluorescent
marker. In both (b) and (d) large open arrows indicate cells that contain both
POMC- and FRA-1/2-like immunoreactivities, while small open arrows show
example of Fra-1/2 only labelled cells and the small arrow shows examples of
POMC only labelled cells. (e), shows a bar chart summary of the proportion of
ARC POMC-containing cells that also express FRA-1/2-like immunoreactivity. (f),
bar chart and representative blots indicating the relative protein content of POMC
within ARC in IH and Norm animals. These values are expressed as a ratio to
total β-actin protein. Data shown are means ± SEM. *, p<0.05. n = 3 per group
for immunohistochemistry; n = 7 per group for western blot analysis.
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2.5 DISCUSSION
This study has demonstrated that acute IH results in significant alterations
in several variables associated with energy balance, adipokine release and
activation of hypothalamic satiety signals. IH reduced body weight, active cycle
food intake, and locomotion. These changes after IH were concomitant with a
rise in plasma leptin and a reduction in plasma adiponectin, while adipose tissue
had less leptin and more adiponectin protein expression after acute IH exposure.
In ARC, acute IH induced phosphorylation of STAT3, reduced total ERK1/2 and
phosphorylated ERK1/2, but did not significantly affect Ob-Rb or its negative
regulator, SOCS3. Acute IH also induced activation, as determined by immediate
early gene product FRA-1/2, of POMC-containing neurons of ARC and increased
the protein expression of POMC in ARC. Taken together these suggest that IH
induces significant alterations to body energy balance through changes in the
secretion of leptin which exerts effects on satiety-inducing pathways within the
hypothalamus.
The 8 h exposure to IH reduced body weight compared to Norm animals.
However, by the following morning (16 h after IH), body weight change was
found not to be different between the two groups. Unexpectedly, this body weight
re-gain occurred despite a reduction in overnight food intake. Although the
mechanism responsible for this re-gain in body weight is not clear, it is possible
that the reduction in active cycle locomotion in IH-exposed animals may have
contributed as a result of decreased energy expenditure. The regain of body
weight in acute IH-exposed animals may be the result of alterations in
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metabolism, as studies in rabbits have suggested that intermittent hypobaric
hypoxia may lower circulating levels of thyroid hormones (Sawhney and
Malhotra, 1990). Additionally, the reduction in food intake after acute IH was
likely associated with the increased plasma leptin concentration, which occurred
despite the lack of change in retroperitoneal or epididymal adipose tissue depot
mass. It is known that leptin is correlated with adipose tissue content (Maffei et
al., 1995). However, it has been reported that under certain pathophysiological
challenges this balance can be altered (Kim and Scarpace, 2003). In this study,
IH was a sufficient stimulus to elevate plasma leptin concentration and this may
have accounted for the overnight reduction in food intake observed in these
animals. Therefore, the actions and secretion of leptin appear to be independent
of body weight changes induced by IH, while appearing inherently associated
with IH. Taken together, these data can be interpreted to indicate that following
acute IH, leptin may induce a state of satiety. As previously suggested, this may
occur regardless of nutritional status (Levin et al., 1996; Rentsch et al., 1995).
This finding is in contrast with reduced plasma concentration of leptin in
individuals exposed to altitude-related hypoxia (Woolcott et al., 2002; Zaccaria et
al., 2004). However, our findings occur following IH, rather than continuous
hypoxia and under normobaric conditions, which may account for this difference.
Consistent with this suggestion, it has been reported that IH can increase
circulating leptin concentrations in mice (Li et al., 2005). It has been suggested
that some IH models can induce sleep deprivation (Gozal et al., 2001). Sleep
deprivation has been reported to reduce body weight and energy expenditure

92

(Vetrivelan et al., 2012), and a reduction (Vetrivelan et al., 2012) or no change
(Bodosi et al., 2004) in leptin levels, with no changes in food intake (Barf et al.,
2010; Vetrivelan et al., 2012). In humans, sleep deprivation has been shown to
increase hunger and reduce leptin levels (Brondel et al., 2010; Spiegel et al.,
2004). As well, corticosterone levels in the acute IH-exposed rats was not
significantly different from Norm-exposed animals, if IH induced sleep deprivation
in these animals, it would be expected that corticosterone levels would higher
than controls (Tartar et al., 2009). Taken together, these data would suggest that
it was unlikely that sleep deprivation played a significant role in the leptin-feeding
responses observed in this study during acute IH.
Adipose tissue leptin content was found to be less in acute IH conditions.
This, coupled with the finding of elevated plasma leptin concentrations, suggests
an increase in the secretion of the adipokine by adipose tissue. Adipocytes have
been demonstrated to increase their secretion of leptin in response to hypoxia
(Famulla et al., 2012), and IH caused a sustained hypoxia in adipose tissue
(Reinke et al., 2011). Taken together, these findings suggest that adipose tissue
hypoxia resulting after acute IH in this study may have increased the release of
leptin from adipocytes. Conversely, adiponectin had a lower circulating level,
though an increased amount of the protein was found within adipocytes. This is
consistent with previous studies showing that hypoxia causes a reduction in
adipocyte secretion of the adipokine (Famulla et al., 2012). The changes in
circulating levels of adipokines as seen in this study, induces a higher
leptin:adiponectin ratio, perhaps as a result of altered adipocyte secretion as a
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result of IH. An increase in leptin:adiponectin ratio is a commonly used measure
associated with cardiometabolic disease (Satoh et al., 2004; Kotani et al., 2005).
The alterations observed in circulating adipokine concentrations, as seen during
IH in this study, are consistent with those found in individuals suffering from
obesity (Dagogo-Jack et al., 1996) and obstructive sleep apnea (Hargens et al.,
2013), of which IH is a major component.
Leptin action in ARC reduces food intake through activation of intracellular
signaling pathways associated with Ob-Rb (Peters et al., 2007; Scarpace et al.,
2007). The primary pathway associated with leptin’s satiety-inducing effects is
the phosphorylation of STAT3 in the rat (Ladyman and Grattan, 2004).
Homodimerization of pSTAT3 results in translocation of the transcription factor to
the nucleus of the affected cell. This induces transcription of several genes, such
as Pomc and immediate early genes, including Fra-1 (Bousquet et al., 2000). Our
results show that after acute IH, POMC protein content within ARC increases.
This finding is supported by the observations of increased Pomc mRNA in
response to leptin (Mizuno et al., 1998). The effect of leptin on specific neurons
within ARC is thought to be dependent on the phenotype of the neurons within
this region. Leptin has been shown to increase the firing rate of POMCcontaining neurons (Cowley et al., 2001; Wang et al., 2008), while inhibiting the
activity of neurons expressing neuropeptide Y (van den Top et al., 2004; Wang et
al., 2008). Increased POMC in the hypothalamus induces hypophagia (Zhang et
al., 2011), and we have found that acute IH induces both an increase in ARC
POMC, as well as hypophagia. Our findings show that the IH leads to activation
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of POMC-containing neurons within this region as it was found that a larger
number of POMC neurons in ARC expressed the immediate early gene product
FRA-1/2. The finding of increased FRA-1/2 expression in cells has been used to
indicate alterations in neuronal activity, including depolarization under a variety of
conditions, including IH (Messenger et al., 2012). These findings are further
supported by the observation of transcriptional upregulation of satiety genes
within the hypothalamus following chronic IH (Volgin and Kubin, 2006).
In summary, acute IH results in reductions in body weight, food intake and
locomotion, and can alter the release of adipokines that regulate food intake from
adipose tissue. Intracellular signaling pathways that are normally associated with
satiety signaling were elevated in response to IH and this likely lead to the
increased activity of POMC-containing neurons within ARC. These findings
suggest that acute IH may result in altered body energy balance possibly through
activation of hypothalamic pathways.
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CHAPTER 3
ACUTE INTERMITTENT HYPOXIA DOES NOT ALTER ENERGY
BALANCE IN THE LEPTIN-DEFICIENT KILO RAT

A version of this chapter has been submitted for publication to Brain Research
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3.

CHAPTER 3

3.1 CHAPTER SUMMARY
Intermittent hypoxia (IH) is a major pathophysiological consequence of
obstructive sleep apnea. Recently it has been described that acute IH results in
complex alterations in body energy balance, induced leptin secretion and
concomitant alterations in feeding pathways within the hypothalamus. To
determine the role of leptin on these changes, leptin-deficient KILO rats were
exposed to IH or normoxic control conditions. Body weights, consumatory and
locomotor behaviours and hypothalamic alterations were assessed immediately
following exposures. IH failed to alter measures of body weight, fat pad mass,
food intake, locomotor activity, and the plasma concentration of angiotensin II.
Plasma leptin concentration was undetectable by enzyme immunoassay. Within
the arcuate nucleus of the hypothalamus, no changes were observed in
phosphorylated signal transducer and activator of transcription 3, proopiomelanocortin, long- or short-form leptin receptor, suppressor of cytokine
signaling 3, nor within phosphorylated extracellular signal-regulated kinase ½.
This study suggests that leptin plays an essential role in mediating the alterations
observed in body energy balance and hypothalamic activity following IH
compared to normoxic controls. Whether this effect is due to a lack of leptin
directly acting in the hypothalamus, failure to initiate the release of a secondary
factor, or altered chemoreceptor reflex sensitivity is not known.
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3.2 INTRODUCTION
Intermittent hypoxia (IH) is a major pathophysiological consequence of
obstructive sleep apnea, a condition during which there is the episodic closures
of the airway during sleep. A substantial reduction in pulmonary oxygen tension
is observed during IH resulting in hypoxemia (Dempsey et al., 2010; Simon and
Collop, 2012). As a result of this whole-body hypoxic insult, several physiological
systems are altered, including the cardiovascular (Levy et al., 2012; Freet et al.,
2013) and respiratory (Debevec and Mekjavic, 2012; Dempsey et al., 2012)
systems. It has been shown that alterations to the endocrine system are also
induced by both sustained hypoxia and IH (Dempsey et al., 2010; Moreau and
Ciriello, 2013; Reinke et al., 2011; Tschop et al., 2000). In particular, studies in
both humans and experimental animal models have shown plasma leptin
concentration to be elevated following IH (Messenger et al., 2012; Moreau and
Ciriello, 2013; Tschop et al., 2000), and this is often associated with alterations in
body energy balance (Moreau and Ciriello, 2013; Tschop et al., 1998). Leptin is
an important modulator of satiety. Released by white adipocytes, the 16-kDa
protein hormone signals arcuate nucleus of the hypothalamus (ARC; Satoh et al.,
1997). Within ARC, leptin increases the activity of pro-opiomelanocortin (POMC)
neurons, while inhibiting neurons expressing neuropeptide Y (Elmquist et al.,
1998). When activated, POMC neurons mediate satiation and anorexigenic
responses (Balthasar et al., 2004; Dhillon et al., 2006).
Recently, we have shown that acute IH can alter central mechanisms important
for the regulation of body energy balance (Moreau and Ciriello, 2013). This study

104

demonstrated that leptin, a satiety-inducing hormone, released into the
circulation occurred after acute IH. Subsequently, a reduction in food intake was
observed, despite an initial loss of body weight. These effects were observed
concomitant to the induction of the anorexigenic factors phosphorylated signal
transducer and activator of transcription 3 (pSTAT3), pro-opiomelanocortin
(POMC), and a reduction of phosphorylated extracellular signal-regulated kinase
1/2 (pERK1/2) within arcuate nucleus of the hypothalamus (Moreau and Ciriello,
2013). Whether leptin played a direct role in these observed effects following IH
is not known.
Therefore, this study was done to determine whether the effects of acute
IH on body energy balance and associated hypothalamic feeding pathways are
initiated as a result of the release of leptin following IH. To determine this, leptindeficient rats were exposed to IH or normoxic conditions, and assessed for
various measures of body weight, behaviors and plasma hormones associated
with body energy balance and compared to wild type Sprague Dawley rats (WT).
ARC was also removed to determine potential alterations in signaling in
hypothalamic feeding pathways.
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3.3 METHODS AND MATERIAL
3.3.1 Animals and study design
Adult male, Sprague-Dawley rats (300-350 g; n=12) were obtained from Charles
River Canada (Sherbrooke, QC). Adult male, homozygous, leptin-deficient KILO
rats (250-400 g; n=8; SD-Leptm1sage) were obtained from Sigma Advanced
Genetic Engineering Laboratories (TGRA3780; Vaira et al., 2012). Rats were
individually housed at a temperature of 22°C and 60% relative humidity with
access to food and water available ad libitum, except during the 8 h IH or
normoxic exposure, in 12h light/dark cycle conditions. Animals were handled in
accordance with the guidelines set forth by the Canadian Council on Animal Care
and the Animal Use Committee at the University of Western Ontario.

3.3.2 IH and normoxic exposures
Animals were assigned to either IH or normoxia group for exposure. Following
these exposures, physiological measures of body weight and consumatory
behaviours were measured. Animals were exposed to IH and normoxic
conditions as previously described (Messenger and Ciriello, 2013; Messenger et
al., 2012, 2013; Moreau and Ciriello, 2013). In brief, animals were placed in
chambers consisting of four tubes (10 cm diameter by 35 cm length) and a zeropressure escape valve. For IH-exposed animals, a computer that regulated
solenoid valves altered the input of N2 or room air to generate IH conditions.

106

Animals were exposed to 80s hypoxia (6.5% O2) followed by 120s normoxia. The
levels of O2 and CO2 were monitored by sensors on the chamber, which relayed
information back to the computer to ensure proper cycling. Conditions within the
chamber were isobaric (770 ± 11 mmHg) and eucapnic (<0.1% CO 2) (Moreau
and Ciriello, 2013). Normoxic animals were exposed to only the air input.

3.3.3 Measures of body weight, food intake and water intake
Animals were weighed immediately before and after IH or normoxic exposure.
These values were used to calculate body weight changes during the exposure
period, overnight body weight gain and 24 h body weight change. Furthermore,
food and water intake were measured over the remaining 16 h following IH or
normoxic exposure (Moreau and Ciriello, 2013).

3.3.4 Locomotion assay
Immediately following IH or normoxic exposure (1700 h), animals were placed in
home cages with access to food and water ad libitum. Animals were placed into
large cages (60 cm x 40 cm) with a floor 4x5 grid system in the dark (red light on)
30 min into the dark (active) cycle (1930 h). Over a 5 min period, the number of
crosses of a line by an animal was determined by two independent, blinded
observers

to

determine

horizontal

locomotion.

Simultaneously,

vertical

locomotion was determined by the number of rearing events. An average value
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was then calculated from these two observers for both horizontal and vertical
locomotion (Moreau and Ciriello, 2013).

3.3.5 Plasma collection and enzyme immunoassays
As previously described (Moreau and Ciriello, 2013), immediately after the crossover exposure, rats were immediately sacrificed under equithesin anaesthesia
(0.3 ml/100 g b.w.; i.p.). Blood samples were collected by cardiac puncture in the
presence of 7% ethylenediaminetetraacetic acid at a volume of 10 µl/ml blood
and immediately centrifuged at 10 000 RPM for 10 min at 4 °C to isolate the
aqueous plasma. This aqueous plasma phase was removed and analyzed using
enzyme immunoassays for rat leptin (Enzo Life Sciences; Farmingdale, NY) and
angiotensin II (Phoenix Pharmaceuticals; Burlingame, CA) according to
manufacturer instructions. Enzyme immunoassay plates were read on a
SpectraMax M5 plate reader using SoftMax Pro v.5 microplate analysis software
(Molecular Devices; Sunnyvale, CA).

3.3.6 Tissue collection and preparation
Immediately after exposure to IH or normoxia, rats were sacrificed under
equithesin anesthesia (0.3 ml/100 g b.w.; Moreau and Ciriello, 2013) and the
brains removed and frozen at -80°C until analyzed. Using a circular micropunch
tool (1 mm internal diameter), 500 µm punches of ARC were taken and
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immediately homogenized in cold radioimmunoprecipitation assay buffer (50 mM
Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium deoxycholate, 1 mM NaF, 1
mM sodium orthovanadate, 25 mM β-glycerophosphate) with protease inhibitor
cocktail (Roche Applied Science; Laval, QC) by an electric homogenizer (VWR
International; Radnor, PA). Homogenates were sonicated over three passages
for 15s each on ice (55%; Sonic Dimembrator Model 150; Fisher Scientific).
Samples were then rotated for 10 min at 4 °C and centrifuged at 4°C for 20 min
at 14000 RPM. Protein content of homogenates was quantified using the BioRad Dc protein assay kit (Bio-Rad Laboratories; Hercules, CA). Protein samples
were added to 25% sample buffer and 10% reducing buffer (Life Technologies;
Burlington, ON) and water to a standard protein concentration of 1.67 mg/ml
(Moreau and Ciriello, 2013; Messenger and Ciriello, 2013).

3.3.7 Western blots
As previously described (Messenger et al., 2012; Moreau and Ciriello, 2013),
electrophoresis was carried out using a 10% discontinuous polyacrylamide BisTris gel (Life Technologies; Burlington, ON), followed by standard protein
immunoblotting techniques. From each animal, 25 µg of protein of each sample
was loaded. Electrophoresis was carried out at 200 V and terminated when the
dye front reached the bottom of the gel. Proteins were transferred to a
polyvinylidene fluoride membrane using a wet transfer method in the presence of
methanol and SDS (50 mM Tris, 40 mM glycine, 0.3% SDS, 20% methanol) and
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wet transfer apparatus (Mini Trans-Blot Electrophoretic Transfer Cell; Bio- Rad
Laboratories; Hercules, CA) at 100 V for 2 h. After transfer, the membrane was
washed in Tris-buffered saline + Tween-20 (TBST; 20 mM Tris-HCl, 0.5 M NaCl,
0.1% Tween-20; pH 8.0) blocked for 1 h with 5% skim milk made in TBST buffer
at room temperature. The membrane was then incubated with primary antibodies
diluted in skim milk over night at 4 °C. The following day, the membrane was
washed with TBST before being incubated with horseradish peroxidaseconjugated secondary antibodies-specific to the appropriate host of the primary
antibody being analyzed, for 1 h at room temperature. For detection, the
membrane was washed with TBST, followed by distilled water and then stained
using a horseradish peroxidase substrate enhanced chemiluminescence system
(Luminata Forte, EMD Millipore; Billerica, MA). Blots were visualized using a
VersaDoc imaging system (Bio-Rad Laboratories; Hercules, CA) and analyzed
using ImageLab v.3.0 (Bio-Rad Laboratories; Hercules, CA).

3.3.8 Antibodies
The following antibodies were used for western blots: rabbit anti-β-actin-HRP
(1:50000; A3854, Sigma-Aldrich; St. Louis MO), chicken anti-ObRB (1:5000;
CH14104, Neuromics; Edina, MN), rabbit anti-STAT3 (1:2000; #9132, Cell
Signaling; Boston, MA), rabbit anti-pSTAT3 (Tyr705) (1:1000; #9131, Cell
Signaling; Boston, MA), rabbit anti-POMC (1:2000; RB-08-0013, RayBiotech;
Norcross GA), donkey anti-rabbit IgG-HRP (1:10000; 711-035-152, Jackson
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Immunoresearch; West Grove, PA), donkey anti-chicken IgY-HRP (1:10000; 703035-155, Jackson Immunoresearch; West Grove, PA).

3.3.9 Statistics and analysis
For physiological measures and circulating factors, differences between IH and
normoxic groups of WT and KILO rats were determined by two-way ANOVA,
followed by a Bonferroni post-hoc analysis. Differences between IH and normoxic
exposures were determined within WT and KILO groups for western blots using
an unpaired, two-tailed Student t-test, and a p-value < 0.05 was taken to indicate
statistical significance. All values were expressed as mean ± standard error. All
bar charts were made using GraphPad Prism v.5 graphing software (GraphPad
Software; La Jolla, CA).
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3.4 RESULTS
3.4.1 Food and water intake
In the 16 h following exposure, WT normoxic animals consumed 30.2 ± 2.3 g of
food, or 8.6 ± 1.3 g/100 g b.w. whereas WT IH exposed animals consumed less
food (21.1 ± 2.1 g, or 5.9 ± 0.5 g of food/100 g b.w.). KILO rats exposed to
normoxia consumed 29.9 ± 1.8 g of food, or 9.4 ± 1.6 g /100 g b.w., while IH
exposed KILO rats consumed 31.2 ± 2.4 g of food, or 9.6 ± 1.5 g/100 g b.w. For
both absolute (Fig 3.1a) and standardized food intakes (Fig 3.1b), WT IH
consumed significantly less food than WT normoxic. In the KILO rats, this effect
was not observed (Fig. 3.1a-b). There was no significant difference between WT
normoxic exposed rats and normoxic and IH exposed KILO rats, though these
relationships were complex as both had an interaction. There were no significant
differences between any groups for water consumption.

3.4.2 Food conversion efficiency
WT animals exposed to normoxia had a food conversion efficiency of 0.46 ± 0.13
g b.w. gain/g food consumed, whereas IH exposed WT rats had food conversion
efficiency of 1.11 ± 0.15 g b.w. gain/g food consumed. Normoxic KILO rats had a
food conversion efficiency of 1.00 ± 0.07 g b.w. gain/g food consumed, while
KILO rats exposed to IH were 1.05 ± 0.05 g b.w. gain/g food consumed. In WT
animals, IH animals had higher food conversion efficiency, while this difference
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Figure 3.1 Energy intake and utilization in KILO rats following IH.
Food intake and food conversion efficiency are altered in WT, but not KILO rats
exposed to IH. Bar charts indicate total (a) and standardized (b) food intake over
16h immediately following exposure to IH or normoxia in WT and KILO rats.
Calculated food conversion efficiency over the same period (c) is also shown.
NS: non-significant; * p < 0.05 as determined by two-way ANOVA followed by a
Bonferroni post-hoc analysis. Data are presented as mean ± standard error. n=6
for WT groups, n=4 for KILO groups.
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was not observed in leptin-deficient KILO rats. KILO rats did not have
significantly different food

conversion efficiency from WT,

though

the

comparisons were complex with a significant interaction being present (Fig 3.1c).

3.4.3 Body weight changes
Prior to exposure, there were no significant differences (p = 0.99) in body weights
between KILO IH (380 ± 63 g) and KILO normoxic (380 ± 75 g), and WT IH (365
± 10 g) and WT normoxic (364 ± 9 g) groups. During the exposure to either IH or
normoxia, WT IH exposed animals lost approximately 8% of their body weight (29.3 ± 1.9 g) and WT normoxic animals lost approximately 3% (-13.8 ± 1.2 g) of
their body weight. KILO IH animals lost 7% of their body weight (-28.4 ± 1.5 g),
and normoxic KILO animals lost about 6% of their body weight (-24.5 ± 2.2 g).
Body weight lost during exposure was significantly higher in WT IH animals
compared to normoxic controls, though this effect was not observed in KILO
animals. There was no significant difference between the body weight lost during
exposure between WT and KILO animals, though a significant interaction was
found (Fig 3.2a). In the 16 h immediately following the exposures, WT normoxic
animals had a regained body weight change of 14.1 ± 3.2 g while IH animals
regained 23.6 ± 4.5 g. KILO normoxic animals regained 29.9 ± 2.0 g overnight
while the KILO IH animals regained 32.6 ± 2.3 g in the same time period. WT
animals exposed to IH gained more body weight overnight, while leptin-deficient
KILO rats did not differ in their response to IH compared to normoxia. KILO
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animals gained significantly more body weight overnight than WT animals (Fig
3.2b). The overall change in body weight for the 24h following the initiation of
exposure was 0.4 ± 3.7 g for WT normoxic, -5.6 ± 2.6 g for WT IH exposed
animals, 5.4 ± 3.2 g for normoxic KILO and 4.2 ± 3.0 g for IH KILO animals.
There were no significant differences between IH and normoxic exposed animals
of either strain though KILO animals gained significantly more body weight
compared to WT animals over the same time period (Fig 3.2c).

3.4.4 Fat pad mass
The mass of the epididymal fat pad was 3.1 ± 0.8 g in WT normoxic animals, 2.8
± 0.6 g in WT IH animals, 15.2 ± 2.6 g in KILO normoxic animals, and 13.2 ± 2.8
g in KILO IH animals. No differences were observed between IH and normoxia
exposures in either WT or KILO animals. However, KILO rats did have
significantly higher fat pad mass compared to WT animals (Fig 3.3a). The
retroperitoneal fat pad mass of WT normoxic animals was 5.2 ± 1.2 g, 4.8 ± 1.2 g
in WT IH animals, 24.4 ± 2.9 g in normoxic KILO rats, and 22.2 ± 3.1 g in KILO
IH animals. There were no statistical differences between normoxia and IH
exposed animals of either genetic background, although KILO rats had
significantly larger retroperitoneal fat pads (Fig 3.3b).
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Figure 3.2 Body weight in KILO rats exposed to IH.
Body weight is significantly altered following IH in WT, but not KILO rats. Bar
charts indicating body weight change during exposure (a), overnight body weight
gain (b), and overall body weight change 24h from baseline (c) in WT or KILO
animals exposed to normoxia or IH. NS: non-significant; * p < 0.05 as determined
by two-way ANOVA followed by a Bonferroni post-hoc analysis. Data are
presented as mean ± standard error. n=6 for WT groups, n=4 for KILO groups.
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3.4.5 Locomotion
Horizontal locomotor activity in normoxic WT animals was 112 ± 9 line
crossings/5 min and in IH WT animals 87 ± 3 line crossings/5 min. In the KILO
rats exposed to normoxia, animals had horizontal locomotion of 93 ± 7 line
crossings/5 min while the IH KILO rats had 87 ± 8 line crossings/5 min. WT
animals exposed to IH had significantly less horizontal locomotor activity. This
effect of IH was not found in KILO animals (Fig. 3.3c). There were no significant
differences between WT and KILO animals, though an interaction was observed
(Fig 3.3c).
Vertical locomotor activity was measured in normoxic WT animals to be 31
± 3 rearings/5 min, 28 ± 4 rearings/5 min in IH WT animals, 26 ± 4 rearings/5 min
in normoxic KILO animals and 23 ± 4 rearings/5 min in IH KILO animals. There
were no significant differences between or among the groups for vertical
locomotor activity (Fig 3.3d).

3.4.6 Plasma leptin concentration
WT rats exposed to normoxia had a circulating leptin level of 3.8 ± 1.0 ng/ml,
while WT rats had significantly elevated plasma leptin concentrations of 11.1 ±
1.3 ng/ml following IH exposure. KILO rats exposed to normoxia had leptin
concentration of 0.2 ± 0.1 ng/ml and IH exposed KILO rats had a similar plasma
level (0.2 ± 0.1 ng/ml). KILO animals had a significantly lower concentration of
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Figure 3.3 Fat pad mass and locomotion in KILO rats following IH.
Fat pad mass and locomotion in WT and KILO animals exposed to either
normoxia or IH. Bar charts indicating epididymal (a) and retroperitoneal (b) fat
pad mass in either WT or KILO animals following either normoxia or IH.
Horizontal (c) and vertical (d) locomotor activities in in WT and KILO animals
exposed to either normoxia or IH are also displayed. NS: non-significant; * p <
0.05 as determined by two-way ANOVA followed by a Bonferroni post-hoc
analysis. Data are presented as mean ± standard error. n=6 for WT groups, n=4
for KILO groups.
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leptin than WT animals, regardless of exposure, and there was an interaction
between both exposure and genetic background of the animals (Fig 3.4a).

3.4.7 Plasma angiotensin II concentration
WT normoxic animals had an angiotensin II plasma concentration of 0.65 ± 0.20
ng/ml. WT IH animals had a greater than 2 fold increase in circulating level of
angiotensin II (1.55 ± 0.17 ng/ml). KILO rats exposed to normoxia had a
circulating angiotensin II concentration of 0.91 ± 0.10 ng/ml. Similarly, KILO rats
exposed to IH had a circulating plasma angiotensin II concentration of 0.87 ±
0.10 ng/ml (Fig 3.4b).

3.4.8 ARC leptin signaling molecules
Within ARC, the amount of ObRB protein was not different between normoxic
and IH exposed animals for either WT (p = 0.65; Fig 3.5a) or KILO animals (p =
0.90; Fig 3.5b). The amount of β-actin protein was not different between
normoxia exposed and IH exposed WT (p = 0.88) or KILO animals (p = 0.68).
IH WT animals had significantly more (p = 0.0031) pSTAT3 compared to
normoxic WT animals (0.78 ± 0.03 A.U. vs. 0.12 ± 0.02 A.U., respectively; Fig
3.5c). This effect was not observed within the ARC of KILO animals (p = 0.72)
exposed to normoxia (0.0056 ± 0.0007 A.U.) or IH (0.0060 ± 0.0008 A.U.; Fig
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Figure 3.4 Plasma hormone concentrations in KILO rats exposed to IH.
Plasma concentration of leptin and angiotensin II in WT and KILO animals in
response to either IH or normoxia. Bar charts indicate the plasma concentration
of leptin (a) and angiotensin II (b) in WT and KILO animals exposed to either IH
or normoxia. NS: non-significant; * p < 0.05 as determined by two-way ANOVA
followed by a Bonferroni post-hoc analysis. Data are presented as mean ±
standard error. n=6 for WT groups, n=4 for KILO groups.
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3.5d). The total amount of STAT3 protein was not different for either WT (p =
0.84) or KILO (p = 0.70) animals.
POMC protein levels were significantly higher (p = 0.022) in ARC of WT
animals exposed to IH (1.10 ± 0.31 A.U.) compared to normoxia (0.51 ± 0.15
A.U.; Fig 3.5e). No significant difference (p = 0.43) was observed in POMC
protein levels within ARC of KILO rats exposed to normoxia (0.034 ± 0.0043
A.U.) or IH (0.029 ± 0.003 A.U.; Fig 3.5f).
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Figure 3.5 Leptin signaling molecules in ARC of KILO rats exposed to IH.
Representative blots and bar graphs depicting important leptin signaling
molecules in ARC of WT and KILO rats. ObRB/β-actin within the ARC of WT (a)
and KILO rats (b). Note that the amount of ObRB to β-actin protein within the
ARC is not changed in WT or the KILO rat. (c-d), representative blots and bar
graphs depicting pSTAT3/STAT3 within ARC of WT (c) and KILO rats (d). Note
that the amount of pSTAT3 to total STAT3 protein within the ARC is elevated in
WT, but not the KILO rat. (e-f), representative blots and bar graphs depicting
POMC/β-actin within ARC of WT (e) and KILO rats (f). Note that the amount of
POMC to β-actin protein within the ARC is elevated in WT, but not the KILO rat.
*, p < 0.05 as determined by unpaired, two-tailed t-test. Data are presented as
mean ± standard error. n=6 for WT groups, n=4 for KILO groups.
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3.5 DISCUSSION
This study has shown that the effects of IH previously described (Moreau
and Ciriello, 2013) on body energy balance, hypothalamic signaling, and
circulating hormones are mediated by the leptin released in responses to IH as
the effects were not present in the leptin-deficient KILO rat. This is based on the
findings that IH in WT animals reduced body weight during exposure, and
increases overnight regain of the body weight. This effect is concomitant with a
reduction in food intake and food conversion efficiency, effects not observed in
the KILO rat. Additionally, elevated circulating angiotensin II and leptin are
observed following IH exposure in WT animals, but these effects were not
observed in KILO animals, suggesting that the absence of leptin in response to
IH in KILO rats is important in the release of angiotensin II into the circulation in
response to IH. Finally, in ARC, activation of downstream pSTAT3 and increased
POMC were found following IH in WT animals. However, these differences are
not observed in ARC of the leptin-deficient KILO animal. Taken together, these
findings suggest that leptin released into the circulation is essentially for body
energy balance and hypothalamic signaling in response to IH.
In an earlier study, significant reduction in body weight during 8h IH and a
subsequent significant increase in body weight regain in the 16 h immediately
following exposure has been described (Moreau and Ciriello 2013). As a result,
the 24 h body weight change was not different between IH and normoxic
exposed animals. As previously argued (Moreau and Ciriello, 2013), the loss of
body weight due to exposure of IH is likely not due to a reduction in specific
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adipose depot tissue mass, although it may be a cumulative effect from all
sources of adipose tissue. Following chronic IH, a reduction in adipose tissue
mass and body weight has also been observed (Martinez et al., 2008). Given that
leptin deficient animals exposed to IH failed to lose more body weight during 8h
IH suggests that the mechanisms resulting in weight loss during IH are
dependent on the presence of leptin released into the circulation during IH
(Messenger et al., 2012; Moreau and Ciriello, 2013).
Circulating leptin can reduce food intake by acting on neurons within
ARC (Satoh et al., 1997). Once bound to the ObRB, leptin causes
autophosphorylation of JAK2 and subsequent homodimerization of pSTAT3
(Banks et al., 2000; Kloek et al., 2002; White et al., 1997). pSTAT3 then acts to
regulate transcription of various genes, including Pomc (Banks et al., 2000). After
acute IH, plasma leptin concentrations were increased and increased levels of
pSTAT3 and POMC were observed in ARC as previously described (Moreau and
Ciriello, 2013). In the absence of leptin, as in the present study, these changes in
anorexigenic signaling molecules are not altered in response to IH. This suggests
the activation of satiety signals in ARC due to IH is dependent upon the presence
of leptin. This effect may not be direct, as other systems have been shown to
increase activation of pSTAT3 and POMC within ARC (Anderson et al., 2003;
Zhang et al., 2011). However, if they were responsible for the observed changes,
they must ultimately fall under the control of leptin, as these changes are
abolished in the leptin-deficient KILO rat.
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An increase in circulating angiotensin II concentration was also observed
in WT animals following IH. Unexpectedly, this effect was abolished in the KILO
rat. This suggests that the release of angiotensin II following IH is dependent on
leptin signaling. The mechanism by which leptin may contribute to the elevation
of angiotensin II is not known, but may involve actions of leptin in the brainstem
(Ciriello, 2013) or at the level of the carotid body (Messenger et al., 2012) to
increase peripheral chemoreceptor sensitivity (Ciriello and Moreau, 2013), which
in turn may increase renal sympathetic nerve activity (Ciriello, 2013), a known
stimulus for the renin-angiotensin hormonal pathway (Froeschl et al., 2013).
In conclusion, this study has shown that leptin plays an essential role in
mediating the effects of acute IH on changes to body energy balance, and
related hormonal secretion and molecular alterations within ARC. Taken
together, these data suggest that leptin may be an essential mediator of the
physiological response to hypoxia.
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CHAPTER 4
CHRONIC INTERMITTENT HYPOXIA INDUCES LEPTIN
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4.

CHAPTER 4

4.1 CHAPTER SUMMARY
Obstructive sleep apnea (OSA) is strongly correlated with the presence of
obesity and it has been determined that patients with OSA experience weight
gain, in addition to elevated leptin concentrations. Chronic intermittent hypoxia
(CIH) is a major pathophysiological manifestation of OSA, and acute IH has
recently been shown to alter body energy balance. Therefore, this study set out
to determine the relationship of body energy balance and leptin signaling in CIH.
To examine this, Sprague-Dawley rats were exposed to 95 days of CIH or
normoxic control conditions, and were assessed for daily measures of body
weight, food intake, and food conversion efficiency. Towards the end of the
study, leptin sensitivity, locomotor activity and circulating leptin was determined
within animals. Following the study period, fat pads and arcuate hypothalamic
nuclei (ARC) were isolated. ARC were assessed for factors associated with leptin
signaling. CIH animals increased their food intake over the study period, whereas
normoxic animals reduced this value. Normoxic animals had a reduced daily
body weight change over the study period, whereas this value was not different
in CIH animals. Epididymal fat mass and food conversion efficiency was less in
CIH animals. Following peripheral leptin injection, normoxic animals reduced
food intake, whereas CIH animals did not. Basal concentrations of leptin were not
different between the groups, but were elevated in CIH when normalized for
epididymal fat mass. Within ARC, CIH animals had elevated SOCS3 protein.

135

This study suggests that CIH, as seen in OSA, can induce a state of leptin
resistance.
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4.2 INTRODUCTION
Obesity is an energy balance disorder that affects a large number of
individuals within society (Ogden et al., 2013). This disease is associated with a
positive energy balance, whereby individuals do not utilize as many calories as
consumed throughout the day. The caloric imbalance observed in obesity is
believed to be the result of leptin resistance, which is considered to be the
primary risk factor for both obesity and overweight (Morris et al., 2010). During
leptin resistance, the satiety and anorexigenic effects of leptin are lost, thus
promoting dysregulation of caloric consumption, preventing negative feedback
onto energy storage sites such as the adipose tissue (Kalra et al., 1998). As a
result, hyperphagia persists, resulting in an increased deposition of adipose
tissue mass (Lin et al., 2000). The resultant increase in adipose tissue causes an
elevation in circulating leptin concentrations, potentially furthering the resistance
to leptin (Scarpace et al., 2002).
Hyperphagia and obesity are caused by a reduced expression of leptin
signaling molecules such as the long-form leptin receptor (ObRB) in the ARC
(Gong

et

al.,

2008).

Once

leptin

binds

ObRB,

phosphorylation

and

homodimerization of signal transducer and activator of transcription 3 (STAT3)
occurs (Vaisse et al., 1996). Activation by phosphorylation of extracellular
regulated kinase 1/2 (ERK1/2) also occurs (Banks et al., 2000). The translocation
of pSTAT3 to the nucleus induces the transcription and production of proopiomelanocortin (POMC), a major effector for satiety, and suppressor of
cytokine signaling 3 (SOCS3; Banks et al., 2000; Munzberg et al., 2003; Bates et
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al., 2003), a negative regulator of ObRB (Bjorbak et al., 2000). Another important
negative regulator of leptin signaling is protein tyrosine phosphatase 1B (PTP1B;
Sahu, 2004). Leptin resistance is associated with a decrease in activity of leptin
within the arcuate nucleus of the hypothalamus (ARC; Ladyman and Grattan,
2004; Munzberg et al., 2004). The mechanisms that drive leptin resistance are
not known, but may occur at the blood-brain barrier leptin transport system, such
as the short forms of the leptin receptor (ObR100; Banks et al., 1999), at the
level of the receptor (Rahmouni et al., 2008) or post-receptor signaling (Cheng et
al., 2002; Mori et al., 2004), including changes in the down-stream melanocortin
system (Marsh et al., 1999).
Obesity is a major risk factor for the development of obstructive sleep
apnea (Peppard et al., 2000), which is a sleep-related breathing disorder
characterized by nocturnal intermittent hypoxia. Patients with obstructive sleep
apnea have elevated leptin levels, and a greater disposition to weight gain
(Phillips et al., 2000). Recently, we have demonstrated that acute intermittent
hypoxia alters energy balance, increases plasma leptin levels and activates
leptin-related signaling mechanisms within ARC (Moreau and Ciriello, 2013).
Taken together, these results would suggest that chronic intermittent hypoxia
(CIH) may induce a state of leptin resistance. To test this possibility, experiments
were done in which leptin resistance was determined by the effects of acute
leptin injections on food intake, altered energy balance, and concomitant
alterations in ARC after exposure to long term CIH.
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4.3 METHODS AND MATERIAL
4.3.1 Animals
Experiments were done in adult male Sprague-Dawley rats (360-400 g)
individually housed in a room maintained at a temperature of 22°C and 60%
relative humidity. All animals had access to food and water ad libitum, except
during the 8h of intermittent hypoxic or normoxic exposure, in 12h light/dark cycle
conditions. Animals were randomly assigned to either CIH (n=8) or normoxia
(n=8) groups and exposed to the corresponding conditions for 95 days. Animals
were handled in accordance with the guidelines set forth by the Canadian
Council on Animal Care and Use Committee at the University of Western
Ontario.

4.3.2 CIH and normoxic exposures
Animals were exposed to CIH and normoxic conditions as previously described
(Moreau and Ciriello, 2013; Messenger and Ciriello, 2013; Messenger et al.,
2012, 2013). Briefly, animals were placed in chambers each consisting of four
tubes (10 cm diameter by 35 cm length) and a zero-pressure escape valve. For
CIH-exposed animals, a computer that regulated solenoid valves altered the
input of N2 or room air to generate CIH conditions. Animals were exposed to 80s
hypoxia (6.5% O2) followed by 120s normoxia. The levels of O2 and CO2 were
monitored by sensors on the chamber, which relayed information back to the
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computer to ensure proper cycling. Conditions within the chamber were isobaric
(770 ± 11 mmHg) and eucapnic (<0.1% CO2). Normoxic animals were exposed
to only the air input.

4.3.3 Measurement of body weight, food and water intake
Each day throughout the study, animals were weighed immediately before and
after CIH or normoxic exposure. These values were used to calculate body
weight changes during the exposure period, overnight body weight gain and 24h
body weight change. Additionally, food and water were measured over the 16h
immediately following CIH or normoxic exposure on each day.

4.3.4 Locomotion assay
Immediately following CIH or normoxic exposure on days 91 and 92, animals
were returned to their home cages and were allowed access to food and water
ad libitum. Thirty min into the dark (active) cycle (1930 h), animals were placed
into large cages (60 cm x 40 cm) with a floor 4x5 grid system in the dark (red
light on). Over a 10 min period, the number of crosses of a line by an animal was
determined by two independent observers blinded to their exposure regime to
determine horizontal locomotion (Moreau and Ciriello, 2013). Simultaneously,
vertical locomotion was determined by the number of rearing events. An average
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value was then calculated from these two observers for both horizontal and
vertical locomotion (Moreau and Ciriello, 2013).

4.3.5 Leptin resistance assay
Following CIH or normoxic exposure on days 93 and 94, animals were placed
into their home cages with ad libitum access to food and water. At the beginning
of the dark cycle (1900 h), animals were randomly assigned to vehicle or leptin
groups, and injected (i.p.) with either 0.4 mg/kg carrier-free recombinant rat leptin
(598-LP; R&D Systems, Minneapolis, MN) dissolved to 1 mg/ml in 20 mM Tris
HCl (pH = 8.0), or vehicle. Food intake measurements were taken at 1, 2, 3 and
14h after the leptin injection. Animals were exposed to CIH or normoxic
conditions the next day, and then were crossed-over to be injected with opposite
injectate (i.e. vehicle instead of leptin and vice versa), such that each animal
received an injection of both the vehicle and leptin for comparisons.

4.3.6 Plasma collection and enzyme immunoassays
The day following exposure, animals were immediately sacrificed under
equithesin anesthesia (0.3 ml/100 g b.w.; i.p.) (Moreau and Ciriello, 2013). Blood
samples were collected by cardiac puncture in the presence of 7%
ethylenediaminetetraacetic acid at a volume of 10 µl/ml blood. This blood was
immediately centrifuged at 10 000 RPM for 10 min at 4°C to isolate the aqueous
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plasma. This aqueous plasma phase was removed and stored frozen at -80 °C
until analyzed for hormone content. Plasma samples were analyzed using
enzyme immunoassay for rat leptin (Enzo Life Sciences; Farmingdale, NY)
according to manufacturer instructions. Enzyme immunoassay plates were read
on a SpectraMax M5 plate reader using SoftMax Pro v.5 microplate analysis
software (Molecular Devices; Sunnyvale, CA).

4.3.7 Tissue collection and preparation
Following exposure to CIH or normoxia, animals were sacrificed under equithesin
anesthesia and the brains immediately removed and frozen at -80°C. Using a
circular 1 mm (internal diameter) micropunch tool, 500 µm punch-outs of ARC
were taken and immediately homogenized in cold radioimmunoprecipitation
assay buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium
deoxycholate, 1 mM NaF, 1 mM sodium orthovanadate, 25 mM βglycerophosphate) with protease inhibitor cocktail (Roche Applied Science;
Laval, QC) by an electric homogenizer (VWR International; Radnor, PA).
Homogenates were then sonicated over three passages for 15s each on ice
(55%; Sonic Dimembrator Model 150; Fisher Scientific). Samples were then
rotated for 10 min at 4°C and centrifuged at 4°C for 20 min at 14000 RPM.
Protein content of homogenates was quantified using the Bio-Rad Dc protein
assay kit (Bio-Rad Laboratories; Hercules, CA). Protein samples were added to
25% sample buffer and 10% reducing buffer (Life Technologies; Burlington, ON)
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and water to a standard protein concentration of 1.67 mg/ml (Messenger and
Ciriello, 2013; Moreau and Ciriello, 2013).

4.3.8 Western blots
Electrophoresis was carried out using a 10% discontinuous polyacrylamide BisTris gel (Life Technologies; Burlington, ON), followed by standard protein
immunoblotting techniques (Messenger et al., 2013; Moreau and Ciriello 2013).
For each animal, 25 µg of protein of each sample was loaded. Electrophoresis
was carried out at 200 V and terminated when the dye front reached the bottom
of the gel. Proteins were transferred to a polyvinylidene fluoride membrane using
a wet transfer method in the presence of methanol and SDS (50 mM Tris, 40
mM glycine, 0.3% SDS, 20% methanol) and wet transfer apparatus (Mini TransBlot Electrophoretic Transfer Cell; Bio- Rad Laboratories; Hercules, CA) at 100 V
for 2h. After transfer, the membrane was washed in Tris-buffered saline +
Tween-20 (TBST; 20 mM Tris-HCl, 0.5 M NaCl, 0.1% Tween-20; pH 8.0) blocked
for 1 h with 5% skim milk made in TBST buffer at room temperature. The
membrane was then incubated with primary antibodies diluted in skim milk over
night at 4°C. The following day, the membrane was washed with TBST before
being incubated with horseradish peroxidase-conjugated secondary antibodiesspecific to the appropriate host of the primary antibody being analyzed, for 1h at
room temperature. For detection, the membrane was washed with TBST,
followed by distilled water and then stained using a horseradish peroxidase
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substrate enhanced chemiluminescence system (Luminata Forte, EMD Millipore;
Billerica, MA). Blots were visualized using a VersaDoc imaging system (Bio-Rad
Laboratories; Hercules, CA) and analyzed using ImageLab v.3.0 (Bio-Rad
Laboratories; Hercules, CA).

4.3.9 Antibodies
For western blots the following antibodies were used: rabbit anti-β-actin-HRP
(1:50000; A3854, Sigma-Aldrich; St. Louis MO),

rabbit anti-ObR (1:1000;

OBR12-A, Alpha Diagnostics International; San Antonio, TX) chicken anti-ObRB
(1:5000; CH14104, Neuromics; Edina, MN), rabbit anti-STAT3 (1:2000; #9132,
Cell Signaling; Boston, MA), rabbit anti-pSTAT3 (Tyr705) (1:1000; #9131, Cell
Signaling; Boston, MA), rabbit anti-ERK1/2 (1:2000; #9102, Cell Signaling;
Boston, MA), rabbit anti-pERK1/2 (Thr202/Tyr204) (1:1000; #9101, Cell
Signaling; Boston, MA), rabbit anti-POMC (1:2000; RB-08-0013, RayBiotech;
Norcross GA), rabbit anti-SOCS3 (1:1000; ab16030, Abcam; Cambridge, MA),
goat anti-PTP1B (1:500; sc-1718, Santa Cruz Biotechnology; Dallas, TX), donkey
anti-rabbit IgG-HRP (1:10000; 711-035-152, Jackson Immunoresearch; West
Grove, PA), donkey anti-chicken IgY-HRP (1:10000; 703-035-155, Jackson
Immunoresearch; West Grove, PA), donkey anti-goat IgG-HRP (1:10000; 705035-003, Jackson Immunoresearch; West Grove, PA).
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4.3.10 Statistics and analysis
Differences between and within CIH and normoxic groups at week 1 and week
13 of physiological variables, as well within basal plasma leptin concentrations of
fasted and non-fasted animals, were determined by two-way ANOVA with a
repeated measure between the exposure time groups, followed by Bonferroni
post-hoc analysis. Western blot analyses and fat pad mass between CIH and
normoxic groups were compared using an unpaired, two-tailed t-test. For leptin
resistance assays, a paired two-tailed t-test was used to compare vehicle
injection to leptin injection within CIH and normoxic groups. For all statistical
analyses, a p-value < 0.05 was taken to indicate statistical significance. All
values are expressed as mean ± standard error. All charts were made using
GraphPad Prism v.5 graphing software (GraphPad Software; La Jolla, CA).
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4.4 RESULTS
4.4.1 Body weight changes
Prior to exposure, body weights between CIH (385.5 ± 9.9 g) and normoxic
(386.5 ± 10.5 g) groups were not significant different (p = 0.95). Average body
weight after the first week CIH exposure was 386 ± 11.3 g, while the normoxic
animals weighed an average of 402.4 ± 9.6 g. After the thirteenth week of
exposure, CIH animals weighed 584.8 ± 12.2 g and normoxic animals weighed
635.6 ± 21.8 (Fig 4.1a). There was both a significant effect of the duration of
exposure and exposure type on body weight (Fig. 4.1a-d). After the first week of
exposure, CIH exposed animals lost on average approximately 6% of their body
weight (-23.7 ± 1.9 g), whereas normoxic controls lost about 3% of their body
weight (-12.6 ± 0.7 g; Fig. 4.1b). After the thirteenth week of exposure, CIH
animals lost an average of 5% of body weight (-31.8 ± 3.2 g) and normoxic
animals lost about 2% of body weight during exposure (-11.9 ± 2.2 g; Fig 4.1b).
There was a significant effect of exposure between CIH and normoxic groups. In
addition, the CIH group lost significantly more body weight on average after 13
weeks of exposure compared to the first week, but no effect of exposure length
on normoxic animals was observed. In the 16h following exposure after the first
week, CIH animals gained an average of 25.9 ± 1.5 g and normoxic animals
gained 18.0 ± 0.6 g. After 13 weeks, CIH animals gained an average of 32.0 ±
3.2 g and normoxic animals gained 12.8 ± 2.0 g overnight (Fig 4.1c). CIH animals
gained significantly more weight overnight than normoxic animals, and this
overnight body weight gain increased over the length of exposure. On the other
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hand, normoxic animals had decreased overnight body weight gain over the
same time period. Average daily body weight change after the first week for CIH
animals was 2.1 ± 0.5 g, while normoxic animals gained an average of 5.5 ± 0.4
g. After 13 weeks, CIH animals had an average daily body weight change of -1.1
± 0.8 g, while normoxic animals had 0.46 ± 0.77 g (Fig 4.1d). There was a
significant effect of exposure on daily body weight change, with CIH animals
gaining less weight daily. The effect of exposure length on daily body weight
change is complex as normoxic exposed animals reduce their daily body weight
change, while CIH animals do not significantly alter this response.

4.4.2 Fat pad mass changes
Epididymal fat pad mass was significantly reduced (p = 0.024) in CIH exposed
animals (6.1 ± 1.1 g) compared to those exposed to normoxia (10.1 ± 0.8 g) (Fig.
4.1e). Although no differences (p = 0.17) were observed in retroperitoneal fat pad
mass between CIH (8.4 ± 1.7 g) and normoxic animals (12.0 ± 1.8 g), a trend
towards a decrease was also observed (Fig. 4.1f). These effects were observed
even when accounting for total body weight. Epididymal fat of CIH animals (1.08
± 0.14 g/100 g b.w.), was significantly less (p = 0.028) than normoxic animals
(1.60 ± 0.11 g/100 g b.w.). Retroperitoneal fat was not different (p = 0.15)
between CIH (1.48 ± 0.23 g/100 g b.w.) and normoxic animals (1.89 ± 0.24 g
/100 g b.w.).
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Figure 4.1 Effect of CIH on body weight changes and fat pad mass.
Bar charts summarizing the changes body weight (a), body weight change during
8h IH exposure (b), 16 h post-exposure overnight body weight gain (c), and daily
change in body weight between animals exposed to CIH or normoxia averaged
for over week 1 and week 13 (d). Bar charts summarize epididymal (e) and
retroperitoneal (f) fat pad mass after 13 weeks of CIH or normoxia exposure.
Note that body weight, body weight changes and adipose tissue mass are altered
by CIH. Data are shown as mean ± standard error. *, p < 0.05 (determined by
two-way ANOVA followed by a Bonferroni post-hoc analysis for body weights,
and as determined by an unpaired, two-tailed Student’s t-test for fat pad mass). n
= 8 per group.
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4.4.3 Food intake
In the 16h following daily exposure after the first week, CIH animals consumed
an average of 25.2 ± 1.0 g of food while the normoxic animals consumed 31.4 ±
0.8 g of food (Fig. 4.2a). Following 13 weeks of exposure, CIH animals
consumed a daily average of 27.5 ± 0.7 g of food, representing an increase of
approximately 9%, and normoxic animals consumed 27.9 ± 1.1 g of food,
representing a decrease of approximately 11% (Fig 4.2a).

4.4.4 Food conversion efficiency
Food conversion efficiency was 1.04 ± 0.08 g b.w. gain/g food in CIH exposed
animals and 0.59 ± 0.03 g b.w. gain/g food in normoxic animals after the first
week. After week 13, CIH animals had a food conversion efficiency of 1.08 ± 0.04
g b.w. gain/g food, and normoxic animals were 0.44 ± 0.04 g b.w. gain/g food
(Fig 4.2b). There was an effect of exposure for CIH to increase food conversion
efficiency, while the relationship of exposure length and exposure interacted to
produce a complex relationship whereby there was no alteration within CIH
animals over the exposure time, but significantly reduced food conversion
efficiency in normoxic animals over the time period.
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4.4.5 Locomotion changes
Horizontal locomotor activity was not different (p = 0.66) between CIH and
normoxic control rats (301.2 ± 25.8 line crosses/10 min and 295.6 ± 26.1 line
crosses/10 min, respectively; Fig 4.2c). Vertical locomotor activity was not
different (p = 0.25) between CIH and normoxic rats (83.5 ± 15.8 rears/10 min and
72.4 ± 12.3 rears/10 min, respectively; Fig 4.2d).

4.4.6 Plasma leptin concentrations
Plasma concentrations of leptin during fasting conditions following 95 days CIH
had 1.2 ng/ml of leptin in their plasma, while normoxia animals had 1.5 ± 0.3
ng/ml of leptin. When these plasma levels are normalized to epididymal fat
content in each animal, CIH exposed animals had a significantly elevated (p =
0.036) plasma leptin than normoxic controls (0.41 ± 0.08 ng/ml/g fat compared to
0.23 ± 0.06 ng/ml/g fat, respectively; Fig 4.2e). Furthermore, a similar finding is
observed if the plasma leptin levels are compared to both epididymal and
retroperitoneal fat pads.

4.4.7 Leptin resistance induced by CIH
In animals exposed to normoxia, food intake 1 h after acute leptin injection was
significantly (p = 0.012) reduced compared to vehicle injected controls (Fig.
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Figure 4.2 Changes in food intake and energy expenditure following CIH.
Bar charts showing food intake (a) and food conversion efficiency (b) over the
16h after 1 week or 13 week exposure to CIH or normoxia. In addition, (c-d)
show that both horizontal (c) and vertical (d) locomotion were not changed by
CIH at the 13 week time-point. Bar chart (e) also shows plasma leptin levels
normalized for epididymal fat pad mass. Note that CIH causes changes in food
intake and body energy utilization without changing locomotor activity.
Furthermore, basal plasma leptin levels are elevated when fat pad mass is taken
into account. Data are shown as mean ± standard error. *, p<0.05 (determined by
two-way ANOVA followed by a Bonferroni post-hoc analysis for food intake, food
conversion efficiency, leptin concentration, and as determined by an unpaired,
two-tailed Student’s t-test for locomotor activities and normalized leptin) n = 4 per
group.
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4.3a). On the other hand, in the CIH exposed animals, food intake was not
altered at this time point (Fig. 4.3a). Similarly, at 2h and 3h after acute leptin
injection, food intake was significantly (2h, p = 0.0092; 3h, p = 0.015) reduced
after acute leptin injections in the normoxic controls compared to vehicle injected
animals, but was not altered in the CIH exposed animals (Fig. 4.3b-c). These
values were not altered at the 14h time point (Fig. 4.3d). Furthermore, neither
vehicle, nor leptin injections in animals exposed to CIH or normoxia altered food
intake from total food intake values over the 16h measured on a daily basis.

4.4.8 Protein expression of leptin receptors after CIH
As shown in Figure 4.4, within ARC, CIH did not alter (p = 0.85) the protein
expression of the long-form leptin receptor (ObRB) compared to normoxia (0.17
± 0.02 A.U. and 0.16 ± 0.02 A.U., respectively; Fig 4.4a). IH also did not alter (p =
0.46) protein expression of the short form leptin receptor ObR 100 compared to
normoxic exposed animals (0.22 ± 0.03 A.U. and 0.24 ± 0.01 A.U., respectively;
Fig 4.4b).

4.4.9 Proteins associated with leptin signaling within ARC
Within the ARC, CIH did not alter pSTAT3 protein expression as a function of
total STAT3 (p = 0.46) compared to normoxic controls (0.15 ± 0.02 A.U. and 0.13
± 0.02 A.U., respectively; Fig 4.5a), and did not change total STAT3 protein
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Figure 4.3 CIH induces resistance to leptin
Bar charts showing cumulative food intake at 1h (a), 2h (b), 3h (c) and 14h (d)
post-injection (i.p.) of either 0.4 mg/kg leptin or vehicle treatment. Note that leptin
induces satiety in normoxic animals, but not in the CIH exposed animals. Data
are presented as mean ± standard error. *, p < 0.05 (determined by a paired,
two-tailed Student’s t-test between vehicle and leptin treatments). n = 8 per group
and injection.
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Figure 4.4 Effect of CIH on ObR in ARC
Representative blots and bar graphs depicting ObRB/β-actin protein expression
(a) and ObR100/β-actin protein expression (b). Note that leptin receptor isoforms
are not altered in ARC following CIH exposure. Data are shown as mean ±
standard error. n = 8 per group.
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expression (p = 0.39). Protein expression levels of POMC were found to be
significantly less (p = 0.045) in CIH (0.41 ± 0.02 A.U.) exposed animals
compared to normoxia animals (0.53 ± 0.06 A.U.; Fig 4.5b). Protein expression of
total ERK1/2 was significantly less (p = 0.0045) in CIH animals (5.72 ± 0.34 A.U.)
compared to ARC of normoxia animals (7.62 ± 0.38 A.U.; Fig 4.5c). However, a
significant increase (p = 0.001) in the proportion of ERK1/2 that was
phosphorylated was observed in CIH animals (0.12 ± 0.01 A.U.) compared to
normoxic control animals (0.043 ± 0.010 A.U.; Fig 4.5d).

4.4.10 Protein markers associated with leptin resistance within ARC
Within ARC, CIH significantly increased (p = 0.022) the expression of SOCS3
protein compared to normoxic controls (0.20 ± 0.03 A.U. and 0.12 ± 0.01 A.U.,
respectively; Fig 4.6a). On the other hand, no significant difference (p = 0.56) in
PTP1B protein expression was observed between CIH (0.038 ± 0.004 A.U.) and
normoxic animals (0.041 ± 0.005 A.U.; Fig 4.6b).
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Figure 4.5 Leptin signaling proteins in ARC following CIH
Representative blots and bar charts depicting (a) pSTAT3/STAT3 protein
expression, (b) POMC protein expression, (c) total ERK1/2 protein expression,
and (d) pERK1/2 / ERK1/2 protein expression in ARC. Note that CIH alters leptin
signaling protein expression within ARC. Data are presented as mean ± standard
error. *, p < 0.05 (determined by an unpaired, two-tailed Student’s t-test). n = 8
per group.
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Figure 4.6 Effect of CIH on negative regulators of leptin signaling in ARC.
Representative blots and bar charts depicting inhibitors of leptin signaling
SOCS3 (a) and PTP1B (b) protein expressions within ARC. Note that CIH alters
SOCS3, but not PTP1B protein expression in the ARC after 13 weeks exposure.
Data are presented as mean ± standard error. *, p < 0.05 (determined by an
unpaired, two-tailed Student’s t-test). n = 8 per group.
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4.5 DISCUSSION
This study has demonstrated that 13 weeks of continuous exposure to
intermittent hypoxia induces a state of leptin resistance. Animals exposed to CIH
have increased food intake over the study period, where normoxic controls
reduce their level of consumption over the same period. This occurs alongside a
significant reduction in daily body weight change by controls, while no change is
observed in CIH animals. Epididymal fat pad mass is significantly less at the end
of the study in CIH compared to normoxic animals. Direct measure of the effect
of leptin on food intake indicated a state of leptin resistance in CIH animals, while
normoxic animals responded normally to acute administration of leptin. Basal
plasma leptin concentrations normalized to epididymal fat mass were was
significantly higher in CIH exposed animals compared to normoxic controls.
These changes are concomitant with a lower protein amount of ERK1/2 and
POMC in ARC, while pERK1/2 and SOCS3 were elevated between CIH and
normoxic groups.
In a recent study, we have described the acute effect of intermittent
hypoxia on body energy balance (Moreau and Ciriello, 2013). Each bout of
exposure to intermittent hypoxia induced a loss of body weight, which was
abrogated following non-hypoxic conditions as a result of reduced locomotion
and altered body energy utilization. In this study, after 13 weeks of CIH, body
weight loss during exposure increases, as opposed to no difference observed
within the normoxic animals. It is likely that this effect could was due to a
potentiation of the peripheral chemoreceptor reflex on sympathetic flow,
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independent of a change in respiration (Prabhakar et al., 2005, 2009; Dick et al.,
2007; Xing and Pilowsky, 2010). This conclusion is supported by the finding that
CIH has long-term effects on sympathetic outflow (Zoccal et al., 2007, 2008).
Given the observed reduction of epididymal fat pad mass, it may be suggested
that the break-down of adipose tissue contributes to the body weight loss, a
finding also reported by others (Martinez et al., 2008; Drager et al., 2011),
although this may not be the primary mediator of the decreased body weight
observed following acute intermittent hypoxia (Moreau and Ciriello, 2013).
Overnight food intake was observed in animals exposed to CIH during the
first week compared to normoxia. This acute effect was also observed following
only 8h of exposure to intermittent hypoxia (Moreau and Ciriello, 2013) and has
been reported in humans exposed to chronic hypoxia (Tschop et al., 1998).
However, by the thirteenth week food intake between CIH and normoxic animals
was not significantly different. In fact, food intake over this time course was
reduced in normoxic controls, but was increased in CIH exposed animals. The
increased food intake could be suggestive in the CIH exposed animals of a
potential manifestation of leptin resistance (Kalra et al., 1998; Trujillo et al.,
2011). Similarly, food conversion efficiency, an indirect measure of whole-body
energy utilization, was reduced in normoxic animals over the exposure period.
This is suggestive of increased body energy utilization. This change was not
observed in CIH animals, suggesting their body energy metabolism was not
changing in a way concurrent to normoxic control animals. Along the exposure
length in the CIH animals, food conversion efficiency was elevated compared to
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normoxic animals, suggestive of reduced body energy utilization. Although the
long-term effects that food conversion efficiency will have on pre-disposition to
weight gain is not well understood, a reduction in metabolic function is associated
with weight gain in humans (Houmard, 2008). Whether the lack of increase in
body energy utilization is due to leptin resistance in CIH animals is not known,
but it is possible that given that leptin augments metabolic activities mediated in
part by the sympathetic nervous system (Harris, 2013), and plasma leptin levels
are elevated following a bout of intermittent hypoxia (Moreau and Ciriello, 2013),
CIH may contribute to leptin resistance. In support of this suggestion, leptin
resistance was measured directly by a repeated comparison to leptin and vehicle
treatment in CIH and normoxia exposed animals. It was found that in normoxic
animals, acute leptin injections caused a significant reduction in food intake in the
first three hours. However, in the CIH exposed animals, leptin did not induce a
satiating effect when compared to vehicle injections.
Leptin resistance is followed by the development of weight gain and
hyperphagia (Kalra et al., 1998; Trujillo et al., 2011). Due to the complex
interaction of CIH and this leptin resistant state on body weight, it may be
suggested that the effects on body weight may not yet have taken hold in these
CIH exposed animals for a long enough period to induce a significant weight gain
as recently reported (Guo et al., 2013). An alternate explanation may be that in
this model, due to its anorexigenic effects through increased sympathetic activity,
an increase in body weight may not be easily demonstrated until animals are
exposed to longer periods of CIH, despite evidence that CIH causes a wide
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range of metabolic pathophysiologies including dyslipidemia, high blood pressure
and insulin resistance (Polotsky et al., 2003; Zoccal et al., 2007; Drager et al.,
2011). It should also be kept in mind that there are individuals that suffer from
the metabolic syndrome that are not obese, and CIH, as a result of obstructive
sleep apnea, can worsen their metabolic profile (Kono et al., 2007).
Another major effect of leptin resistance is chronic hyperleptinemia.
Fasting leptin concentrations in the CIH animals were not different compared to
normoxic controls. However, given that CIH animals had less body weight and
epididymal fat pad mass, it suggested that the observed levels of leptin in the
CIH animals were in fact elevated compared to normoxic controls. When fat
mass was taken into account, it was found that CIH animals had significantly
higher plasma leptin concentrations than their normoxic counterparts. It should
be noted that the epididymal fat mass is thought to be the largest producer of
leptin in the rat (Zheng et al., 1996). Previous reports by us (Messenger et al.,
2012; Moreau and Ciriello, 2013) and others (Polotsky et al., 2003; Li et al.,
2006) have shown that acute short-term intermittent hypoxia can increase
plasma leptin concentrations. This elevated leptin release immediately following
bouts of intermittent hypoxia on a daily basis may contribute to the development
of the leptin resistance observed in the 13 week exposed CIH animals.
Following CIH, within ARC, no alterations were observed in the protein
expression of either the long- or short form leptin receptors. While the precise
mechanism surrounding leptin resistance is not understood, it has been
suggested that a reduction in ObRB may prevent appropriate leptin signaling
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(Schwartz et al., 1997). From these data, it appears that this may not be the
mechanism driving the leptin resistance in this model. Similar suggestions have
been made regarding ObR100, where a reduction in this protein would prevent
sufficient transport of leptin across the blood-brain barrier (Banks et al., 2001).
CIH animals were found not to have altered ObR100 protein expression in ARC.
However, it should be kept in mind that these do not take into account changes in
affinity for the receptor (Mooradian et al., 2000), or changes in receptor
localization (Gan et al., 2012).
Within ARC, it was observed that CIH animals had less POMC protein
expression than normoxic control animals. Consistent with this finding, a
reduction in POMC within ARC has been shown to be associated with
hyperphagia (Richard et al., 2011). This could be the result of reduced signaling
in leptin resistance, or could function as a mediator of the resistance itself. Also
within ARC, SOCS3 protein was found to be higher in CIH than normoxic
animals. An increase in SOCS3 would prevent activation of the leptin receptor
signaling cascade (Bjorbak et al., 2000), and preventing downstream activation
of factors associated with the effect of leptin, such as POMC (Banks et al., 2000).
SOCS3 overexpression has previously been shown to occur in leptin resistant
states, and experimentally can increase food intake (Bjørbaek et al., 1998; Reed
et al., 2010).
Taken together, these data have demonstrated for the first time that
exposure to CIH can induce a state of leptin resistance. This pathophysiological
state is associated with increased energy balance. Furthermore, this leptin
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resistant state is associated with an increased protein expression of SOCS3 and
with a concomitant reduction in POMC protein expression within ARC. These
findings suggest a possible link between patients exposed to CIH, such as
obstructive sleep apnea and the development of obesity and metabolic disorders.
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OF NEUROPLASTICITY MARKERS IN THE NUCLEUS OF THE SOLITARY
TRACT
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5.

CHAPTER 5

5.1 CHAPTER SUMMARY
Intermittent hypoxia (IH) has been shown to alter the response of neurons in
nucleus of the solitary tract (NTS) to cardiovascular inputs. The mechanisms
involved in these effects may involve pre- and/or post-synaptic neuroplasticity
alterations in NTS. To investigate this possibility, Sprague-Dawley wild-type rats
were exposed to 1, 7 or 95 days of IH or normoxia. Additionally, to determine
whether leptin exerted an effect on the 1 day changes to IH, leptin-deficient
(KILO) rats were exposed to IH or normoxia. Arterial pressure (AP) was also
measured at these time intervals in conscious wild-type animals. Additionally, at
each time point protein was extracted from NTS and analyzed by western blot for
the expression of brain-derived neurotrophic factor (BDNF), tropomyosin receptor
kinase B (TrkB), synaptophysin and growth-associated protein-43 (GAP-43). AP
was not different between the IH and normoxic animals at 1 or 7 days. However,
after 95 days of IH, AP was significantly elevated compared to normoxic controls.
After 1 day IH, TrkB protein expression in NTS was higher while synaptophysin
was lower than normoxic wild-type rats. No changes were found in TrkB protein
expression in KILO rats after 1 day IH, although synaptophysin protein
expression was decreased. BDNF and GAP 43 protein expression levels were
not altered in any group following 1 day IH or normoxia. After 7 days of IH, BDNF
and TrkB protein expression was found to be elevated in NTS compared to
normoxic controls. After 95 days of IH expression of BDNF, synaptophysin, and
GAP-43 proteins were less abundant in NTS than in normoxic controls. These
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results suggest that neuroplasticity changes occurring within NTS may be
associated with the development of autonomic dysregulation often seen in
patients with chronic obstructive sleep apnea, including elevated blood pressure.
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5.2 INTRODUCTION
Obstructive sleep apnea is a chronic, progressive disease that is
characterized by episodic closures of the upper airway during sleep (Dempsey et
al., 2010). One of the physiological consequences of obstructive sleep apnea is
intermittent hypoxia (IH; Freet et al., 2013). IH has previously been shown to
activate peripheral carotid chemoreceptors (Cooper et al., 2005). These
specialized cells respond to lowered blood oxygen tension and in response
increase afferent neural activity to the nucleus of the solitary tract (NTS), the
primary site of peripheral chemoreceptor afferent termination (Ciriello et al 1994).
It has previously been shown that chronic intermittent activation of the carotid
chemoreceptor pathway can result in sympathetic long-term facilitation (Dick et
al., 2007; Xing and Pilowsky, 2010), which plays an important role in the
exaggerated sympathetic responses seen by further chemoreceptor activation
(Xing and Pilowsky 2010).
IH may also induce alterations in the sensitivity of the baroreceptor reflex
(Bonsignore et al., 2002; Carlson et al., 1996). Intermittent apneas have been
shown to reset the baroreceptor reflex to a higher level (Monahan et al., 2006;
Prabhakar and Khumar, 2010) suggesting a possible interaction between
activation of the chemoreceptor reflex and a depression of the baroreceptor
reflex (Cooper et al., 2005; Somers et al., 1991) during IH. Although the central
mechanisms that may induce sympathetic long-term facilitation and baroreceptor
reflex depression are not known, they may be important in the development and
maintenance of hypertension observed in individuals suffering from chronic
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obstructive sleep apnea. We have recently demonstrated that IH can increase
plasma leptin concentration (Messenger et al., 2012; Moreau and Ciriello, 2013).
Circulating leptin has been shown to potentiate the chemoreceptor reflex (Ciriello
and Moreau, 2013; Ciriello and Moreau, 2012) and inhibit the baroreceptor reflex
(Arnold et al., 2009; Ciriello, 2013a, 2013b) at the level of the NTS. Interestingly,
the NTS region has been identified as one of the few neurogenic sites within the
central nervous system (Bauer et al 2005; Chigr et al 2009), and the NTS has a
high level of expression of factors associated with neuroplasticity including the
neurite outgrowth protein brain-derived neurotrophic factor (BDNF) and its
receptor tropomyosin receptor kinase B (TrkB), growth-associated protein-43
(GAP-43), and the synaptogenic marker synaptophysin (Jin et al., 2010;
Korshunova and Mosevitsky, 2010; Moyse et al., 2006). Leptin has been shown
to affect neuroplasticity and synaptogenesis within extra-hypothalamic regions of
the brain (Harvey, 2013; Shanley et al., 2001; Wayner et al., 2004). Previous
studies have suggested BDNF, TrkB, GAP-43 and/or synaptophysin may be
important in mediating alterations associated with activity-dependent functional
changes in cardiovascular afferents that terminate within NTS (Martin et al 2009).
This study was designed to investigate whether neuroplasticity occurred
within NTS in response to acute (1 day), short term chronic (7 days) and long
term chronic (95 days) IH and whether changes in mean arterial pressure (MAP)
and heart rate (HR) occurred that may be associated with chronic IH. Finally, the
role of leptin in the neuroplastic alterations in NTS following acute IH was also
determined in the leptin deficient KILO rat (Vaira et al., 2012).
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5.3 METHODS AND MATERIAL
5.3.1 Animals
Adult, male Sprague-Dawley rats (300-350 g; n=36) were purchased from
Charles River Canada and served as wild-type control animals (WT). Adult, male,
homozygous, leptin-deficient KILO rats (250-400 g; n=8; SD-Leptm1sage) were
obtained from SAGE Laboratories (TGRA3780; Vaira et al., 2012). Animals were
housed singly at a temperature of 22°C and 60% relative humidity with access to
food and water available ad libitum, except during the daily 8 h IH or normoxic
exposure, in 12h light/dark cycle conditions. All experimental procedures were
done in accordance with the guidelines on the use and care of laboratory animals
as set by the Canadian Council on Animal Care and approved by the Animal
Care Committee at The University of Western Ontario.

5.3.2 IH or normoxic exposure
Animals were exposed to 8 h (0900-1700) of IH or normoxia each day as
previously described (Messenger et al., 2012, 2013; Moreau and Ciriello, 2013).
WT rats were exposed for 1-day, 7-days or 95-days of IH or normoxia. KILO rats
were exposed only for 1-day of IH or normoxia. In brief, animals were placed in a
chamber consisting of four tubes (10 cm diameter x 35 cm length) with a zeropressure escape valve. For IH-exposed animals, a computer that regulated
solenoid valves altered the input of N2 or room air to generate IH conditions.
Animals were exposed to 80s hypoxia (6.5% O2) followed by 120s normoxia. The
levels of O2 and CO2 were monitored by sensors in the chamber, which relayed
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information back to the computer to ensure proper cycling. Conditions within the
chamber were isobaric (770 ± 11 mmHg) and eucapnic (<0.1% CO 2). Normoxic
animals were exposed to same conditions except that only room air was cycled
(Messenger et al., 2012, 2013; Moreau and Ciriello, 2013).

5.3.3 Hemodynamic recordings
Following exposure to IH or normoxia at 1 day, 7 days and 95 days, WT animals
had their systolic, diastolic and MAP and HR measured using the non-invasive
tail cuff method (CODA System; Kent Scientific; Torrington, CT). This approach
has been previously validated with direct hemodynamic measures (Feng et al.,
2008).

5.3.4 Tissue collection and preparation
Following exposure to IH or normoxia, animals were sacrificed under equithesin
anesthesia (0.3 ml/100 g b.w.; Moreau and Ciriello, 2013) and the brains
removed and frozen at -80°C until analyzed. Using a circular 1 mm (internal
diameter) micropunch tool, 500 µm bilateral punches of NTS from each animal
were taken and immediately homogenized in cold radioimmunoprecipitation
assay buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium
deoxycholate, 1 mM NaF, 1 mM sodium orthovanadate, 25 mM βglycerophosphate) with protease inhibitor cocktail (Roche Applied Science;
Laval, QC) using an electric homogenizer (VWR International; Radnor, PA).
Homogenates were then sonicated over three passages for 15s on ice (55%;
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Sonic Dimembrator Model 150; Fisher Scientific). Samples were then rotated for
10 min at 4 °C and centrifuged at 4°C for 20 min at 14000 RPM. Protein content
of homogenates was quantified using the Bio-Rad Dc protein assay kit (Bio-Rad
Laboratories; Hercules, CA). Protein samples were added to 25% LDS sample
buffer and 10% reducing buffer (Life Technologies; Burlington, ON), and water to
a standard protein concentration of 1.67 mg/ml (Messenger et al., 2013).

5.3.5 Western blots
Electrophoresis was carried out using a 10% discontinuous polyacrylamide BisTris gel (Life Technologies; Burlington, ON), followed by standard protein
immunoblotting techniques (Messenger et al., 2013). For each animal, 25 µg of
protein of each sample was loaded. Electrophoresis was carried out at 200 V and
terminated when the dye front reached the bottom of the gel. Proteins were
transferred to a polyvinylidene fluoride membrane using a wet transfer method in
the presence of methanol and SDS (50 mM Tris, 40 mM glycine, 0.3% SDS,
20% methanol) and wet transfer apparatus (Mini Trans-Blot Electrophoretic
Transfer Cell; Bio- Rad Laboratories; Hercules, CA) at 100 V for 2 h. After
transfer, the membrane was washed in Tris-buffered saline + Tween-20 (TBST;
20 mM Tris, 0.5 M NaCl, 0.1% Tween-20; pH 8.0) blocked for 1 h with 5% skim
milk made in TBST buffer at room temperature. The membrane was then
incubated with primary antibodies diluted in skim milk over night at 4 °C. The
following day, the membrane was washed with TBST before being incubated with
horseradish

peroxidase-conjugated

secondary

antibodies-specific

to

the
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appropriate host of the primary antibody being analyzed, for 1 h at room
temperature. For detection, the membrane was washed with TBST, followed by
distilled water and then detected using a horseradish peroxidase substrate ECL
chemiluminescence system (Luminata Forte, EMD Millipore; Billerica, MA). Blots
were visualized using a VersaDoc imaging system (Bio-Rad Laboratories;
Hercules, CA) and analyzed using ImageLab v.3.0 (Bio-Rad Laboratories;
Hercules, CA).

5.3.6 Antibodies
For western blots, the following antibodies were used: rabbit anti-β-actin-HRP
(1:50000; A3854, Sigma-Aldrich; St. Louis MO), rabbit anti-TrkB (1:1000; sc8316, Santa Cruz Biotechnology; Dallas, TX), mouse anti-synaptophysin (1:1000;
ab8049, Abcam; Cambridge, MA), rabbit anti-GAP-43 (1:1000; #8945, Cell
Signaling Technology; Danvers, MA), rabbit anti-BDNF (1:1000; sc-20981, Santa
Cruz Biotechnology; Dallas, TX), donkey anti-rabbit IgG-HRP (1:10 000; 711035-152, Jackson Immunoresearch; West Grove, PA), donkey anti-mouse IgGHRP (1:5000; 715-035-151, Jackson Immunoresearch; West Grove, PA).

5.3.7 Statistics and analysis
All values are expressed as mean ± standard error. Differences between IH and
normoxic groups were determined by unpaired, two-tailed Student t-test. A pvalue < 0.05 was taken to indicate statistical significance. All bar charts were
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made using GraphPad Prism v.5 graphing software (GraphPad Software; La
Jolla, CA).
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5.4 RESULTS
5.4.1 AP following exposure to IH
Following 1 day and 7 days of IH, systolic (Fig. 5.1a), diastolic (Fig. 5.1b), MAP
(Fig. 5.1c), and HR (Fig. 5.1d) were found not to be altered compared to
normoxic controls at the same time points. After 95 days of IH, animals had a
significantly higher (p = 0.030) systolic blood pressure, compared to normoxic
controls (152 ± 6 mmHg vs. 130 ± 8 mmHg, respectively; Fig. 5.1a). Additionally,
these animals had significantly elevated diastolic blood pressure (p = 0.05; IH,
113 ± 6 mmHg vs. normoxic controls, 99 ± 4 mmHg; Fig 5.1b). As a result, MAP
was significantly elevated within these animals (p = 0.026; IH, 124 ± 6 mmHg vs.
normoxic controls, 107 ± 4 mmHg; Fig 5.1c). On the other hand, no differences
(p = 0.13) were observed in HR between the normoxic control and IH groups
(400 ± 12 bpm vs. 419 ± 12 bpm, respectively; Fig. 5.1d). Figure 5.1e also shows
that the gain as measured by the MAP level compared to HR was decreased at
95 days following IH compared to normoxic controls.

5.4.2 BDNF protein expression in NTS following IH
BDNF protein expression was found not to be different (p = 0.42) in NTS
between IH and normoxic WT after 1 day exposure (Fig. 5.2a). Following 7 days
of IH exposure, there was 53% increase (p = 0.0062) in BDNF protein expression
in NTS compared to normoxic WT (Fig 5.2b). On the other hand, after 95 d of IH
exposure, there was 34% less BDNF protein expression in NTS compared to
normoxic WT (p = 0.008; Fig 5.2c).
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Figure 5.1 Effect of IH on hemodynamic variables
Bar chart showing arterial pressure and heart rate changes following 1, 7 and 95
days of exposure to IH or normoxia. Shown are: (a), systolic pressure, (b),
diastolic, (c) mean arterial pressure and (d) heart rate in the conscious rat. In
addition, (e) shows the effect of IH on heart rate in relation to the level resting
arterial pressure (Gain; bpm/mmHg). Note that systolic, diastolic and mean blood
pressures and gain are significantly (*, p<0.05) altered after 95 days of IH
exposure. n=7 for all the 1 and 7 days groups and n=8 for the 95 day groups.
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Figure 5.2 NTS expression of BDNF following IH
Representative western blots and bar charts indicating the change in protein
expression of BDNF determined by western blot in the same NTS samples at 1
day (a), 7 days (b) and 95 days (c) after IH or normoxic exposure. Note that
BDNF protein expression is elevated after 7 days of IH exposure and then
reduced after 95 days of IH exposure. *, p<0.05 determined by two-tailed,
unpaired Student t-test. n=7-8.
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5.4.3 TrkB protein expression in NTS following IH
After 1 day of IH, there was a significant elevation in protein expression of both
the short (gp95) and long (gp145) isoforms of the TrkB neurotropic receptor in
the NTS region of WT (Fig 5.3a). The gp95 isoform was increased (p = 0.028) by
about 28% in IH compared to normoxic controls (Fig. 5.3). Over the same time
period in the NTS, the gp145 isoform was also increased (p = 0.018) by about
166% in IH compared to normoxic controls (Fig. 5.3a). The ratio of gp145:gp95
isoform was 100% higher (p = 0.012) in IH compared to normoxic control NTS in
WT (Fig. 5.3d).
Following 7 days of IH (Fig 5.3b), gp95 was significantly higher (p = 0.043)
from normoxic controls in NTS, with about 43% more gp95 protein expression in
IH animals. The gp145 isoform was also significantly greater (p = 0.038) by about
52% in IH compared to normoxic controls (Fig. 5.3b). The ratio of gp145:gp95
isoform was not significantly different (p = 0.39) in IH compared to normoxic
control (Fig. 5.3d).
After 95 days of IH (Fig 5.3c), gp95 was significantly lower (p = 0.013) by
approximately 52% compared to normoxic control animals, while the gp145
isoform was not different (p = 0.27). The gp145:gp95 ratio was also not different
(p = 0.29) between 95 d IH exposed and 95 d normoxic animals (Fig. 5.3d).

5.4.4 Synaptophysin protein expression in NTS following IH
The expression of the synaptic marker protein synaptophysin was significantly
lower (p = 0.042) by about 16% in NTS after 1 day IH exposure compared to
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Figure 5.3 NTS expression of TrkB isoforms following IH
Representative western blots and bar charts indicating the change in protein
expression of gp95 (a), gp145 (b) and the ratio of gp145:95 (c) TrkB isoforms in
NTS following 1 day (a), 7 days (b), and 95 days (c) IH or normoxic exposure.
(d), the ratio of gp145:gp95 TrkB isoforms. Note that both TrkB isoforms are
increased after acute and short term exposure to IH. However, after 95 days IH
exposure, only the gp95 isoform is reduced. Differences were determined
between IH and normoxia within isoform and ratio of each group. *, p<0.05 as
determined by two-tailed, unpaired Student t-test. n=7-8.
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normoxic control WT (Fig 5.4a). On the other hand, no differences were found in
synaptophysin protein expression (p = 0.34) between IH and normoxic controls in
the NTS region following 7 days of exposure (Fig 5.4b), although there was a
trend towards a decrease. After 95 days, there was about 42% less expression
(p = 0.0029) of the synaptophysin protein in NTS of the IH animals compared to
normoxic WT animals (Fig 5.4c).

5.4.5 GAP-43 protein expression in NTS following IH
GAP-43 protein was not different in NTS between IH and normoxic WT rats at 1
day (p = 0.42) and at 7 days (p = 0.48) exposure (Fig 5.5a-b). Following 95 days,
GAP-43 protein expression was reduced by about 34% (p = 0.045) in NTS of the
IH exposed animals compared to the normoxic animals (Fig 5.5c).

5.4.6 Changes in neuroplastic markers in NTS of KILO rats following IH
To determine whether leptin contributed to the changes observed in the
neuroplastic markers in NTS, leptin deficient rats (KILO rat) were exposed to
acute (1 day) IH. IH failed to induce any changes in BDNF in the KILO (p=0.44)
or WT rat (Fig. 5.6a). Similarly, in the KILO rat, acute IH did not induce changes
in TrkB isoforms (Fig. 5.6b) which were present in the WT rat. Neither gp95 (p =
0.27; Fig. 5.3b), gp145 (p = 0.20) nor the ratio of gp145:gp95 TrkB isoforms (p =
0.44) were altered in NTS of the KILO rats following IH exposure. On the other
hand, 1 day exposure of KILO rats to IH induced a lower (p = 0.043) protein
expression of synaptophysin in NTS by about 26% compared to normoxic KILO
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Figure 5.4 NTS expression of synaptophysin following IH.
Representative western blots and bar charts showing changes in protein
expression of synaptophysin in NTS after 1 day (a), 7 days (b) and 95 days (c) of
exposure to IH or normoxic. Note the synaptophysin decreases in response to
acute/short term and long term IH exposure. *, p<0.05 as determined by twotailed, unpaired Student t-test. n=7-8.
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Figure 5.5 NTS expression of GAP-43 following IH.
Representative western blots and bar charts showing the change in protein
expression of GAP-43 in NTS at 1 day (a), 7days (b) and 95 days (c) after IH or
normoxic exposure. Note that at only 95 days of IH exposure is GAP-43 altered
in NTS. *, p<0.05 as determined by two-tailed, unpaired Student t-test. n=7-8.
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controls (Fig. 5.6c). IH as previously shown induced a decrease in synaptophysin
protein expression in the WT rat after 1 day exposure. Acute IH exposure in the
KILO rat did not induce changes in GAP-43 (p = 0.44; Fig. 5.6d).
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Figure 5.6 Effect of IH in KILO rats on neuroplastic markers in NTS.
Representative western blots and bar charts showing the change in protein
expression of BDNF (a), TrkB (b), synaptophysin (c)m and GAP-43 in NTS at 1
day IH exposure in WT and KILO-/- rats. Note that the lack of leptin abolishes the
TrkB effects to IH (b), but not those associated with synaptophysin (c) after IH. In
addition, note that the lack of leptin does not induce changes in BDNF nor GAP43 after IH. *, p<0.05 as determined by two-tailed, unpaired Student t-test. n=4-8.
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5.5 DISCUSSION
This study has demonstrated that both acute and long term IH exposure
induces changes in neuroplasticity markers in NTS. In addition, some of these
changes observed following acute IH exposure were due to leptin signaling in
NTS as they were not observed in the leptin deficient rats. Finally, long term
exposure to IH induced an increase in MAP, but not HR, suggesting that some of
the neuronal plasticity changes observed in NTS may be associated with the
hypertension resulting from long term activation of peripheral chemoreceptors.
BDNF protein expression levels were elevated in NTS following 7 days of
IH exposure. On the other hand, after 95 days of IH exposure, BDNF levels were
found to be lower than those of animals exposed to normoxia. These changes
suggest an initial elevated responsiveness of the BDNF-TrkB system, whereas
this effect is diminished over long-term exposure to IH as gp145:gp95
normalizes, and BDNF ligand is reduced. The neurotrophin BDNF has been
demonstrated in NTS cardiovascular afferent synapses (Martin et al., 2009), and
has been suggested to be released in response to activation of the carotid
chemoreceptor reflex (Chavez-Valdez et al., 2012; Montero et al., 2012). BDNFcontaining terminal boutons come in close apposition to second-order neurons
shown to express its receptor, TrkB (Kline et al., 2010). Within NTS, BDNF has
been reported to modulate glutamatergic neurotransmission and thus altering
cardiovascular responses (Clark et al., 2011).
It was found that the TrkB receptor isoforms within NTS increased in
response to acute and short term IH exposure, whereas after 95 day IH
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exposure, the gp95 isoform was decreased. The gp145 TrkB subunit is
considered the full-length isoform of the receptor, whereas gp95 TrkB is a
truncated version lacking an intracellular kinase domain (Klein et al., 1990;
Middlemas et al., 1991). The gp95 TrkB acts as a dominant negative receptor
inhibiting the responsiveness of the full-length gp145 TrkB to stimulation by
BDNF (Haapasalo et al., 2001). Due to the dominant negative nature of the gp95
TrkB isoform, the ratio of gp145:gp95 may be an important indicator of BDNFTrkB signaling capability (Haapasalo et al., 2001). This ratio was found to be
higher in animals exposed to 1 day IH, but not different following 7 or 95 days of
exposure. As BDNF-TrkB signaling plays an important role in long-term
neuroplastic alterations such as neurite outgrowth (Hartnick et al., 1996; Hu et
al., 2005) and synaptogenesis (Seil and Drake-Baumann, 2000; Hu et al., 2005),
it is likely that these changes begin within the first day of IH exposure and
diminish over time once neuroplasticity has been induced. The finding that BDNF
protein expression decreases after long term exposure is consistent with a recent
study by Chavez-Valdez and colleagues (2012) demonstrating a decrease of
NTS BDNF content following hyperoxia in juvenile rats.
TrkB may also mediate the effects of hormonal signaling molecules such
as leptin within NTS (Spaeth et al., 2012) and other brain regions (Liao et al.,
2012). The changes in TrkB isoforms observed following acute IH were not seen
in NTS of leptin-deficient KILO rats. This observation, coupled with the earlier
finding that plasma leptin levels are elevated after acute IH (Messenger et al.,
2012; Moreau and Ciriello, 2013) suggests that leptin is important for the
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increase in TrkB. Although the importance of leptin over longer periods of IH
exposure is not known and warrants further study, on the basis of the finding that
TrkB protein expression remains elevated compared to normoxic controls after
short term IH exposure suggests that it may continue to signal TrkB.
Interestingly, the decrease in TrkB after 95 days of IH exposure is also consistent
with the finding of decreased plasma levels of leptin observed in these animals
after long term IH exposure (unpublished observations).
We observed reduced synaptophysin during exposure to IH and reduced
GAP-43 protein expression only following 95 days of IH. The reduction in
synaptophysin in NTS following 1 day exposure of IH was not due to leptin
signaling as it was still observed within the leptin deficient animals. This suggests
that these alterations in synaptophysin expression may be due to activitydependent signaling (Li et al., 2002) or a direct effect of hypoxia (Ding et al.,
2009). Synaptophysin is a marker for synapses and synaptic strength, and has
been used for the quantification of synapses (Calhoun et al., 1996). On the other
hand, GAP-43 is an important mediator of neurite outgrowth (Jap Tjoen San et
al., 1991), neuronal regeneration (Meiri et al., 1988) and a marker of the presynaptic terminals (Eastwood et al., 2007). Consistent with the findings in this
study, it has recently been shown that IH exposure reduces afferent
neurotransmission in the intermediate and caudal NTS (Almado et al., 2012). It
was also determined that this synaptic depression was the result of a loss of
active synapses (Almado et al., 2012). Thus, the reduction in synaptophysin and
GAP-43 observed in this study could be interpreted to suggest a reduction in
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NTS active synapses, synaptic strength and afferent neurites. Although it would
be expected that chemoreceptor afferent activity would be elevated following IH,
the depression of neurotransmission may be selectively related to reduced
baroreceptor reflex activity and output observed in animals exposed to chronic IH
(Lai et al., 2006). Consistent with this suggestion, it was found that after chronic
IH, the animals exhibited an elevated MAP and a decreased HR response to the
elevated arterial pressure further suggesting an impairment of the baroreceptor
reflex.
In conclusion, the present results support the notion that the NTS complex
functions as an important site of integration of afferent inputs. The IH induced
changes

observed

in

neuroplastic

molecules

including

BDNF-TrkB,

synaptophysin and GAP-43 suggest this integration is dynamic, and may be
altered over acute, short- and long-term IH and at least the short term effects
appear to be dependent on leptin. The direct contribution of these alterations to
cardiovascular changes observed are not known, but do appear to be associated
with hypertension and possibly baroreceptor reflex resetting.
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CHAPTER 6
EFFECTS OF ANGIOTENSIN II ON LEPTIN AND DOWNSTREAM LEPTIN
SIGNALING IN THE CAROTID BODY DURING ACUTE INTERMITTENT
HYPOXIA

A version of this chapter has been submitted for publication to Neuroscience
NSC-13-1392, October 8, 2013.
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6.

CHAPTER 6

6.1 CHAPTER SUMMARY
Angiotensin II (ANG II) is known to promote leptin production and
secretion. Although ANG II type 1 receptors (AT 1R) and leptin are expressed
within the carotid body, it is not known if AT 1R and leptin are co-expressed in the
same glomus cells nor if these peptides interact to alter the carotid body function.
This study was done to investigate whether ANG II altered leptin signaling in the
carotid body during acute intermittent hypoxia (IH). Rats were treated with
captopril or the AT1R blocker losartan in the drinking water for 3 days prior to
being exposed to IH (8h) or normoxia (8h). IH induced increases in plasma ANG
II and leptin compared to normoxic controls. Captopril treatment abolished the
plasma leptin changes to IH, whereas losartan treatment had no effect on the IH
induced increase in plasma leptin. Additionally, carotid body glomus cells
containing both leptin and the long form of the leptin receptor (OB-Rb) were
found to co-express AT1R protein, and IH increased the expression of only AT 1R
protein within the carotid body in both captopril and non-captopril treated
animals. On the other hand, losartan treatment did not alter AT1R protein
expression to IH. Additionally, captopril and losartan treatment eliminated the
elevated carotid body leptin protein expression, and the changes in
phosphorylated signal transducer and activator of transcription 3 protein, the
short form of the leptin receptor (OB-R100), suppressor of cytokine signaling 3,
and phosphorylated extracellular-signal-regulated kinase 1/2 protein expression
induced by IH. However, captopril elevated the expression of OB-Rb protein,
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whereas losartan abolished the changes in OB-Rb protein to IH. These findings,
taken together with the previous observation that ANG II alters carotid body
chemosensitivity, suggest that the increased circulating levels of ANG II and
leptin induced by IH act at the carotid body to alter leptin signaling within the
carotid body which in turn may influence chemoreceptor function.
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6.2 INTRODUCTION
The carotid body is a highly vascularized organ located bilaterally at the
bifurcations of the common carotid arteries (Heymans et al., 1930; Nurse, 2005).
The carotid body, composed of specialized oxygen-sensing type-I glomus cells,
signals carotid sinus nerve endings that transmit the afferent information to the
nucleus of the solitary tract (Ciriello et al., 1994), activating homeostatic
mechanisms involving respiratory, cardiovascular and hormonal systems
(Schultz and Li, 2007; Kumar, 2009).
There are now considerable data suggesting that substances within the
circulation gain access to carotid body glomus cells and alter their excitability
(Allen 1998; Chen et al., 2005; Leung et al., 2000, 2003; Nurse & Piskuric, 2012;
Peng et al., 2006). One vasoactive compound shown to alter the discharge of
carotid body afferent fibers independent of its circulatory effects is angiotensin II
(ANG II) (Allen 1998; Leung et al., 2000). The carotid body has been shown not
only to contain ANG II binding sites (Allen, 1998), but to also possess its own
intrinsic renin-angiotensin system (RAS) (Lam & Leung, 2002), suggesting that
ANG II within the carotid bodies may act in an autocrine/paracrine manner. Key
elements of the RAS, including protein and mRNA of angiotensinogen as well as
mRNA of angiotensin I converting enzyme (ACE) have been localized to the
type-I glomus cells (Lam & Leung, 2002). A role for ANG II in chemosensitivity is
supported by the finding that gene expression for the ANG II type 1 receptor
(AT1R) is up-regulated in the carotid bodies during chronic hypoxia (Leung et al.,
2000; Fung et al., 2002), and this increased expression of the AT1R is associated
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with the increased sensitivity of carotid chemoreceptors (Leung et al., 2000; Fung
et al., 2001, 2002). In addition, administration of the ANG II type 1 receptor
(AT1R) antagonist losartan abolishes these effects on chemoreceptors (Allen,
1998; Leung et al., 2000), including the increased intracellular calcium levels in
type-I cells induced by ANG II (Fung et al., 2001). Consistent with these results,
a recent study has demonstrated that signaling through the AT 1R is critical for
carotid chemoreceptor sensitivity and signal transduction of the carotid
chemoreceptor reflex during hypoxia (Marcus et al., 2010).
The increases in intracellular calcium induced by ANG II suggest that
through activation of the AT1R, ANG II may impact vesicle secretion from type-I
glomus cells and therefore promote the release of other potential modulators
involved in chemoreceptor function and for the signal transduction of glomus
cells to the carotid sinus nerve (Gomez-Nino et al., 1990; Eyzaguirre and Zapata,
1968; Bock, 1980). One possibility may be that ANG II may signal changes in
leptin signaling within the carotid body as ANG II signaling is known to affect
leptin production and secretion in other tissues such as ventricular myocytes,
bone marrow and adipocytes (Cassis et al., 2004; Danser et al., 1999;
Haznedaroglu and Buyukasik, 1997; Haznedaroglu et al., 1996; Rajapurohitam et
al., 2006, 2012). Leptin is a 16 kDa protein product of the obese gene and is
produced in proportion to, and secreted primarily, but not exclusively, by
adipocytes (Lonnquist et al., 1995; Caro et al., 1996). Circulating leptin is thus an
indicator of body fat content and acts as a satiety hormone, as well as increasing
energy expenditure to balance body energy stores (Lonnquist et al., 1995; Caro
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et al., 1996). Leptin signals primarily through the long-form leptin receptor (OBRb), although 6 splice variants of the leptin receptor exist (OB-Ra-OB-Rf) of
which only a few have known functions (Lee et al., 1996; Wang et al., 1996).
Leptin has been shown to possess a signaling capability within the carotid body
(Messenger et al., 2012; Messenger and Ciriello, 2013), and both circulating and
carotid body protein expression levels of leptin have been found to increase in
response to acute intermittent hypoxia (IH) and chronic intermittent hypoxia
challenge (Messenger et al., 2012; Messenger and Ciriello, 2013), although its
function within carotid body glomus cells remains unclear. The discovery of
leptin, as well as four leptin receptor isoforms within carotid body glomus cells
(Messenger et al., 2012, 2013; Porzionato et al., 2011), as well as the finding that
circulating leptin induces phosphorylated signal transducer and activator of
transcription 3 (pSTAT3) and immediate early gene Fra-1/2 expression within
glomus cells (Messenger et al., 2012) is suggestive of a role in chemosensitivity
for the adipokine.
ANG II has been shown to be released and is required along with
increased sympathetic nerve activity for the chronic hypertension in both human
and the animal model of obstructive sleep apnea (Fletcher et al., 1999, 1992a/b;
Moller et al., 2003; Yuan et al., 2004). In addition, in the animal model of
obstructive sleep apnea, circulating and carotid body leptin is elevated
(Messenger et al., 2012; Messenger and Ciriello, 2013; Moreau and Ciriello,
2013), a finding consistent with clinical data (Phillips et al., 2000; Harsch et al.,
2003). However, it is not known whether ANG II may affect leptin signaling in the
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carotid body, which in turn may contribute to altered sensitivity within the
chemoreceptor reflex pathway (Ciriello and Moreau, 2012, 2013). Therefore, this
study was done to determine: (1) whether, selective chronic inhibition of ACE by
captopril or the selective blockade of the AT1R by losartan had an effect on
circulating levels of leptin during IH; (2) whether glomus cells expressing the
AT1R co-express leptin and the OB-Rb, and whether AT1R levels in carotid
bodies are altered following exposure to IH; (3) whether chronic inhibition of ACE
or the AT1R alters leptin, leptin receptor or downstream mediators of the OB-Rb
signaling within the carotid body.
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6.3 METHODS AND MATERIAL
6.3.1 General animal procedures
Experiments were done in male Sprague–Dawley rats (Charles River Canada,
St. Constant, Canada) weighing 250-350 g. All animals were housed under
controlled conditions with a 12 h light/dark cycle. Food and water were available
ad libitum. All experimental procedures were done in accordance with the
guidelines on the use and care of laboratory animals as set by the Canadian
Council on Animal Care and approved by the Animal Care Committee at the
University of Western Ontario.

6.3.2 Angiotensin converting enzyme inhibition
Inhibition of angiotensin converting enzyme was performed by administration of
captopril (Sigma-Aldrich, St. Louis, MO) in the drinking water (2 mg/ml) of each
animal three days prior to IH (n=7) or normoxic conditions (n=7). Captopril was
freshly dissolved daily in the drinking water which was monitored daily and it was
calculated that the animals received 146 ± 6 mg/kg/day of captopril. At this dose,
ACE inhibition has been shown to occur (Schiffrin & Genest, 1982; Ferrone &
Antonaccio, 1979).
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6.3.3 Selective blockade of AT1R
Selective blockade of the AT1R was accomplished by the administration of
losartan (Merck, Whitehouse Station, NJ) in the drinking water (0.12 mg/ml) of
each animal three days prior to AIH (n=7) or normoxic conditions (n=7). Losartan
was freshly dissolved daily in the drinking water which was monitored daily and it
was calculated that the animals received 14.2 ± 0.7 mg/kg/day of losartan. At this
dose, AT1R blockade has been shown to occur (Boustany et al., 2005; Kline &
Liu, 1994).

6.3.4 Induction of IH
IH or normoxia was induced in the captopril or losartan treated animals described
above and in a separate set of animals that were not treated with the drugs (IH,
n=11; normoxia, n=11) as previously described (Messenger et al., 2012;
Messenger and Ciriello, 2013; Moreau and Ciriello, 2013). Animals were exposed
to the 8h IH or the normoxic stimuli each day of the experimental period during
daylight hours (900h-1700h).

6.3.5 Plasma collection and immunoassays

Measurement of plasma levels of leptin and ANG II were made immediately after
the exposure of the animals to IH or the normoxic stimuli (Messenger et al.,
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2012; Messenger & Ciriello 2013; Moreau and Ciriello, 2013). Blood samples
were collected by cardiac puncture in 7% ethylenediaminetetraacetic acid at a
volume of 10 µl/ml blood. The blood was immediately centrifuged at 10 000 RPM
for 10 min at 4 °C to isolate the aqueous plasma. This aqueous plasma phase
was removed and stored frozen at -80 °C until analyzed for hormone content.
Plasma samples were analyzed using enzyme immunoassays for rat leptin (interassay variability: 6.5% intra-assay variability: 7.1%; Enzo Life Sciences;
Farmingdale, NY), and rat ANG II (inter-assay variability: <15%; intra-assay
variability: <10%; Phoenix Pharmaceuticals, Burlingame, CA) according to
manufacturer instructions. Enzyme immunoassay plates were read on a
SpectraMax M5 plate reader using SoftMax Pro v.5 microplate analysis software
(Molecular Devices; Sunnyvale, CA).

6.3.6 Carotid body protein extracts and immunoblot analysis
Carotid body protein extracts were obtained following bilateral carotid body
excision from the normoxia- or IH-exposed animals as described previously
(Messenger et al., 2012; Messenger & Ciriello 2013). In brief, the carotid bodies
(bilaterally) from each animal were snap frozen, pooled together, homogenized in
200µl of RIPA buffer solution (150 mM NaCl, 1 mM NaF, 1 mM NaVO 4, 0.5 mM
β-glycerophosphate, 1mM EDTA, 1% Triton-X 100, 50mM Tris-HCL at pH of 7.5)
with a protease inhibitor cocktail (Roche Diagnostics, Laval, QC, Canada) and
sonicated. The homogenate was centrifuged at 4°C for 15 min at 2100 RPM. The
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supernatant was retained and then centrifuged a second time at 4°C for 20 min
at 13200 RPM. The resultant supernatant was retained as the protein
preparation.

Equal

concentrations

of

extracted

proteins

normalized

by

colorimetric DC assay (Bio-Rad laboratories, Hercules, CA) underwent gel
electrophoresis in 10% Bis-acrylamide gel (Life Technologies Inc., Carlsbad, CA)
and transferred onto a polyvinylidene fluoride membrane. Blots were probed
using: polyclonal rabbit anti-AT1R (1:1000; Cat. # sc-1173; Santa Cruz
Biotechnology Inc., Dallas, TX), anti-AT2R (1:1000; Cat. # sc-7420; Santa Cruz),
polyclonal rabbit anti-leptin (1:1000, Cat. # sc843; Santa Cruz Biotechnology
Inc.), polyclonal rabbit anti-OB-R (1:1000, Cat. # OBR12-A; Alpha Diagnostics
International Inc., San Antonio, TX), affinity purified polyclonal chicken anti-OBRb (1:1000, Cat. # CH14104; Neuromics, Edina, MN), polyclonal rabbit antiSOCS3 (1:1000, Cat. # ab16030; Abcam Inc., Cambridge, MA), monoclonal
rabbit anti-STAT3 (1:2000, Cat. # 4904S; Cell Signaling Technology), polyclonal
rabbit anti-pSTAT3 (1:1000, Cat. #9131S; Cell Signaling Technology, Danvers,
MA), monoclonal rabbit anti-ERK1/2 (1:1000, Cat. # 4695S; Cell Signaling
Technology), monoclonal rabbit anti-pERK1/2 (1:1000, Cat. # 4376S; Cell
Signaling Technology), and monoclonal horseradish peroxidase-conjugated βactin (1:50000, catalog no. A3854, Sigma-Aldrich) diluted in 5% milk-Trisbuffered saline-Tween 20 buffer and with horseradish peroxidase conjugated
donkey anti-rabbit IgG, donkey anti-goat, or donkey anti-chicken IgG (1:10000,
catalog # 711- 035-152, 705-035-003 or 703-035-155, respectively; Jackson
ImmunoResearch Laboratories, West Grove, PA) diluted in 5% milk-1X Tris-
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buffered saline-Tween 20 buffer as the secondary antibody. Immunoreactive
bands were visualized using an enhanced chemiluminescence detection system
(Millipore Canada Ltd, Toronto, ON, Canada).

6.3.7 Immunofluorescence

Immediately after the application of the 8h IH or normoxic stimuli, the animals
(IH, n=3; normoxia, n=3) were anesthetized with 0.3 ml/100g equithesin and
perfused transcardially using 500 ml ice-cold phosphate buffered saline (PBS;
0.1M, pH 7.4) followed by 4% paraformaldehyde in 0.1 M PBS (Messenger et al.,
2012; Messenger & Ciriello 2013). The carotid arteries at their bifurcations, along
with the attached carotid bodies were removed bilaterally, and stored overnight in
Zamboni’s fixative at 4 ºC. The following day the tissues were gradually
dehydrated through a series of alcohols, and placed in xylene followed by
paraffin wax. Serial transverse sections were cut at 6 µm on a RM 2155
microtome (Leica Microsystems Inc., Buffalo Grove, IL), floated in a warm water
bath and mounted on double-gelatinized glass microscope slides and placed on
a slide warmer. Tissue sections were later de-paraffinized in xylene and
rehydrated using graded alcohol solutions. For each animal, 1 in every 5 slides
was stained with thionin to identify the region of the carotid body and blood
vessels. Additionally, adjacent sections to those stained for thionin from the
normoxic and IH-exposed animals were rinsed in PBS and processed for doubleimmunofluorescence (Vectastain Elite ABC Kit, Cat. # PK6100; Vector
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Laboratories, Burlingame, CA) for leptin, Ob-Rb and AT1R. Sections underwent
an antigen-retrieval protocol using a citrate buffer (10 mM sodium citrate/0.05%
Tween; pH 6.0) heated to 90-95ºC in a microwave for 15 min and then were
rinsed in PBS before being placed in 5% normal goat serum ((Cat. # S-1000;
Vector Laboratories) in PBS containing 0.3% Triton X-100 for 30 min (Messenger
et al., 2012). The sections were later rinsed in PBS and placed overnight (12 h)
into a primary polyclonal rabbit anti-leptin (Cat. # sc843; Santa Cruz
Biotechnology Inc.; 1:1000 in PBS/0.3% Triton X-100) or affinity purified
polyclonal chicken anti-OB-Rb (1:1000, Cat. # CH14104; Neuromics) at room
temperature. Sections were then rinsed in PBS and incubated in goat biotinylated
anti-rabbit IgG (Cat. # BA-1000; Vector Laboratory) diluted 1:500 in PBS/ 0.3%
Triton X-100 for 1 h. Following PBS rinses, sections were placed in Streptavidin
Alexafluor-488 (Cat. # S11223; Life Technologies) diluted 1:100 for 1 h.
Following PBS rinses, sections were exposed to an avidin containing solution for
15 min followed by a biotin containing solution for an additional 15 min
(Avidin/Biotin blocking kit, Cat. # SP-2001; Vector Laboratories) to block nonspecific binding sites. Sections were then rinsed in PBS and incubated overnight
at room temperature in primary polyclonal rabbit anti-AT1R (Cat. # sc-1173;
Santa Cruz Biotechnology Inc.) diluted 1:1000 in PBS/0.3% Triton-X 100 and 5%
normal goat serum. Following PBS washes, the sections were placed in goat
biotinylated anti-rabbit IgG diluted 1:500 in PBS/ 0.3% Triton X-100 or goat
biotinylated anti-chicken IgY (Vectastain Elite ABC Kit) diluted 1:200 in PBS/
0.3% Triton X-100 for 1 h. Sections were rinsed in PBS and placed in
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Streptavidin Texas Red (Code: RPN1233; GE Healthcare, Baie d’Urfe, QC,
Canada) diluted 1:100 for 1 h. Following PBS rinses, sections were placed in
100% ethanol containing 5% glacial acetic acid on dry ice for 10 min. Sections
were then immediately cover-glassed using Fluoromount mountant.

6.3.8 Statistical analysis

Statistical comparisons between the normoxia and IH exposed animals were
made using a two-tailed, unpaired Student t-test. In all comparisons, a minimum
p-value of < 0.05 was taken to indicate statistical significance (GraphPad Prism;
GraphPad Software, San Diego, CA, USA).
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6.4 RESULTS

6.4.1 Plasma ANG II and leptin levels following captopril or losartan
treatment

IH significantly increased plasma ANG II (p < 0.002) (Fig. 6.1a) levels about 3
fold above those found in the normoxic controls. Plasma leptin (Fig. 6.1b) levels
were also significantly increased in IH exposed animals by approximately 6 fold
(p < 0.01) above those found in the normoxic controls. Following captopril
treatment, no differences were found between the IH and normoxic controls in
both ANG II and leptin levels within the plasma. Following losartan treatment
ANG II levels were found not to be different between the normoxic controls and
IH exposed animals (Fig. 6.1a), whereas the increased levels of leptin induced by
IH was not affected by the selective blockade of AT 1R with losartan (Fig. 6.1b).

6.4.2 Leptin, OB-Rb and AT1R co-expression in carotid body
Figure 6.2 shows the effect of IH on leptin, OB-Rb and AT1R immunoreactivity
within glomus cells of the carotid body. Glomus cells expressed low levels of
leptin (Fig. 6.2a), OB-Rb and AT1R (Fig. 6.2b) immunofluorescence under
normoxic conditions. However, following exposure to IH, carotid body glomus
cells exhibited an elevated immunofluorescence associated with leptin (Fig.
6.2c), ObRB (Fig. 6.2e), and AT1R (Fig. 6.2d and 6.2f). Figure 6.2 also shows
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Figure 6.1 Change in plasma levels of ANG II and leptin following IH.

Bar charts showing the effect of IH on plasma levels of ANG II (a), and leptin (b)
compared to levels observed in normoxic controls under sham (non-captopril
treatment), and captopril and losartan treatment. Note that plasma ANG II (a) and
leptin (b) are significantly elevated following IH in the non-captopril treated
(sham) group compared to normoxic group. Additionally, note that captopril and
losartan prevented the rise in ANG II to IH. Furthermore, note that while captopril
blocked the rise in leptin to IH, this increase in leptin to IH was not affected by
losartan treatment. Values are shown as means ± S.E. *p < 0.01.
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Figure 6.2 Leptin, ObRB and AT1R in glomus cells in the carotid body.
Fluorescent photomicrographs of the carotid body showing glomus cells
immunoreactive to leptin (a,c), Ob-Rb (e) and angiotensin type-1 receptor (AT1R;
b,d,f) following exposure to IH (c,d,e,f) or normoxia (a,b). Note that cells
immunoreactive to leptin and Ob-Rb also contain immunoreactivity to AT 1R.
Calibration marks indicate 25 µm.
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that AT1R immunoreactivity is co-localized within the same glomus cells of the
carotid body that express leptin and Ob-Rb immunoreactivity.

6.4.3 Effect of IH on AT1R and AT2R in carotid body
Figure 6.3 shows the effect of IH on AT1R and AT2R protein expression in the
carotid body. When exposed to IH, the expression of AT 1R was significantly
increased by about 33 % (Fig. 6.3a). However, the protein expression of AT 2R
was not different following IH exposure (Fig. 6.3b). This same pattern was
evident in animals that were treated with captopril (Fig. 6.3c-d). However,
following losartan treatment, neither AT1R nor AT2R protein expression was
altered in the carotid body after IH exposure (Fig. 6.3e-f).

6.4.4 Effect IH in animals treated with captopril or losartan on leptin within
the carotid body

As previously reported by Messenger and Ciriello (2013), IH induced an increase
in the leptin protein expression in the carotid body. Figure 6.6 shows the effect of
captopril treatment on carotid body leptin protein levels following normoxia (Fig.
6.4a) or IH (Fig. 6.4b) exposure. In normoxic animals (Fig. 6.4a), captopril
treatment lowered leptin levels to about 50% of non-captopril treated animals. In
the IH animals, captopril (Fig. 6.4b) lowered leptin levels within the carotid body
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Figure 6.3 Effect of IH on AT1R and AT2R within carotid body.
Western blots showing the effect of IH on AT 1R (a) and AT2R (b) the protein
expression in the carotid bodies. Note that AT 1R protein levels are significantly
elevated following IH, whereas levels of the AT2R are not altered in the carotid
bodies (a-b). These effects on the AT1R were maintained after captopril
treatment (c-d). However, losartan treatment eliminated the effects of IH on AT 1R
protein expression (e), and did not alter AT2R (f) protein expression. *,
significantly different from normoxic control animals.
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Figure 6.4 Carotid body leptin protein following IH.
Western blots showing changes in leptin protein expression within the carotid
body following IH with or without captopril (Capt; a-c) or losartan (Los; d)
treatment. Note that captopril treatment lowered leptin levels within the carotid
body in both normoxic (Norm) (a) and the IH (b) group. In addition, the decrease
in leptin following captopril treatment was greater in the IH group compared to
the normoxic group (c).

A similar decrease in leptin protein expression is

observed following losartan treatment (d). *, significantly different from noncaptopril IH treated animals.
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to about 58%, of those levels found within the IH non-captopril treated animals. In
addition, when the effects of captopril (Fig. 6.4c) in the normoxic animals were
compared to those in the IH animals, it was found that captopril lowered the
leptin levels of the IH animals to about 60% of the normoxic captopril animals
(Fig. 6.4c). Similarly, losartan significantly lowered carotid body leptin protein
expression to IH (Fig. 6.5d; Table 6.1).

6.4.5 Effect of IH on OB-Rb and OB-R100 protein expression within the
carotid body following captopril or losartan treatment

Captopril treatment in either the normoxic controls (Fig. 6.5a) or the IH exposed
(Fig. 6.5c) animals resulted in a lower carotid body OB-Rb (Fig. 6.5a and 6.5c)
protein levels (31% and 44%, respectively) compared to normoxic controls, while
the protein expression levels of OB-R100 (Fig. 6.5b and 6.5d) were increased to
about 100% and 140% above the levels within the non-treated normoxic (Fig.
6.5b) and IH (Fig. 6.5d) animals, respectively. Additionally, when the effects of
captopril in the normoxic animals were compared to those of the IH animals (Fig.
6.6a), it was found in the IH animals that captopril raised the expression levels of
the OB-Rb protein to about 140% more than the normoxic controls. On the other
hand, no differences were found with the expression of the OB-R100 protein (Fig.
6.6b) between normoxic- and IH-captopril treated animals. In contrast, both OBRb and OB-R100 protein expression were not altered in the IH group compared to
the normoxic controls after treatment with losartan (Table 6.1).
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Table 6.1 The effect of captopril or losartan treatment on ANG II receptors
and leptin signaling molecules in the carotid body following IH.
________________________________________________________________________
IH

IH +
Captopril

IH +
Losartan

Protein

(p value)

(p value)

(p value)

AT1R

↑ 0.0129

↑ 0.0138

0.9201

AT2R

0.4406

0.3641

0.4634

Leptin

↑*

↓ 0.05

↓ 0.0452

OB-Rb

↓*

↑ 0.0348

0.5232

OBR100

↑*

Treatment

0.2471

0.7864

pSTAT3

No Change *

0.2219

0.8345

pERK1/2

↑*

0.246

0.2093

SOCS3

↑*

0.28

0.3421

________________________________________________________________________
All p values are in comparison to normoxic controls with captopril or losartan
treatment. *, adapted from Messenger and Ciriello, 2013.
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Figure 6.5 ObR isoforms following Capt in carotid body.

Western blots showing changes in OB-Rb (a-b) and OB-R100 (c-d) protein within
the carotid body following IH and captopril treatment. Note that captopril
treatment lowered Ob-Rb protein levels within the carotid body in both normoxic
(Norm) (a) and the IH (b) group. On the other hand, the protein levels of OB-R100
were increased in both the normoxic (c) and the IH (d) groups. *, significantly
different from non-captopril treated animals within each group.
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Figure 6.6 ObR isoforms following Capt: IH vs. normoxic groups.
Western blots showing changes in OB-Rb (a) and OB-R100 (b) protein within the
carotid body following captopril treatment in both the normoxic and IH groups.
Note that the protein level of Ob-Rb was significantly (*) lower in the IH animals
compared to the normoxic animals (a) treated with captopril.
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6.4.6 Effect of captopril or losartan on STAT3, pSTAT3, SOCS3 and pERK
1/2 in the carotid body after IH

Figures 6.7-6.11 summarize the effects of captopril treatment on carotid body
protein expression of STAT3 (Figs. 6.7a-b and 6.8a), pSTAT3 (Figs. 6.7c-d and
6.8b), SOCS3 (Fig. 6.9a-c), and pERK 1/2 (Figs. 6.10 and 6.11a-c; Table 6.1) in
normoxic and IH exposed animals. Captopril treatment in normoxic animals
resulted in decreased STAT3 protein expression (Fig. 6.7a) to about 47% of nontreated group, whereas no differences were found between IH-exposed animals
(Fig. 6.7b) or between normoxic and IH animals treated with captopril (Fig. 6.8a)
or losartan (Table 6.1). Captopril treatment in normoxic and IH exposed animals
also decreased pSTAT3 (52% and 49% of non-captopril treated animals,
respectively) protein expression (Fig. 6.7c-d). However, STAT3 and pSTAT3
protein levels in the IH-captopril treated animals were not different from those in
the normoxic-captopril treated animals (Fig. 6.8; Table 6.1). Similarly, pSTAT3
protein levels in the IH-losartan treated animals were not different from those in
the normoxic-losartan treated animals (Table 6.1).

Captopril treatment in normoxic and IH exposed animals increased
SOCS3 protein expression within the carotid body (Fig. 6.9a-b). In normoxic
animals, captopril increased the expression of SOCS3 protein by almost 1036%
(Fig. 6.9a), while in the IH exposed animals captopril increased the expression of
SOCS3 protein by about 2490% (Fig. 6.9b). However, the protein expression
level of SOCS3 in the IH captopril treated animals compared to the normoxic
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captopril treated animals was not different (Fig. 6.9c; Table 6.1). Similarly,
SOCS3 protein levels in the IH-losartan treated animals were not different from
those in the normoxic-losartan treated animals (Table 6.1).

ERK1/2 and pERK1/2 protein levels were decreased (to about 48% and
42% of non-captopril treated animals, respectively) following captopril treatment
(Fig 6.10a and 6.10c). On the other hand, neither ERK1/2 or pERK1/2 protein
levels in the IH captopril treated animals were different from those in the noncaptopril treated IH exposed group (Fig, 6.10b and 6.10d) or from the normoxic
captopril treated groups (Fig. 6.11). Similarly, ERK1/2 and pERK1/2 protein
levels in the IH-losartan treated animals were not different from those in the
normoxic-losartan treated animals (Table 6.1).
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Figure 6.7 Changes in STAT3 following Capt
Western blots showing changes in STAT3 (a-b) and pSTAT3 (c-d) protein within
the carotid body following IH and captopril treatment. Note that captopril
treatment significantly (*) lowered STAT3 protein levels within the carotid body
only in normoxic (Norm) group (a). However, pSTAT3 levels were significantly (*)
lower in both the normoxic (c) and the IH (d) groups after captopril treatment.
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Figure 6.8 Changes in STAT3 following Capt: IH vs. normoxic groups
Western blots showing changes in STAT3 (a) and pSTAT3 (b) protein within the
carotid body following captopril treatment in both the normoxic and IH groups.
Note that the protein level of pSTAT3 was significantly (*) lower in the IH animals
compared to the normoxic animals (b) treated with captopril.
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Figure 6.9 Changes in SOCS3 following IH and Capt treatment.
Western blots showing changes in SOCS3 protein expression within the carotid
body following IH and captopril treatment. Note that captopril treatment
significantly (*) elevated SOCS3 protein levels within the carotid body in the
normoxic (Norm) (a) and IH group (b). However, SOCS3 levels were significantly
(*) lower in the IH captopril treated group compared to the normoxia captopril
treated group (c).
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Figure 6.10 Changes in ERK1/2 following IH and Capt treatment
Western blots showing changes in ERK 1/2 (a-b) and pERK 1/2 (c-d) protein
within the carotid body following IH and captopril treatment. Note that captopril
treatment significantly (*) lowered ERK 1/2 and pERK 1/2 protein levels within the
carotid body only in normoxic (Norm) group (a and c).
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Figure 6.11 Changes in ERK1/2 following Capt: IH vs. normoxic groups
Western blots showing changes in ERK 1/2 (a) and pERK 1/2 (b) protein within
the carotid body following captopril treatment in both the normoxic and IH groups.
Note that the protein levels were not altered in either group treated with captopril.
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6.5 DISCUSSION
These data provide the first direct evidence that ANG II plays an important
role in the regulation of leptin not only within the carotid body, but also within the
circulation during IH, and that within the carotid body ANG II through activation of
AT1R contributes to changes in downstream leptin signaling during IH. These
conclusions are based on the findings that within the carotid body, cells that
expressed leptin and the OB-Rb also expressed the AT1R. Additionally, inhibition
of ANG II by blocking ACE following captopril treatment decreased leptin not only
within the carotid body, but also the plasma levels of leptin during IH.
Furthermore, the decrease in available leptin to the carotid body was
accompanied by an increase in the OB-Rb protein expression in captopril treated
animals, but no change in the losartan treated animals. This coupled with the
lower carotid body levels of leptin during IH in the captopril and losartan treated
animals suggests a dampening of the entire leptin signaling system within the
carotid body by the lack of ANG II and activation of AT1R. This suggestion is
consistent with the observation that both captopril and losartan treatment
resulted in an inhibition of the downstream mediators of leptin signaling within the
carotid body following IH. Finally, contrary to the increase in OB-Rb protein
expression levels following captopril treatment, OB-R100 protein levels in the
carotid body were increased suggesting either an increase in transport of leptin
out of cells or an increase in leptin degradation within the cells. Taken together,
these data can be interpreted to suggest that ANG II effects on carotid body
chemosensitivity may be mediated in part through the activation of the carotid
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body leptin system, and that ANG II signaling is also critical for the maintenance
of circulating levels of leptin in normoxia and during IH.
The finding that ANG II influences leptin activity and requires functional
leptin receptors is supported by the observation that AT 1R blockade results in a
decreased body mass index and food intake, but has no effect in obese Zucker
rats with a genetic mutation in the leptin receptor (Muller-Fielitz et al., 2011). In
addition, it has been shown that the brain RAS facilitates renal and brown
adipose tissue sympathetic nerve responses to leptin (Hilzendeger et al., 2012).
However, the finding that plasma leptin levels induced by IH are not altered after
losartan treatment, whereas carotid body leptin is inhibited suggests that not all
leptin effects are mediated by the selective activation of the ANG II AT 1R.
The finding of a decrease in circulating leptin following ANG II inhibition is
consistent with earlier data suggesting that ANG II signaling stimulates not only
leptin production, but also leptin secretion (Cassis et al., 2004; Premaratna et al.,
2012). Considering that the main production/secretion site of leptin into the
plasma is adipose tissue (Lonnquist et al., 1996; Caro et al., 1996), this study
provides further supports the suggestion that the leptin system may be in part
under the control of ANG II. This latter suggestion is also consistent with the
observation in a mouse model deficient in the AT 1Ra isoform, in which plasma
leptin concentrations were found to be reduced when compared to wild-type
(Kaneko et al., 2011).
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Carotid body leptin levels were also found to be decreased in animals
treated with captopril during both normoxia and IH conditions. This finding is
similar to that observed within adipocytes taken from rats treated with captopril,
in which both circulating leptin and leptin release was decreased (Cassis et al.,
2004). Additionally, incubation of adipocytes with ANG II resulted in an upregulation of leptin mRNA, as well as leptin secretion (Cassis et al., 2004) while
in ventricular myocytes, ANG II promotes de novo synthesis and secretion of
leptin (Rajapurohitam et al., 2006). Furthermore, blocking OB-Rs in these
cardiomyocytes prevented the hypertrophic effects ANG II normally has on these
cells suggesting that leptin may mediate effects normally attributed to direct ANG
II action (Rajapurohitam et al., 2012). Finally, in human vascular smooth muscle
cells, it has been previously found that increased ANG II results in increased
leptin protein and mRNA expression (Shyu et al., 2012). Thus, it is not
unreasonable to suggest that leptin may be involved in mediating some of the
changes in carotid body chemosensitivity normally attributed to ANG II (Gomeznino et al., 1990; Eyzaguirre and Zapata, 1968; Bock, 1980).
Interestingly, the increased leptin protein and mRNA expression observed
in human vascular smooth muscle cells as a result of the elevated ANG II has
been attributed to increases in reactive oxygen species (Shyu et al., 2012). The
IH induced changes in the carotid body chemosensitivity have been suggested to
be related to an enhanced reactive oxygen species production (Pawar et al.
2009; Iturriaga et al., 2009). In addition, the IH effects associated with increases
in superoxide have been shown to be blocked by losartan, a specific AT 1R
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blocker (Marcus et al., 2010). Therefore, taken together, these data suggest a
possible mechanism by which ANG II signaling may modulate ROS activity and
subsequently leptin activity within the carotid body.
Captopril treatment in both normoxia and after IH reduced protein levels of
OB-Rb compared to their respective controls. This finding suggests that ANG II
plays an important role in the regulation of Ob-Rb, although due to the low levels
of available leptin both locally and from the circulation following captopril
treatment, ligand-induced endocytosis seems unlikely (Bennett et al., 1998;
Uotani et al., 1999). The short-form leptin receptor displayed increased levels of
protein expression in the carotid bodies following captopril-treated animals in
both the normoxic and IH conditions. Generally, OB-Ra is believed to be involved
in leptin transport, specifically across the blood-brain barrier (Banks et al., 1996;
Golden et al., 1997; Bjorbaek et al., 1998). One potential explanation may be that
the reduced leptin availability stimulates OB-Ra protein expression to aid in leptin
secretion from glomus cells. Additionally, the OB-Ra has been suggested to
function in the degradation process of leptin (Iida et al., 1996; Merabet et al.,
1997; Sharma et al., 1997) and may provide one mechanism through which the
decreases seen in carotid bodies occurs. However, the functional significance of
ANG II effects on Ob-Ra is unknown.
The lower protein levels of leptin and OB-Rb in the carotid bodies after
captopril treatment is consistent with the decreases in activation of STAT3. In
normoxic and IH conditions, captopril treatment reduced pSTAT3 levels, a
downstream signaler involved in OB-Rb activation (Elmquist et al., 1997;
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Fruhbeck, 2006; Wang et al., 1998; Huo et al., 2006, 2007). The down-regulation
of both the ligand and the receptor would be expected to result in a decrease in
activation of the signaling pathway (Elmquist et al., 1997; Fruhbeck, 2006; Wang
et al., 1998; Huo et al., 2006, 2007). One other potential explanation for the
decrease in pSTAT3 levels found in captopril treated animals is the decrease in
ANG II levels as ANG II signaling, through AT 1R, can activate the JAK/STAT
pathway resulting in phosphorylation of STAT3 (Ji et al., 2012; Omura et al.,
2001). However, it has also been shown that leptin injections resulted in upregulation of pSTAT3 protein expression (Messenger et al., 2012), and thus this
decrease after ANG II inhibition most likely occurs at least in part through
decreased leptin signaling.
Consistent with the decrease in pSTAT3 is the concomitant rise in SOCS3
levels.

SOCS3 acts as a negative feedback loop on JAK/STAT signaling

(Bjorbaek et al., 2000; Fruhbeck et al., 2006). The decrease in pSTAT3
accompanied by the SOCS3 rise would be expected in the IH condition, which
has previously been shown to stimulate the JAK/STAT pathway (Messenger et
al., 2012; Messenger & Ciriello, 2012). In some cell types, ANG II has been
known to stimulate the JAK/STAT pathway which results in increased SOCS3
expression (Calegari et al., 2003; Ji et al., 2012; Omura et al., 2001). However,
as to the reason why such a profound increase was found in both the normoxic
and IH condition is unknown.
In addition to the JAK/STAT pathway, OB-Rb signaling can also activate
the MAPK cascade (Bjorbaek et al., 1997; Banks et al., 2000) and thus activation
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of ERK1/2 is an indicator of pathway activation. In normoxic animals, captopril
treatment resulted in a decrease in pERK1/2 protein levels, however no changes
were observed in the IH animals. This finding suggests during IH, other
mechanisms in addition to leptin (Bjorbaek et al., 1997; Banks et al., 2000) or
ANG II (Li et al., 1998; Nakai et al., 2012) may activate ERK1/2.
In summary, this study has demonstrated that the RAS modulates the
leptin system not only in the circulation, but also within the chemosensitive
carotid body. Inhibition of ANG II by ACE results in a dampening effect on
circulating leptin levels as well as local carotid body leptin protein levels. There is
also a decrease in the OB-Rb and downstream indicators of OB-Rb activation,
and this appears to be mediated through an interaction with the activation of the
AT1R. Angiotensin signaling through the AT1R is critical for this chemosensitivity
by the carotid bodies (Marcus et al., 2010), and given its co-localization with OBRb and leptin within the glomus cells suggests that AT 1R has a stimulatory effect
on the carotid body leptin system and ANG II chemosensitive role may be
mediated in part through leptin signaling.
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7.

CHAPTER 7

7.1 SUMMARY OF MAJOR FINDINGS
This thesis examined the effects of intermittent hypoxia (IH) exposure on
physiological responses related to energy balance and cardiovascular regulation
in rats. Physiological alterations were observed following both acute and chronic
exposure to IH, and included changes in neural pathways associated with these
physiological systems. The role of leptin signaling in these pathways was an
underlying theme, and was altered in both acute and chronic models, an
important factor in mediating many of the observed effects.
In Chapter 2 of this thesis, I wanted to evaluate alterations in body energy
balance associated with exposure to acute IH. This study was performed given
that chronic models of IH have significant, detrimental metabolic alterations and
that OSA patients also present with altered metabolism and body energy balance
(Martinez et al., 2008; Dempsey et al., 2010). The role of leptin in these major
changes was also determined using a leptin-deficient transgenic rat in Chapter 3.
These KILO animals have the leptin gene removed through zinc-finger nuclease
technology (Vaira et al., 2012). Body energy balance is significantly altered in
wild-type rats exposed to IH, displaying a negative body energy balance,
including body weight loss likely due to decreased food intake. Interestingly, the
body energy expenditure appeared to be reduced in these animals, given that
food conversion efficiency and locomotion were both decreased compared to
normoxic controls. These alterations were associated with a significant elevation
in circulating leptin, concomitant with reduced adipose leptin content. Circulating
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adiponectin was reduced, whereas adipose adiponectin content was elevated.
Leptin:adiponectin ratio was elevated in animals exposed to IH, as a result. The
ARC of animals was isolated and protein expression of pSTAT3 was shown to be
higher in animals exposed to IH, suggestive of activation of a cytokine receptor
dependent on the JAK2/STAT3 signaling pathway. POMC was also higher in the
ARC of IH animals, and this was mirrored by an increased number of POMC
cells expressing immediate early gene product immunoreactivity. When leptindeficient KILO rats were used, none of these differences were observed between
IH and normoxic exposed animals, suggesting that leptin is a necessary
component of mediating the body energy balance phenotype in animals exposed
to IH.
Since the role of leptin in mediating the effects of IH on body energy
balance appeared to be critical, we looked at the role of chronic IH in body
energy balance and whether a state of leptin resistance could potentially be
induced in Chapter 4. Certainly animals exposed to 95 days of IH had reduced
body weight compared to controls, but by the end of the study period, animals
exposed to IH were gaining no more body weight than at the start of the period,
compared to a reduction in body weight gain in controls, an effect mirrored by
energy utilization. These changes were concomitant to an elevation in food
intake in CIH animals over the study period, whereas normoxic animals had a
significant reduction in food intake over the same time. This may be suggestive
of a physiological manifestation of leptin resistance. Leptin sensitivity was
measured directly, and it was shown that CIH animals were resistant to leptin
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compared to normoxic controls. Animals had elevated leptin/epididymal fat pad
mass, an important factor given the alterations observed in body energy balance.
No changes in locomotion were observed. CIH animals exhibited no differences
in the protein expression level of neither ObRB, nor ObR100, nor pSTAT3,
though pERK1/2 was curiously elevated. POMC protein was decreased and
SOCS3 increased in the ARC, suggesting that leptin resistance may occur
following CIH through SOCS3 induction, and POMC is reduced as a result of the
decreased leptin signaling. This study suggests that IH may be able to induce a
state of positive body energy balance over long-term exposures.
In Chapter 5, the role of acute, short-term and chronic IH on hemodynamic
measures were assessed and associated with neuroplastic alterations within the
NTS region of the brainstem. Hypertension without concomitant alterations in
heart rate was observed in animals following 95 days of IH, but not at any other
time point. The basal gain of the baroreflex was also reduced following this
exposure. It was observed that specific alterations in the TrkB-BDNF signaling
system change over time, which may be the result of differential leptin signaling.
Interestingly, the amount of synaptophysin within the NTS region was reduced
following IH, indicative of a loss of synapses within the region. However, in acute
IH this effect was still observed in KILO leptin-deficient animals, suggesting leptin
does not play a role in this effect. The neurite growth factor GAP-43 was reduced
following CIH, suggesting a potential reduction in cardiorespiratory afferent
neurites or potential for neurite sprouting within the NTS region. We believe this
may be a novel mechanism mediating hypertension following IH, an effect
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supported by other groups observing a reduction in glutamatergic synapses
following IH (Almado et al., 2012).
Finally in Chapter 7, the role of angiotensin II in mediating leptin signaling
within the carotid body following IH was assessed. This was done by exposing
animals to acute IH following angiotensin converting enzyme (ACE) inhibition or
blockade of the type 1 angiotensin II receptor (AT1R), and served as a follow-up
to initial findings describing the effects of acute IH on leptin signaling in the
carotid body (Messenger and Ciriello, 2013). Here, we show that leptin protein
within the carotid body is reduced in animals exposed to IH compared with
controls in both conditions of reduced angiotensin II signaling. The treatments
also prevented all the alterations observed in leptin signaling within the carotid
body following IH under sham conditions, suggesting that angiotensin II plays a
critical role in mediating the effect of leptin at the carotid body during IH.
Likewise, it was observed that circulating leptin concentrations were not different
in IH animals following ACE inhibition, but were elevated during AT1R blockade
following IH, similar to sham animals. This suggests that leptin secretion
following IH is dependent on angiotensin II acting through non-AT1Rs.

7.2 LIMITATIONS AND FUTURE STUDIES
The animal model of IH used in these studies under both acute and chronic
exposures is a sleep-independent model, which is applied during the rest phase
of the sleep/wake cycle of the rats used. Due to the sleep-independent nature of
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this exposure, it could be that for some short periods of time animals were being
exposed to IH while actually awake. The effect this may have on the outcomes of
these studies is not known, but may be negligible since studies using IH
exposure during an aroused state in humans showed effects consistent with that
observed in patients with obstructive sleep apnea (OSA; Louis and Punjabi,
2009). Likewise, alterations in oxygen availability in patients with OSA may
persist throughout the waking hours (Shiota et al., 2013).
In addition to potential inconsistencies of hypoxia between the model of IH
utilized and OSA, it has previously been shown that rodents exposed to IH
experience an elevated ventilator response, resulting in eucapnea and no
alterations in intrathoracic pressure (Fletcher et al., 1992). In patients with OSA,
both hypercapnemia and reductions in intrathoracic pressure similar to that seen
in the Muller manoeuvre have been noted during apnea (Dempsey et al., 2010).
This is the result of difference between the inductions of IH experimentally and
clinically. In the model of IH, environmental oxygen levels are altered, but the
airway of the animal or subject remain intact. This occurs without a change in
environmental pressure or carbon dioxide, and thus breathing is free to go
unimpeded and without any change in carbon dioxide within the lungs. In
contrast, a reduction in airway flow during OSA results in reduced gas exchange
and unsuccessful attempts to breathe during apnea (Dempsey et al., 2010).
Since these models do not mimic OSA, but rather the specific IH component of
OSA, is precisely the reason that models of IH are not described as models of
OSA, and so differences between the model and the disease are important to
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take into consideration. Despite this, it is believed that the cardiovascular and
metabolic responses in OSA are largely due to the observed IH. The
neurocognitive components appear to be largely due to disruption in sleep
architecture and IH. Interestingly, it has been determined in rodent models that
hypercapnea does not alter responses to IH (Dempsey et al., 2010).
Despite the overwhelming contributions of IH in exploring mechanistic and
causal roles of OSA-induced IH to other disease states, there are other
unresolved issues in modelling OSA with current IH models. The most important
of which, is the sudden nature of IH exposure. OSA is a chronic, progressive
disease that can persist for a significant portion of an individual’s life. Most
current models of CIH involve exposing rodents to IH with an apnea-hypopnea
index (AHI) within the moderate-severe range immediately. This massive change
in oxygen availability is likely a massive insult to the homeostasis of an animal,
and does not mimic what is observed in OSA. In an attempt to resolve this issue,
I have proposed a model of CIH that includes a progressive component,
increasing hypoxic exposure to a plateau level that coincided with that normally
exposed in our CIH model. This so-called ramped IH model consists of starting
animals with an AHI of 1 event/h, with progressive steps of AHI by 1 event/h
every four days. Animals are then exposed to CIH in the plateau phase for 28
days, for a total hypoxic exposure of 96 days (on par with our 95 day CIH model).
I believe this model will allow for appropriate adaptation in neural signaling
networks, such as the carotid body afferent system and sympathetic and phrenic
efferent systems. This model must be further studied to validate these claims,
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and determine the appropriateness for use in better modelling the chronic, yet
dynamic exposure to IH experienced in OSA. On this topic, it may also be
advisable that models of CIH be utilized for longer time periods. Given that
rodents exposed to 95 days IH developed leptin resistance and had small initial
alterations in food intake and body weight changes, it would be better suited to
observe

these

models

over

long

periods

of

time

to

determine

the

pathophysiological manifestation of obesity and/or metabolic syndrome. As well
other, currently unstudied pathologies and their association to CIH such as heart
failure and sudden cardiac death could also be studied over longer exposure
times.

7.3 SIGNIFICANCE OF RESEARCH AND CONCLUSIONS
OSA represents a significant disease burden to both patients and healthcare
systems globally. Given the associations of OSA with other diseases such as
obesity and cardiovascular disease, the time has come to determine the true role
OSA has in mediating mechanisms that lead to, and are part of, these deadly
disease states. Understanding the factors that link these diseases is important for
1) an understanding of the importance of diagnosing and treating OSA, 2)
mechanisms which may be targeted by OSA treatment, 3) the development of
novel treatment approaches to OSA, and 4) the development of novel treatment
approaches for OSA-related pathologies.
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Clinical studies have shown that obesity is an important risk factor for the
development of OSA, and patients with OSA tend to gain weight compared to
normal individuals (Phillips et al., 2000). Likewise, OSA patients have more
trouble losing weight than normal individuals. These findings form the basis for a
bidirectional relationship between OSA and body weight gain. For the first time,
body energy balance within animals has been assessed in a model of CIH. My
study has shown that a primary and potentially causative hallmark of obesity is
induced by CIH. In this study, leptin resistance occurs despite a reduction in body
weight gain, though is accompanied by an increase in food intake over the
exposure time, compared to controls. This may provide a mechanism by which
body weight gain and obesity could be induced by the CIH observed in patients
with OSA. Likewise, most of the short-term effects of IH on body energy balance
are due to leptin signaling. This is concomitant to the finding that hypoxia and
OSA in humans increases circulating leptin. Acute IH causes changes such as
an alteration in leptin:adiponectin ratio, which is believed to be an important
variable in cardiovascular disease development (Kappelle et al., 2012), though
this measure has not been assessed in OSA patients.
Another common comorbidity with OSA is hypertension. My studies
suggest a potential novel mechanism by which neuroplastic alterations in the
nucleus of the solitary tract is associated with hypertension in animals exposed to
IH. The development of hypertension in patients with OSA is often described as
resistant in nature. This suggests that classical mechanisms of blood pressure
elevation, which are largely targeted by drugs, are not likely the mechanisms
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mediating the hypertension-inducing effects of OSA. Instead, new approaches to
hypertension must be addressed in complicated forms of secondary resistant
hypertension, such as the one induced by the CIH model. It cannot be ruled out
that selective leptin resistance, which permits the activity of the hypertensive
effects but inhibits the satiety effects of leptin, played a role in mediating this
hypertension. Likewise, the alterations observed in neuroplastic markers,
especially considering that leptin deficient animals do not develop the same
alterations in some of the markers of neuroplasticity, may also be the result of
leptin acting selectively in this area to drive blood pressure. Nonetheless, these
potential pathways warrant a closer look in additional studies to determine the
role of these changes following IH in hypertension.
Finally, in Chapter 4 of this thesis I have shown that leptin signaling
pathways within the carotid body are regulated by the AT 1R, while the IHdependent release of leptin is regulated by angiotensin II through non-AT1R. The
clinical relevance of this data is not obvious, but these effects may be important
in suggesting a role for a complex interaction between leptin and angiotensin II
both peripherally and specifically within the carotid body. The functional effects of
this interaction are unknown, but it is known that angiotensin II is an important
modulator of the carotid chemoreceptor reflex (Marcus et al., 2010), and so leptin
may interact with this to potentiate hypoxic responses. This is important, as data
suggest a potentiation of carotid body signaling and sympathetic nervous drive
following exposure to IH (Dick et al., 2007).
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Collectively, the studies in this thesis provide many new avenues for
research into cardiometabolic diseases associated with IH exposure, presumably
to determine mechanism of diseases associated with OSA. Addressing these
mechanisms may provide novel therapeutic targets in addressing the disease
burden associated with OSA. This disease burden will become increasingly
important as OSA increases in prevalence within our population.
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